<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sedation of children undergoing dental treatment - Ashley, PF - 2018 | Cochrane Library</title> <meta content="Sedation of children undergoing dental treatment - Ashley, PF - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003877.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sedation of children undergoing dental treatment - Ashley, PF - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003877.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003877.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Sedation of children undergoing dental treatment" name="citation_title"/> <meta content="Paul F Ashley" name="citation_author"/> <meta content="UCL Eastman Dental Institute" name="citation_author_institution"/> <meta content="p.ashley@ucl.ac.uk" name="citation_author_email"/> <meta content="Mohsin Chaudhary" name="citation_author"/> <meta content="University College London Hospital" name="citation_author_institution"/> <meta content="Liege Lourenço‐Matharu" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD003877.pub5" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/12/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003877.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003877.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003877.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Non‐Narcotic [administration &amp; dosage]; Anti‐Anxiety Agents [administration &amp; dosage, *therapeutic use]; Chloral Hydrate [administration &amp; dosage]; Dental Anxiety [*drug therapy]; Dental Care for Children [methods, *psychology]; Hydroxyzine [administration &amp; dosage]; Hypnotics and Sedatives [administration &amp; dosage, *therapeutic use]; Meperidine [administration &amp; dosage]; Midazolam [administration &amp; dosage]; Nitrous Oxide [administration &amp; dosage]; Preanesthetic Medication [methods]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003877.pub5&amp;doi=10.1002/14651858.CD003877.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tlnpj831";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003877\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003877\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","de","hr","fa","pt","ro","ja","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003877.pub5",title:"Sedation of children undergoing dental treatment",firstPublishedDate:"Dec 17, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003877.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003877.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003877.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003877.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003877.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003877.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003877.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003877.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003877.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003877.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13086 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003877.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0144"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0048"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0049"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/appendices#CD003877-sec-0155"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/table_n/CD003877StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/table_n/CD003877StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sedation of children undergoing dental treatment</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#CD003877-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Paul F Ashley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#CD003877-cr-0003">Mohsin Chaudhary</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information#CD003877-cr-0004">Liege Lourenço‐Matharu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information/en#CD003877-sec-0165">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 December 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003877.pub5">https://doi.org/10.1002/14651858.CD003877.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003877-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003877-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003877-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003877-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003877-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003877-abs-0015">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003877-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003877-abs-0001" lang="en"> <section id="CD003877-sec-0001"> <h3 class="title" id="CD003877-sec-0001">Background</h3> <p>Children's fear about dental treatment may lead to behaviour management problems for the dentist, which can be a barrier to the successful dental treatment of children. Sedation can be used to relieve anxiety and manage behaviour in children undergoing dental treatment. There is a need to determine from published research which agents, dosages and regimens are effective. This is the second update of the Cochrane Review first published in 2005 and previously updated in 2012. </p> </section> <section id="CD003877-sec-0002"> <h3 class="title" id="CD003877-sec-0002">Objectives</h3> <p>To evaluate the efficacy and relative efficacy of conscious sedation agents and dosages for behaviour management in paediatric dentistry. </p> </section> <section id="CD003877-sec-0003"> <h3 class="title" id="CD003877-sec-0003">Search methods</h3> <p>Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 22 February 2018); the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 1) in the Cochrane Library (searched 22 February 2018); MEDLINE Ovid (1946 to 22 February 2018); and Embase Ovid (1980 to 22 February 2018). The US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform were searched for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. </p> </section> <section id="CD003877-sec-0004"> <h3 class="title" id="CD003877-sec-0004">Selection criteria</h3> <p>Studies were selected if they met the following criteria: randomised controlled trials of conscious sedation comparing two or more drugs/techniques/placebo undertaken by the dentist or one of the dental team in children up to 16 years of age. We excluded cross‐over trials. </p> </section> <section id="CD003877-sec-0005"> <h3 class="title" id="CD003877-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted, in duplicate, information regarding methods, participants, interventions, outcome measures and results. Where information in trial reports was unclear or incomplete authors of trials were contacted. Trials were assessed for risk of bias. Cochrane statistical guidelines were followed. </p> </section> <section id="CD003877-sec-0006"> <h3 class="title" id="CD003877-sec-0006">Main results</h3> <p>We included 50 studies with a total of 3704 participants. Forty studies (81%) were at high risk of bias, nine (18%) were at unclear risk of bias, with just one assessed as at low risk of bias. There were 34 different sedatives used with or without inhalational nitrous oxide. Dosages, mode of administration and time of administration varied widely. Studies were grouped into placebo‐controlled, dosage and head‐to‐head comparisons. Meta‐analysis of the available data for the primary outcome (behaviour) was possible for studies investigating oral midazolam versus placebo only. There is moderate‐certainty evidence from six small clinically heterogeneous studies at high or unclear risk of bias, that the use of oral midazolam in doses between 0.25 mg/kg to 1 mg/kg is associated with more co‐operative behaviour compared to placebo; standardized mean difference (SMD) favoured midazolam (SMD 1.96, 95% confidence interval (CI) 1.59 to 2.33, P &lt; 0.0001, I<sup>2</sup> = 90%; 6 studies; 202 participants). It was not possible to draw conclusions regarding the secondary outcomes due to inconsistent or inadequate reporting or both. </p> </section> <section id="CD003877-sec-0007"> <h3 class="title" id="CD003877-sec-0007">Authors' conclusions</h3> <p>There is some moderate‐certainty evidence that oral midazolam is an effective sedative agent for children undergoing dental treatment. There is a need for further well‐designed and well‐reported clinical trials to evaluate other potential sedation agents. Further recommendations for future research are described and it is suggested that future trials evaluate experimental regimens in comparison with oral midazolam or inhaled nitrous oxide. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003877-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003877-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003877-abs-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003877-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003877-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003877-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003877-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003877-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003877-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003877-abs-0016">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD003877-abs-0017">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003877-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003877-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003877-abs-0019">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003877-abs-0005" lang="en"> <h3>Sedation of children undergoing dental treatment</h3> <p><b>Review question</b> </p> <p>The aim of this Cochrane Review was to find out which drugs used to sedate children during dental treatment were the most effective. </p> <p><b>Background</b> </p> <p>Fear of the dentist may be expressed as unco‐operative behaviour in children requiring dental treatment. Behaviour management problems can result in a child's tooth decay going untreated. While behavioural techniques play an important role in managing children, some children still find it difficult to co‐operate with dental treatment and may require sedation. This review examined the effects of drugs to sedate a child whilst keeping them conscious. </p> <p><b>Study characteristics</b> </p> <p>Authors from Cochrane Oral Health carried out this review and the evidence is up to date to 22 February 2018. A total of 50 randomised controlled trials were included with a total of 3704 participants. Within these studies 34 different sedatives were used, often with inhalational nitrous oxide as well. Dosages and delivery of these drugs varied widely. We grouped studies into those where drugs were compared to a placebo, where drugs were compared to other drugs or where different dosages of drugs were compared. Because all the studies were so different we could only carry out a meta‐analysis for studies comparing oral midazolam to a placebo. The review showed that use of oral midazolam made patients more co‐operative for dental treatment than a placebo drug. Where reported, adverse effects were few and minor. </p> <p><b>Key results</b> </p> <p>Oral midazolam probably improves behaviour of children during dental treatment. We evaluated other sedatives but there is insufficient evidence to draw any conclusions. </p> <p><b>Certainty of the evidence</b> </p> <p>There is some moderate‐certainty evidence that midazolam administered in a drink of juice is effective. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003877-sec-0144" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003877-sec-0144"></div> <h3 class="title" id="CD003877-sec-0145">Implications for practice</h3> <section id="CD003877-sec-0145"> <p>There is moderate‐certainty evidence from six trials that oral midazolam is an effective agent for sedation of children. Although other sedatives have been evaluated, the range of sedatives, regimens, doses, modes of administration and comparisons included makes it impossible to produce a clear statement of implications for practice regarding other agents. </p> </section> <h3 class="title" id="CD003877-sec-0146">Implications for research</h3> <section id="CD003877-sec-0146"> <p>This is the second update of the Cochrane Review first published in 2005 and previously updated in 2012. It is unfortunate that there has been little improvement in the design, statistical power and reporting of studies carried out since then. </p> <p>The shortfalls of studies reported in this review are many. The principles that researchers should adhere to when designing, carrying out and reporting clinical trials in the future are the CONSORT guidelines (<a href="./references#CD003877-bbs2-0174" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. Lancet2001;357(9263):1191‐4. ">Moher 2001</a>). There also needs to be a improvement in reporting of variables like gender, weight, time starved, time of onset of sedation, dropouts, reason for patient failing to complete treatment, etc. </p> <p>More specific recommendations for studies assessing sedative agents are as follows.</p> <section id="CD003877-sec-0147"> <h5 class="title">Blinding</h5> <p>Ideally the operator, participant and assessor should all be blinded to the sedation agent used, however blinding of the operator is problematic. When comparing drugs with different modes of delivery e.g. oral midazolam versus nitrous oxide/oxygen, it would not be possible to blind the operator as techniques of administration are totally different. If this is the case then it is important that the assessor is blinded to the allocation. In the aforementioned example this could be achieved by using an inhalation mask to deliver air in the midazolam group and the patient videotaped, to enable blinded outcome assessment. </p> </section> <section id="CD003877-sec-0148"> <h5 class="title">Sample</h5> <p>Obviously calculating and reporting sample sizes should be carried out before starting any clinical trial, something that has not been done well to date in trials of sedation agents in children requiring dental treatment. More consideration also needs to be given to the children included in trials, in particular their age. Consideration should be given to dividing age into three broad groups (as recommended by the British National Formulary (BNF) when prescribing drugs to children). These groups are: from 1 to 6 years, from 6 to 12 years and over 12 years of age. There is a need to establish which sedation is more effective for a given age group. </p> <p>Consideration should also be given to the reasons for sedation which may well vary widely between groups. In pre‐co‐operative children (under 6) the intention is often to get treatment done. In older children (e.g. over 12) the intention might be to provide a pleasant experience for the patient thus reducing anxiety for further visits. It would also be helpful for research to investigate suitable sedative regimens for dental treatment in medically compromised children of various ages, those with learning difficulties or other behavioural problems such Attention Deficit Hyperactivity Disorder (ADHD). </p> </section> <section id="CD003877-sec-0149"> <h5 class="title">Design</h5> <p>Only studies of a parallel design should be carried out. Cross‐over trials are not appropriate because the level of baseline anxiety/behaviour in the second treatment phase is highly dependent on the success or otherwise of the first treatment period. </p> </section> <section id="CD003877-sec-0150"> <h5 class="title">Baseline and outcome variables</h5> <p>Behaviour is the most commonly used outcome measured in a range of ways. Anxiety is sometimes measured before the study commences but rarely afterwards. Treatment completion is not always reported and very rarely statistically tested between groups. Outcome variables are very clinician centred ‐ what was the quality of the sedation? How immobile was the child? etc. These approaches need to change. </p> <p>Outcome variables need to be more patient‐centred. This might include satisfaction, reduction in anxiety or other measures relating the patient's perception. </p> <p>A wider debate needs to be had on the purpose of sedation. The majority of studies to date, focus on the use of sedation as a tool to facilitate the delivery of dental treatment in children. This is important; but sedation could (and should) have a larger role. It could be used to facilitate the introduction of treatment to anxious children with a view to reducing or removing sedation in subsequent visits (an approach taken by <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>). Outcome variables should be chosen to reflect this. </p> <p>Where behaviour‐type outcome measures are used, thought must be given to the appropriateness of movement‐based measures for children who are restrained e.g. by a papoose board. </p> <p>Considering the above comments the review authors would suggest that reviews have the following 'key' or 'core' variables in common to allow comparison between studies in future. </p> <p> <ol id="CD003877-list-0015"> <li> <p>Some measurement of baseline anxiety.</p> </li> <li> <p>Completion of treatment as the primary outcome variable.</p> </li> <li> <p>Patient satisfaction or preference.</p> </li> </ol> </p> </section> <section id="CD003877-sec-0151"> <h5 class="title">Deep versus conscious sedation</h5> <p>It was originally intended to exclude any papers that dealt with deep sedation for reasons outlined in the introduction. This proved to be impossible because many papers did not state explicitly whether they were practicing conscious or deep sedation, sleeping was also poorly reported. We believe that in some of these papers deep sedation was undertaken, as participants were reported as falling asleep and mouth props were used. This highlights the importance of reaching a consensus definition of conscious sedation, or at the very least using the definitions already available. Without this information it is impossible for researchers or clinicians in countries where the existing regulatory framework does not permit deep sedation to make appropriate use of published data. Alternatively the definition of deep sedation could be abandoned, as it is not used. </p> </section> <section id="CD003877-sec-0152"> <h5 class="title">Agents/regimens under test</h5> <p>There are 32 sedative drugs or drug combinations tested for conscious sedation in this review, given either orally, by inhalation, intramuscular injections, intranasally and/or rectally and at varying dosages. The majority were not compared against a placebo or even a drug of known efficacy. Future trials should consider the use of either oral midazolam or nitrous oxide sedation as a comparator. </p> <p>As mentioned, not all agents are available in all countries and the choice of sedation will depend on cultural acceptance and also laws and availability. It would seem appropriate to identify agents of particular interest and co‐ordinate research on these internationally. Furthermore, it would seem appropriate for different countries to investigate those drugs and modes of delivery that are most appropriate for them. </p> <p>A further problem is the use of supplemental nitrous oxide/oxygen. This is often used in studies (particularly from North America) and would be expected to increase the overall level of sedation. Whilst there is nothing wrong in using supplemental nitrous oxide/oxygen it needs to be made clear from the outset that this is the case in clinical trials. Unfortunately it is often not mentioned initially when agents under test are described. For example the drug under investigation should be given as chloral hydrate and nitrous oxide/oxygen rather than just chloral hydrate with a subsequent note buried in the text describing the use of supplemental nitrous oxide oxygen. </p> <p>Finally the use of papoose boards needs to be clarified. What is the impact of physical restraint on sedative effectiveness? Or anxiety reduction? Further work needs to be done on the role of physical restraints in sedation of children. However, it is important that use of papoose board in a clinical trial of sedation should also be specified clearly from the outset. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003877-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003877-sec-0043"></div> <div class="table" id="CD003877-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sedative compared to placebo for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Sedative compared to placebo for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sedative</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Midazolam (oral) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>midazolam (oral)</b> group was on average <b>1.96 SDs higher</b> (1.59 higher to 2.33 higher) than the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>Adverse events: vomiting/hiccupping reported in 1 study. Amnesia reported in 1 study</p> <p>Oral midazolam probably improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Midazolam (intravenous) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>midazolam (intravenous)</b> group was on average <b>1.21 SDs higher</b> (0.24 higher to 2.18 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether intravenous midazolam improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Nitrous oxide </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>nitrous oxide</b> group was on average <b>0.69 SDs higher</b> (0.13 higher to 1.26 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether nitrous oxide improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Diazepam (oral) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>diazepam (oral)</b> group was on average <b>0.62 SDs higher</b> (0.28 lower to 1.53 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether oral diazepam improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Good or better behaviour ‐ Chloral hydrate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.80 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: associated with airway problems</p> <p>Uncertain whether chloral hydrate improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>533 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>709 per 1000<br/> (427 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Good or better behaviour ‐ Meperidine</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.33<br/> (1.45 to 19.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: nausea, vomiting and unmanageable behaviour were associated with meperidine use </p> <p>Meperidine may improve behaviour</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>711 per 1000<br/> (193 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>*</sup><b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (lack of blinding and randomisation processes unclear).<br/> <sup>2</sup>Downgraded for imprecision (large confidence interval and small numbers).<br/> <sup>3</sup>Downgraded for imprecision (large confidence interval).<br/> <sup>4</sup>Downgraded for risk of bias (randomisation unclear and incomplete outcome assessment).<br/> <sup>5</sup>Downgraded for risk of bias (randomisation unclear) and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003877-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sedative compared with different dosage of the same sedative for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Sedative compared with different dosage of the same sedative for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> different dosage of the same sedative </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (any mode of delivery)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 (10)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is insufficient evidence to determine whether any specific dose of intranasal midazolam is effective </p> <p>There is weak evidence from two trials that oral midazolam at a dose of 0.5 mg/kg to 0.75 mg/kg is an effective sedative for children. However, one trial administered both nitrous oxide and midazolam so it is difficult to attribute benefit to midazolam alone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Hydroxyzine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is insufficient evidence to determine whether any specific dose of hydroxyzine is effective </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias, inconsistency and/or imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003877-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sedative compared with a different sedative for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Sedative compared with a different sedative for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> different sedative </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Chloral hydrate/hydroxyzine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 (6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>No two studies evaluating the same intervention and comparison found the same effect. There is insufficient evidence to draw any conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Chloral hydrate/promethazine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Dexmedetomidine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 (2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Ketamine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>494 (8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Ketamine/midazolam versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (oral) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>654 (7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (intravenous) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 (2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐ Midazolam (rectal) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Sevoflurane versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1140 (3)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias, inconsistency and/or imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003877-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003877-sec-0044"></div> <section id="CD003877-sec-0045"> <h3 class="title" id="CD003877-sec-0045">Description of the condition</h3> <p>Dental decay is one of the most common human diseases and affects almost 100% of adults and 60% to 90% of school children across the world (<a href="./references#CD003877-bbs2-0179" title="World Health Organization (WHO). Oral Health Factsheet 3018, April 2012. www.who.int/mediacentre/factsheets/fs318/en/index.htm (accessed 20 March 2016). ">WHO 2012</a>). This decay in children is often untreated. In 2015, 25% of 5‐year olds in England had teeth affected by dental decay with each of these children having on average three teeth damaged. Only 12% of these damaged teeth were filled (<a href="./references#CD003877-bbs2-0175" title="Public Health England, National Dental Epidemiology Programme for England. National Dental Epidemiology Programme for England: oral health survey of five‐year‐old children 2015. A report on the prevalence and severity of dental decay. www.nwph.net/dentalhealth/14_15_5yearold/14_15_16/DPHEP%20for%20England%20OH%20Survey%205yr%202015%20Report%20FINAL%20Gateway%20approved.pdf (accessed 15 May 2016). ">NDEP 2015</a>). This represents a significant problem, if dentine caries is left it will usually lead to pain and sepsis which can often only be managed by extraction or extensive restoration of the affected teeth. Historically this has been managed in children by use of general anaesthetic. Whilst a proportion of children will always require this process, it is now recognised that it should be avoided wherever possible due to the associated rare risk of death. General anaesthesia is also very costly, it requires the use of specialist facilities and staff such as anaesthetists and specialist nurses. </p> <p>The obvious alternative is to provide treatment under local anaesthesia, however some children will not be able to accept to this. Barriers to treatment may be dental fear or behaviour management problems (BMP). Estimates of the prevalence of dental fear and BMP are hard to find, however one Swedish study reported a value of 10.5% of children with BMP out of a population of 4 to 11‐year olds (<a href="./references#CD003877-bbs2-0171" title="KlingbergG , Vannas LofqvistL , BjarnasonS , NorenJG . Dental behaviour management problems in Swedish children. Community Dentistry and Oral Epidemiology1994;22(3):201‐5. ">Klingberg 1994</a>). Dental fear and BMP are closely related phenomena. Dental fear or anxiety is associated with increased levels of caries and BMP, however not all children who are dentally anxious will present with BMP, one study reported that only 60% of children with dental fear presented with BMP (<a href="./references#CD003877-bbs2-0172" title="KlingbergG , BerggrenU , CarlssonSG , NorenJG . Child dental fear: cause‐related factors and clinical effects. European Journal of Oral Science1995;103(6):405‐12. ">Klingberg 1995</a>). In turn, children exhibiting BMP may also be dentally anxious, though in the same study only 25% of those children with BMP were dentally anxious. </p> <p>Methods of managing anxiety and behaviour are therefore required to meet this need. Whilst behavioural techniques that do not involve the use of drugs can play an important part in a child's management, many children will still find it difficult to tolerate dental treatment. In these cases sedation could be considered as a method for reducing anxiety and facilitating the provision of dental treatment. </p> </section> <section id="CD003877-sec-0046"> <h3 class="title" id="CD003877-sec-0046">Description of the intervention</h3> <p>Views of what constitutes sedation differ between clinicians, however any definition should seek to differentiate sedation from general anaesthetic. Unfortunately many sedative agents can also act as general anaesthetics and the difference in dose required to move from a sedated patient to an anaesthetised patient can be very small and extremely variable between patients. The ideal sedative agent would reduce anxiety and improve behaviour thus facilitating the completion of dental treatment and providing a positive experience for the patient. It could be carried out safely in the primary care sector and have a wide margin of safety. For the purposes of this review, therefore, a widely used definition of sedation will be followed which clearly states the level of consciousness beyond which a patient could be considered to be anaesthetised (<a href="./references#CD003877-bbs2-0167" title="American Academy of Pediatrics Committee on Drugs. American Academy of Pediatrics Committee on Drugs: Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics1992;89(6 Pt 1):1110‐5. ">AAP 1992</a>):<br/> "a state of depression of the central nervous system which reduces anxiety thus enabling treatment to be carried out satisfactorily. During sedation the patient will be able to independently maintain an open mouth, and respond sensibly to verbal commands. In addition, the patient will retain adequate function of protective reflexes such as the laryngeal reflex. The drugs used should carry a margin of safety sufficient to render unintended loss of consciousness extremely unlikely." </p> <p>This type of sedation will be referred to as conscious sedation or moderate sedation.</p> <p>This review will not consider agents used to induce so‐called 'deep sedation' for the above mentioned reasons. Deep sedation can be defined as (<a href="./references#CD003877-bbs2-0167" title="American Academy of Pediatrics Committee on Drugs. American Academy of Pediatrics Committee on Drugs: Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics1992;89(6 Pt 1):1110‐5. ">AAP 1992</a>):<br/> "a medically controlled state of depression consciousness or unconsciousness from which the patient is not easily aroused. Deep sedation may be accompanied by a partial or complete loss of protective reflexes, including the inability to maintain an airway independently and to respond purposefully to physical stimulation or to verbal command. The state and risks of deep sedation may be indistinguishable from those of general anaesthesia." </p> </section> <section id="CD003877-sec-0047"> <h3 class="title" id="CD003877-sec-0047">Why it is important to do this review</h3> <p>Commonly used agents for sedation include the benzodiazepines, nitrous oxide or other agents. Unfortunately these agents are delivered by a large variety of methods (such as oral, rectal and nasal), in a bewildering variety of combinations and in varying doses. They may also be used in conjunction with forms of physical restraint (such as a papoose board). A preliminary search of the literature suggests that very few of these drugs have been assessed against a negative or placebo control to test their efficacy. In addition many of the agents or combinations of agents may induce deep sedation rather than conscious sedation. Finally, outcome variables in the majority of studies assessing the different sedative agents appear to focus predominantly on its effect on behaviour rather than anxiety. </p> <p>The aim of this review was to determine which sedative agents are effective for behaviour management in children who are receiving dental care in order to allow completion of dental treatment. This is the second update of the Cochrane Review first published in 2005 and previously updated in 2012 (<a href="./references#CD003877-bbs2-0181" title="MatharuLM , AshleyPF . Sedation of anxious children undergoing dental treatment. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003877.pub2] ">Matharu 2005</a>; <a href="./references#CD003877-bbs2-0183" title="Lourenço‐MatharuL , AshleyPF , FurnessS . Sedation of children undergoing dental treatment. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD003877.pub4] ">Matharu 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003877-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003877-sec-0048"></div> <p>To evaluate the efficacy and relative efficacy of conscious sedation agents and dosages for behaviour management in paediatric dentistry. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003877-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003877-sec-0049"></div> <section id="CD003877-sec-0050"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003877-sec-0051"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (including cluster‐randomised). Quasi‐randomised trials were excluded. We also excluded cross‐over trials from this review, as they are not an appropriate study design when the intervention can have a long lasting effect (<a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The relationship between pain and anxiety is well established, it is clear that the child's experience of any procedure will have an impact on any subsequent one (<a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>). </p> </section> <section id="CD003877-sec-0052"> <h4 class="title">Types of participants</h4> <p>Both the following criteria had to be met for a study to be included in this review.</p> <p> <ul id="CD003877-list-0001"> <li> <p>Children and adolescents aged 0 to 16 years of age (including children with specific medical or behavioural problems). </p> </li> <li> <p>Children having simple restorative treatment with local anaesthesia (e.g. fillings, stainless steel crowns), simple extractions or management of dental trauma (e.g. repositioning of tooth, splinting, removal of nerve from tooth). </p> </li> </ul> </p> <p>Studies where children were having complex surgical procedures were not included in this review. We included studies regardless of whether a measure of anxiety was reported at baseline. </p> </section> <section id="CD003877-sec-0053"> <h4 class="title">Types of interventions</h4> <section id="CD003877-sec-0054"> <h5 class="title">Test group</h5> <p>Any sedative agent via any route of admission that can be administered by a dentist, anaesthetist, sedationist or dental auxiliary in an outpatient setting or dental office. Studies that reported induction of deep sedation were excluded. </p> </section> <section id="CD003877-sec-0055"> <h5 class="title">Control group</h5> <p>Placebo (including no intervention) or alternative sedation agent or different dosage of the same agent. </p> </section> </section> <section id="CD003877-sec-0056"> <h4 class="title">Types of outcome measures</h4> <section id="CD003877-sec-0057"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003877-list-0002"> <li> <p>Behaviour.</p> </li> </ul> </p> <p>This was measured by a range of different indices; where possible these were combined to allow meta‐analysis to be carried out. Behaviour for the procedure overall would be recorded; if this information was not available then behaviour at the time of injection was used. </p> </section> <section id="CD003877-sec-0058"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003877-list-0003"> <li> <p>Completion of treatment (yes/no).</p> </li> <li> <p>Postoperative anxiety.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003877-sec-0059"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003877-sec-0060"> <h4 class="title">Electronic searches</h4> <p>Cochrane Oral Health's Information Specialist conducted systematic searches in the following databases for randomised controlled trials and controlled clinical trials without language or publication status restrictions: </p> <p> <ul id="CD003877-list-0004"> <li> <p>Cochrane Oral Health's Trials Register (searched 22 February 2018) (<a href="./appendices#CD003877-sec-0156">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 1) in the Cochrane Library (searched 22 February 2018) (<a href="./appendices#CD003877-sec-0157">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 22 February 2018) (<a href="./appendices#CD003877-sec-0158">Appendix 3</a>); </p> </li> <li> <p>Embase Ovid (1980 to 22 February 2018) (<a href="./appendices#CD003877-sec-0159">Appendix 4</a>). </p> </li> </ul> </p> <p>Subject strategies were modelled on the search strategy designed for MEDLINE Ovid. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6 (<a href="./references#CD003877-bbs2-0173" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). </p> </section> <section id="CD003877-sec-0061"> <h4 class="title">Searching other resources</h4> <p>The following trial registries were searched for ongoing studies:</p> <p> <ul id="CD003877-list-0005"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 22 February 2018) (<a href="./appendices#CD003877-sec-0160">Appendix 5</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 22 February 2018) (<a href="./appendices#CD003877-sec-0161">Appendix 6</a>). </p> </li> </ul> </p> <p>The reference lists of all eligible trials were checked for additional studies.</p> <p>Specialists in the field known to review authors were contacted for any unpublished data. </p> <p>Titles and abstracts were assessed by review authors for inclusion in the review.</p> <p>We did not perform a separate search for adverse effects of interventions used, we considered adverse effects described in included studies only. </p> </section> </section> <section id="CD003877-sec-0062"> <h3 class="title" id="CD003877-sec-0062">Data collection and analysis</h3> <section id="CD003877-sec-0063"> <h4 class="title">Selection of studies</h4> <p>Following the electronic search, two review authors independently screened the titles and abstracts to exclude all articles clearly not meeting the inclusion criteria. The search was designed to be sensitive and include controlled clinical trials, these were filtered out early in the selection process if they were not randomised. Of all the remaining articles, full texts were obtained and assessed independently by two review authors and only articles fully meeting the inclusion criteria were considered. Any disagreements were resolved by discussion. </p> </section> <section id="CD003877-sec-0064"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out on a specially designed form independently by two review authors who were blinded to each other's data. Results were compared to check for inconsistencies and disagreements resolved by discussion. Review authors were not blinded to the journal of publication or the author's names on the papers. </p> <p>Descriptive data collected (where available) in addition to that already outlined included: </p> <p> <ul id="CD003877-list-0006"> <li> <p>year study started, if not available, year it was published,</p> </li> <li> <p>country where study was carried out,</p> </li> <li> <p>use of supplemental nitrous oxide gas (N<sub>2</sub>O), </p> </li> <li> <p>use of restraints during the procedure,</p> </li> <li> <p>previous dental treatments of patients,</p> </li> <li> <p>anxiety prior to treatment,</p> </li> <li> <p>baseline behaviour,</p> </li> <li> <p>sample size calculation,</p> </li> <li> <p>dental treatment procedure,</p> </li> <li> <p>fasting before the procedure,</p> </li> <li> <p>level of consciousness throughout the procedure,</p> </li> <li> <p>adverse effects,</p> </li> <li> <p>monitoring used,</p> </li> <li> <p>procedure and recovery time,</p> </li> <li> <p>assessment of examiner variability,</p> </li> <li> <p>patient satisfaction/acceptance.</p> </li> </ul> </p> <p>The characteristics of the trial participants, interventions and outcomes for the included trials are presented in <a href="./references#CD003877-sec-0171" title="">Characteristics of included studies</a> table. Where information in the published report was incomplete or unclear, we contacted the trial authors for clarification or for further information. </p> </section> <section id="CD003877-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias in included studies using Cochrane's risk of bias tool and the methodology set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We analysed data using Review Manager software (<a href="./references#CD003877-bbs2-0177" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We completed a 'Risk of bias' table for each included study. Each study was assessed on the following domains: </p> <p> <ul id="CD003877-list-0007"> <li> <p>sequence generation (selection bias),</p> </li> <li> <p>allocation concealment (selection bias),</p> </li> <li> <p>blinding ‐ of participant and operator/sedationist (performance bias), and outcome assessor (detection bias). If the authors stated that a study was double‐blinded then it was assumed that at least the patient and outcome assessor were blinded, </p> </li> <li> <p>incomplete outcome data (attrition bias),</p> </li> <li> <p>free of selective outcome reporting (reporting bias),</p> </li> <li> <p>free of other bias.</p> </li> </ul> </p> <p>For each domain the risk of bias was judged either low, unclear or high.</p> <p>We categorised the overall risk of bias of individual studies. Studies were categorised as being at low, high, or unclear risk of bias according to the following criteria: </p> <p> <ul id="CD003877-list-0008"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all domains were at low risk of bias; </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more domains were at high risk of bias; or </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more domains were at unclear risk of bias. </p> </li> </ul> </p> <p>We also presented the 'Risk of bias' summary graphically.</p> </section> <section id="CD003877-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous outcomes such as treatment completion were compared by calculating risk ratios along with 95% confidence intervals. Continuous outcomes (e.g. Frankl behaviour scale) were reported as mean and standard deviations in each group. </p> <p>In this review outcome measures were reported either using scales where a higher score is associated with desired behaviour, or scales where a higher score indicates greater anxiety (i.e. undesirable outcome). In order for outcomes to be comparable between studies, anxiety scores (as measured on the Venham scale) were transformed by subtracting the mean score per group from the maximum possible score of five (see <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Section 9.2.3.2 (<a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)). </p> </section> <section id="CD003877-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. Cross‐over trials were excluded because the level of baseline anxiety/behaviour in the second treatment phase is highly dependent on the success or otherwise of the first treatment period. </p> </section> <section id="CD003877-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>Only available data were analysed. We attempted to contact the author(s) of all included studies, where feasible, for clarification, and missing data. </p> </section> <section id="CD003877-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity in the results of the trials was assessed where appropriate by inspection of a graphical display of the results and by formal tests of heterogeneity (<a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD003877-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>If sufficient number of studies were included in a meta‐analysis, we would have assessed publication bias according to the recommendations on testing for funnel plot asymmetry (<a href="./references#CD003877-bbs2-0168" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>), as described in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If asymmetry were identified, we would have examined possible causes. </p> </section> <section id="CD003877-sec-0071"> <h4 class="title">Data synthesis</h4> <p>Where either dichotomous outcome variables or continuous outcome variables with means and standard deviations were available, these data were recorded. </p> <p> <ul id="CD003877-list-0009"> <li> <p>Completion of treatment (yes/no).</p> </li> <li> <p>Difference in behaviour between test and control groups.</p> </li> <li> <p>Difference in postoperative anxiety between test and control groups.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>Because the trials included in this review presented complex data with a range of different interventions being compared and different outcome measures, we separated studies into three groups: </p> <p> <ul id="CD003877-list-0010"> <li> <p>those comparing active treatment with a placebo;</p> </li> <li> <p>those comparing different doses of the same agent (or different routes of administration of the same agent); </p> </li> <li> <p>those which compare different agents head to head.</p> </li> </ul> </p> <p>Results of individual studies are presented in a narrative format and differences between interventions are reported as statistically significant if the trial reported P &lt; 0.05. Data from these three groups were summarised in Additional <a href="#CD003877-tbl-0004">Table 1</a>; <a href="#CD003877-tbl-0005">Table 2</a>; and <a href="#CD003877-tbl-0006">Table 3</a> respectively. There were few opportunities to combine data from similar trials for meta‐analysis, but where this was possible the data are presented in forest plots in Analyses 1 to 5 in the <a href="./references#CD003877-sec-0154" title="">Data and analyses</a> section. Data from trials evaluating active interventions compared to placebo, or the following four commonly used agents: chloral hydrate, ketamine, midazolam or nitrous oxide were presented. It was not possible nor did we attempt to combine these data by meta‐analysis. However, we decided that presenting data within forest plots would help the reader to understand the data. The following rules were used when compiling this information. </p> <div class="table" id="CD003877-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Placebo study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Group 1 (n = 15), mean age 3.6 years, 11 males, 4 females</p> <p>Group 2 (n = 15), mean age 3.3 years, 7 males, 8 females<br/> Group 3 (n = 15), mean age 3.8 years, 9 males, 6 females<br/> Group 4 (n = 15), mean age 3.9 years, 7 males, 8 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo<br/> Group 2: chloral hydrate (20 mg/kg)<br/> Group 3: chloral hydrate (40 mg/kg)<br/> Group 4: chloral hydrate (60 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour evaluations Completion of treatment</p> <p>Analysed using Chi<sup>2</sup> and Fisher's exact test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference (P &lt; 0.05) seen between placebo and 60 mg/kg chloral hydrate group for outcome of positive behaviour in operatory. No statistically significant differences between placebo and other groups </p> <p>Data reported as numbers and percentage per group, at different stages of the treatment and displayed in graphical form </p> <p>Adverse effects: not clear, 4 children failed to respond to obstruction (Group 4) after nitrous oxide/oxygen started </p> <p>Monitoring: cardiovascular and respiratory monitoring mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dexmedetomidine (intranasal)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD) kg: 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2<br/> Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and end of treatment‐baseline) (e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation) </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Diazepam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter (e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively)) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Melatonin</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1: n = 15, 4.87 (0.99), 7 males, 8 females, 18.87 (2.5)</p> <p>Group 2: n = 15, 4.93 (1.11), 7 males, 8 females, 17.87 (3.88)</p> <p>Group 3: n = 15, 4.93 (1.10), 8 males, 7 females, 18.6 (3.31)</p> <p>Group 4: n = 15, 5.01 (1.03), 9 males, 6 females, 19.73 (4.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: melatonin (3 mg)</p> <p>Group 2: melatonin (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: placebo</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed with Kruskal‐Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score significantly higher (i.e. more sedated) for Group 3 versus all other groups (P &lt; 0.05). Sedation significantly likely to be scored as satisfactory in Group 3 versus other groups (P &lt; 0.05). Data presented graphically. No sedations scored as unsatisfactory in Group 3 </p> <p>Adverse effects: vomiting, hiccupping and coughing seen in all groups, amnesia reported in Group 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Meperidine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60<br/> Mean age (SE) in months:<br/> Group 1: n = 15, 36.5 (2.7)<br/> Group 2: n = 15, 41.7 (3)<br/> Group 3: n = 15, 35.9 (2.7)<br/> Group 4: n = 15, 43 (2.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo<br/> Group 2: meperidine (0.25 mg/lb)<br/> Group 3: meperidine (0.50 mg/lb)<br/> Group 4: meperidine (1 mg/lb) </p> <p>All intramuscular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt<br/> Dichotomous Behavior Scale </p> <p>10‐point behaviour scale</p> <p>Global Rating Scale</p> <p>Analysed using Kruskal‐Wallis, multivariant analysis of covariance (MANCOVA) and Mann‐Whitney U test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global rating scale (good to excellent) significantly favoured meperidine compared to placebo. All doses of meperidine were significantly better than placebo (P &lt; 0.05) for values of global sedation scale. All 3 scales significantly contributed to overall MANCOVA. Global rating reported as individual frequencies </p> <p>Sleep mentioned</p> <p>Adverse effects: sleep/drowsiness (Groups 1 and 3), nausea/vomiting (Groups 3 and 4), hyperexcited (Group 3) </p> <p>Monitoring: precordial stethoscope, automatic sphygmomanometer, pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant from 0.25 mg/lb group and 1 from 0.5 mg/lb group became unmanageable and treatment was not completed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam (intravenous)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32<br/> Age range = 4 to 10 years<br/> 17 males and 15 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (7.5 mg) (regardless of weight)<br/> Group 2: placebo<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall sedation mental attitude<br/> Hypnotic effects<br/> Motor activity Ease of treatment<br/> Analysed using Wilcoxon rank </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam significantly better than placebo (P &lt; 0.001) in all categories. Data presented graphically </p> <p>Sleeping mentioned</p> <p>Adverse effects and monitoring: not mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1: n = 15, 4.87 (0.99), 7 males, 8 females, 18.87 (2.5)</p> <p>Group 2: n = 15, 4.93 (1.11), 7 males, 8 females,</p> <p>17.87 (3.88)</p> <p>Group 3: n = 15, 4.93 (1.10), 8 males, 7 females, 18.6 (3.31)</p> <p>Group 4: n = 15, 5.01 (1.03), 9 males, 6 females, 19.73 (4.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: melatonin (3 mg)</p> <p>Group 2: melatonin (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: placebo</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed with Kruskal‐Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score significantly higher (i.e. more sedated) for Group 3 versus all other groups (P &lt; 0.05). Sedation significantly likely to be scored as satisfactory in Group 3 versus other groups (P &lt; 0.05). Data presented graphically. No sedations scored as unsatisfactory in Group 3 </p> <p>Adverse effects: vomiting, hiccupping and coughing seen in all groups, amnesia reported in Group 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Age: younger than 4 years old ‐ no differences at baseline with regards to age, sex and body weight </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral/transmucosal)<br/> Group 2: placebo (same volume) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation score, treatment completion, time</p> <p>No statistical tests described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly better sedation in Group 1 (mean 3.75, SD 0.85) compared to Group 2 (mean 4.6, SD 0.5) (P &lt; 0.01). 18 completed Group 1 versus 7 Group 2 (P &lt; 0.01) </p> <p>Monitored with pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (SD) years: 3.99 (0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo</p> <p>Group 2: midazolam (0.25 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant improvement in overall behaviour in midazolam group compared to placebo group (5.1 versus 1.6, P &lt; 0.05) </p> <p>Adverse effects: none</p> <p>Monitoring: pulse oximeter, precordial stethoscope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 20 patients aborted treatment in placebo group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1: n = 11, 27.1 (8.3), 6 males, 5 females</p> <p>Group 2: n = 18 (parents refused treatment for 2), 27.7 (5.5), 9 males, 7 females</p> <p>Group 3: n = 15 (parents refused treatment for 1), 27.3 (6.4), 9 males, 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hours post‐operatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Group 1: n = 19</p> <p>Group 2: n = 21</p> <p>Mean age (range) in years all subjects: 7.3 (5‐10)</p> <p>Mean weight (range) in kg all subjects:</p> <p>22.9 (16‐32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo</p> <p>Group 2: midazolam (0.5 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsey</p> <p>Brietkopf and Buttner scale</p> <p>Frankl scale</p> <p>Houpt scale</p> <p>Analysed using 1‐way ANOVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scores significantly lower in placebo group for all outcomes (P &lt; 0.001)</p> <p>Adverse effects: 15 subjects reported amnesia ‐ all in the midazolam group</p> <p>Monitoring: blood pressure, pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam and ketamine (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD) kg: 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2 </p> <p>Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and end of treatment‐baseline) e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1: n = 11, 27.1 (8.3), 6 males, 5 females</p> <p>Group 2: n = 18 (parents refused treatment for 2), 27.7 (5.5), 9 males, 7 females</p> <p>Group 3: n = 15 (parents refused treatment for 1), 27.3 (6.4), 9 males, 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All Groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hours post‐operatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Nitrous oxide</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 35<br/> Age range = 48 to 72 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: no intervention</p> <p>Group 2: placebo</p> <p>inhalation</p> <p>Group 3: 20‐50:50 nitrous oxide/oxygen</p> <p>inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham<br/> Parental questionnaire<br/> Behavioral screening instrument </p> <p>Ratings of anxiety and behaviour analysed using 2‐way ANOVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly lower anxiety and behaviour ratings in nitrous oxide group (P &lt; 0.05). Data presented graphically </p> <p>Adverse effects: not mentioned Monitoring: precordial electrodes: heart rate using Epstein's measure of mean heart rate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 56<br/> Group 1: n = 27<br/> Group 2: n = 29<br/> Age range all subjects = 6 to 11 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: behaviour management</p> <p>Group 2: up to 40:60 nitrous oxide/oxygen</p> <p>All inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham scale</p> <p>Analysed using t‐test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Venham scores from T1 p177 transformed for forest plots</p> <p>Significantly better outcome (P &lt; 0.05) in nitrous oxide group (mean overall score Group 1 = 2.84, SD 0.80, Group 2 = 3.45, SD 0.92) </p> <p>Adverse effects and monitoring not mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ANOVA = analysis of variance; MANCOVA = multivariant analysis of covariance; n = number; SD = standard deviation; SE = standard error. </p> </div> </div> <div class="table" id="CD003877-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosage study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Hydroxyzine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30</p> <p>14 females, 16 males</p> <p>Mean age (SD) months:</p> <p>Group 1</p> <p>61.9 (11.9)</p> <p>Group 2</p> <p>53.7 (12.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (20 mg 24 hours before) + hydroxyzine (3.7 mg/kg at the appointment)</p> <p>Group 2: hydroxyzine (3.7 mg/kg at the appointment)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using ANOVA and Mann‐Whitney</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences at any time point. At 20 minutes Houpt Group 1, 5.2 (SD 1.5) and Group 2, 4.6 (SD 1.6) </p> <p>No adverse effects reported in either group</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (intranasal)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 children<br/> Mean age (SD) in years and gender:<br/> Group 1 (n = 12)<br/> 3.75 (0.75), 6 males, 6 females<br/> Group 2 (n = 13)<br/> 4.3 (0.65), 6 males, 7 females<br/> Group 3 (n = 13)<br/> 4 (0.71), 6 males, 7 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.3 mg/kg)<br/> Group 2: midazolam (0.4 mg/kg)<br/> Group 3: midazolam (0.5 mg/kg)<br/> All intranasal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Tukey's range test and non‐parametric 2‐factor ANOVA</p> <p>Duration of sedation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in Houpt behavioural scores between Group 3 and Group 1 (P &lt; 0.0001) and between Group 3 and Group 2 (P &lt; 0.01) </p> <p>No difference in outcomes between fasting and no‐fasting in each group (P = 0.8286)</p> <p>None of the children were asleep</p> <p>Adverse effects: sneezing and coughing during administration and drowsiness (Groups 1 and 2), diplopia (only in Group 3) </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79% 0.3 mg/kg, 96% 0.4 mg/kg and 100% 0.5 mg/kg completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 23 (12 Group 1, 11 Group 2)</p> <p>Mean age (range) in years: 5.13 (2‐9)</p> <p>Mean weight (range) in kg: 21.74 (12‐30)</p> <p>15 males, 7 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intramuscular)</p> <p>Group 2: midazolam (0.2 mg/kg) (intranasal)</p> <p>All used as premed for unspecified intravenous sedation drug</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Mann‐Whitney. Inter‐examiner variability assessed using Spearmans rank correlation </p> <p>Good/excellent sedation levels in each group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients more deeply sedated in Group 1 at time of local anaesthesia administration and venepuncture (P &lt; 0.048, P &lt; 0.015 respectively). 1 observer found Group 1 (intramuscular) significantly more effective than Group 2 (P &lt; 0.04). Not significant for the second observer (P = 0.056). Individual outcomes for each observer not reported </p> <p>Good/excellent sedation 12/12 (100%) in intramuscular group and 6/11 (54%) in the intranasal group </p> <p>Children more likely to be drowsy in Group 1</p> <p>Adverse effects: none reported</p> <p>Monitoring: heart rate, respiratory rate, blood pressure, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completed by all participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (unclear, possibly SD) in months; mean weight (unclear, possibly SD) in kg; gender: </p> <p>Group 1 (n = 20) 40.8 (11), 17 (3.6), 11 males, 9 females</p> <p>Group 2 (n = 20) 38.5 (9.8), 16.2 (4), 10 males, 10 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.7 mg/kg) (oral)</p> <p>Group 2: midazolam (0.3 mg/kg) (nasal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt ‐ domains of sleep movement and crying but no overall measure. Analysed with ANOVA, Chi<sup>2</sup> statistic and t‐test </p> <p>Mean time of onset and mean working time in each group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented on graphs only and text states no significant differences in Houpt using multivariate ANOVA (P = 0.749) </p> <p>Onset of sedation mean 5.55 minutes (SD 2.2) for nasal and mean 15.5 minutes (SD 5) for oral (P &lt; 0.001) </p> <p>Mean working time was 29.3 minutes (SD 11.6) for nasal and &amp; 38.1 min (SD 7.58) for PO (P = 0.007) </p> <p>Adverse effects: none reported, no differences between groups.</p> <p>Monitoring: oxygen saturation, heart rate, respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Group 1: 11 males, 9 females, mean age (SD) in years 3.4 (0.6), mean weight (SD) in kg 12.2 (1.2) </p> <p>Group 2: 8 males, 12 females, mean age (SD) in years 3.5 (0.7), mean weight (SD) in kg 12.6 (1.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intramuscular)</p> <p>Group 2: midazolam (0.2 mg/kg) (intranasal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt and Fukuta. Analysed using Chi<sup>2</sup> statistic and Mann‐Whitney U test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in behaviour between groups (Chi<sup>2</sup> = 0.37, P = 0.83), but both groups showed improvement from baseline. Intranasal midazolam was significantly faster acting at all time points and allowed a shorter treatment time overall (P &lt; 0.001) </p> <p>Mean onset times 15.7 ± 2.0 minutes intramuscular versus 10.8 ± 2.0 minutes intranasal</p> <p>Adverse effects: 2 patients in the intramuscular group and 6 patients in the intranasal group showed instances of sneezing/coughing/hiccups after the administration of the sedative (difference not statistically significant) </p> <p>No fasting pretreatment and no vomiting in either group</p> <p>Monitoring: heart rate, respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Score 3 given to excellent, 2 to satisfactory, 1 to unsatisfactory</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 20</p> <p>Age range = 4‐7 years</p> <p>Group 1 (n = 10)</p> <p>Group 2 (n = 10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intranasal)</p> <p>Group 2: midazolam (0.2 mg/kg) (sublingual)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham's Clinical Anxiety Scale</p> <p>Salivary cortisol level</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant decrease in anxiety in Group 1 (P = 0.004) and Group 2 (P = 0.0.003) 20 minutes after drug administration </p> <p>Group 1 showed statistically significant decrease in anxiety at each of the 4 points of measurement during operative procedure (T1, T2, T3, T4), whereas Group 2 did not show statistically significant change at T1, T2 and T3 </p> <p>No significant difference in salivary cortisol levels before and after drug administration in Group 1 and Group 2 (P = 0.07, P = 0.38 respectively) </p> <p>No significant correlation between decrease in clinical anxiety and salivary cortisol level in Group 1 and Group 2 (P = 0.554, P = 0.457 respectively) </p> <p>Adverse effects: not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (SD) in years, gender, weight (SD) in kg:</p> <p>Group A: 5.1 (1.07), 12 males and 8 females, 17.5 (4.39)</p> <p>Group B: 5.2 (1.15), 12 males and 8 females, 17.4 (4.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group A: midazolam (0.2 mg/kg) (intranasal)</p> <p>Group B: midazolam (0.2 mg/kg) (sublingual)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham's Clinical Anxiety Scale</p> <p>Acceptance (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference in Venham's anxiety score between groups at baseline or at the end time point (T4) </p> <p>Mean (SD) Venham's score at T4 in Group A 0.35 (0.59) and Group B 0.45 (1.10) P = 0.001 </p> <p>Statistically significant difference in acceptance with better acceptance in Group B compared to Group A (95% versus 40%, P = 0.001) </p> <p>Adverse effects not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 50</p> <p>Mean age (unclear, possibly SD) in years; mean weight (unclear, possibly SD) in kg; gender: </p> <p>Group 1 (n = 25), 5.36 (1.7), 19.068 (3.43), 18 males and 7 females</p> <p>Group 2 (n = 25), 4.96 (1.513), 17.804 (3.08), 12 males and 13 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral)</p> <p>Group 2: midazolam (0.35 mg/kg) (rectal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score, acceptance of application, acceptance of local anaesthesia, operating conditions, state of amnesia </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acceptance of application significantly better in oral group (72% excellent in oral group compared to 20% excellent in rectal group, P &lt; 0.05) </p> <p>No significant difference seen (P &gt; 0.05) between acceptance of local anaesthesia, state of amnesia or operating conditions. Ramsay's Sedation Scores not reported </p> <p>Adverse effects: no significant difference (P &gt; 0.05) in adverse effects between groups (56% oral, 44% rectal, included hypoxaemia, vomiting and nausea, disinhibition) </p> <p>Monitoring: oxygen saturation, heart rate, blood pressure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completed by all participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1 (n = 14), 4.6 (1.2), 7 males and 7 females, 15.6 (2.8)</p> <p>Group 2 (n = 13), 4.4 (1.0), 8 males and 5 females, 16.2 (2.4)</p> <p>Group 3 (n = 13), 4.4 (0.9), 6 males and 7 females, 16.1 (2.4)</p> <p>Group 4 (n = 13), 4.3 (0.9), 5 males and 8 females, 15.8 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg)</p> <p>Group 2: midazolam (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: midazolam (1 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed using Kruskal‐Wallis, Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At the 20 minute time point, mean Ramsay Sedation Score was 1.2 (0.4), 1.6 (0.5), 2.2 (0.6), 2.7 (1.0) in Groups 1‐4 respectively. Children in Groups 3 and 4 were more sedated than children in Groups 1 and 2 (P &lt; 0.05) </p> <p>Sedation considered inadequate in 12/14, 5/13, 3/13 and 5/13 in Groups 1‐4 respectively</p> <p>Mean recovery time was 45 (0), 45 (0), 47.3 (8.3), and 57.7 (42.8) minutes in Groups 1‐4 respectively </p> <p>Adverse effects: most of the adverse effects were seen in Group 4 with 1 patient desaturating and 3 presenting with delayed recovery, no adverse effects in Group 1 and "very few" in Groups 2 and 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90 (30 per group)</p> <p>Age range = 3‐10 years</p> <p>Mean age (SD) in years, weight (SD) in kg:</p> <p>Group 1: 5.6 + 1.85 years, 19.2 + 3.68 kg</p> <p>Group 2: 5.6 + 1.67 years, 19.7 + 3.38 kg</p> <p>Group 3: 6.2 + 2.00 years, 20.3 + 3.65 kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)</p> <p>Group 2: midazolam (0.75 mg/kg)</p> <p>Group 3: midazolam (1 mg/kg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wisconsin Sedation Scale</p> <p>Houpt behavioural rating scale</p> <p>Parent satisfaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation and behaviour co‐operation scores were noted at baseline, 15 minutes, 30 minutes and 45 minutes. Significant difference with sedation scores in Group 1 lower than Group 2 and Group 3 (P &lt; 0.001) </p> <p>No significant difference (P &lt; 0.001) in sedation score of Group 2 and Group 3 except at baseline </p> <p>Behavioural co‐operation score was significantly lower (P &lt; 0.001) in Group 1 compared to Group 2 and Group 3. Significant difference (P &lt; 0.001) in behaviour scores of Group 2 and Group 3 with Group 2 having lower scores at baseline and 45 minutes </p> <p>Significant difference (P = 0.025) in completion scores between Group 1 and Group 3 </p> <p>No significant difference (P = 0.43) in duration between the groups</p> <p>Significant difference in discharge time between the groups. Group 1 had shorter mean inpatient stay (85 minutes + 18.5, P &lt; 0.001) compared to Group 2 (103.7 + 13.3 minutes) and Group 3 (137 + 14.7 minutes) </p> <p>Significant difference in parent satisfaction (P &lt; 0.001) where Group 1 is lower than Group 2 and Group 3. No significant difference (P = 0.147) between Group 2 and Group 3 </p> <p>Adverse effects: respiratory events Group 2 (3/30), Group 3 (10/30)</p> <p>Nausea and drowsiness Group 1 (3/30), Group 2 (7/30), Group 3 (12/30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 20% (n = 6), Group 2 6.7% (n = 2) did not complete treatment</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ANOVA = analysis of variance; n = number; SD = standard deviation.</p> </div> </div> <div class="table" id="CD003877-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drug comparison study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate/hydroxyzine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (SD) in months and gender:<br/> Group 1 (n = 20), 27.7 (2.9), 13 males and 7 females<br/> Group 2 (n = 20), 29.2 (3.6), 14 males and 6 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (70 mg/kg)<br/> Group 2: chloral hydrate (70 mg/kg) + hydroxyzine (2 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Kruskal‐Wallis and Mann‐Whitney U tests</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P &gt; 0.05) for overall behaviour evaluation (mean values reported at 7 different time intervals e.g. at injection mean behaviour Group 1 = 4.9 (SD 1.1), Group 2 = 5.0 (SD 0.68) </p> <p>Crying and movement evaluations significantly better (P &lt; 0.05) at 45‐60 minutes after application of rubber dam for Group 1 </p> <p>Sleep mentioned</p> <p>Adverse effects: Group 1 15%‐30% children has oxygen saturation &lt; 90% but in Group 2 range was 10%‐45% </p> <p>Monitoring: precordial stethoscope, pulse oximeter and sphygmomanometer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (age range) in months:<br/> Group 1 (n = 20), 44 (21 to 74)<br/> Group 2 (n = 20), 42 (23 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate<br/> (40 mg/kg) + hydroxyzine (25 mg)<br/> Group 2: triazolam (0.02 mg/kg) </p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using ANOVA and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences between groups (mean overall behaviour Group 1 and Group 2 the same with a value of 4.3 (SE 0.4354) </p> <p>Sleeping mentioned</p> <p>Adverse effects: vomiting (1 child in Group 1)</p> <p>Monitoring: pulse oximeter and precordial stethoscope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30<br/> Mean age in months:<br/> Group 1 (n = 10), 39.6<br/> Group 2 (n = 10), 42<br/> Group 3 (n = 10), 38.4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) (oral)<br/> Group 2: chloral hydrate (50 mg/kg) (rectal)<br/> Group 3: chloral hydrate (30 mg/kg) + hydroxyzine (25 mg) (oral) </p> <p>All received nitrous oxide inhalation 30%‐50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Barker<br/> Overall quality sedation </p> <p>Behavioural data not statistically analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good or excellent sedation achieved in 4/10, 7/10 and 7/10 of children in oral chloral hydrate, rectal chloral hydrate and oral chloral hydrate/hydroxyzine groups respectively </p> <p>Adverse effects: not mentioned</p> <p>Monitoring: precordial stethoscope and pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 31</p> <p>Mean age in months (SD), gender, mean weight in kg (SD):</p> <p>CH Group 44.5 (14.1), 6 males and 9 females, 15.6 (2.7)</p> <p>CH‐M Group 34.3 (9.3), 11 males and 5 females, 15.1 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CH Group: chloral hydrate (60 mg/kg) + hydroxyzine (1 mg/kg) (both oral)</p> <p>CH‐M Group: chloral hydrate (60 mg/kg oral) + hydroxyzine (1 mg/kg oral) + midazolam (0.1 mg/kg submucosal) </p> <p>All received nitrous oxide inhalation 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Requirement for restraint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects in the CH‐M Group showed better overall behaviour as measured by Houpt. Mean score 0.47 (SD 0.5) in CH Group versus 0.81 (0.39) in CH‐M Group, P = 0.004 </p> <p>Less restraint was required in the CH‐M Group (P &lt; 0.05)</p> <p>Adverse effects: not reported</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (age range) in months, gender:<br/> Group 1 (n = 20), 48 (32 to 73), 11 males and 9 females<br/> Group 2 (n = 20), 42 (27 to 70), 10 males and 10 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) +<br/> hydroxyzine (25 mg)<br/> Group 2: midazolam (0.5 mg/kg) + acetaminophen (10 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Wilcoxon matched pairs test and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects in chloral hydrate/hydroxyzine group were in a significantly deeper sleep (P &lt; 0.05). Data presented graphically. Sleeping mentioned </p> <p>Adverse effects: not reported</p> <p>Monitoring: pulse oximeter, precordial stethoscope and capnograph</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant from chloral hydrate/hydroxyzine group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 54</p> <p>Mean age (age range) in years; mean weight (range) in kg; gender:</p> <p>Group 1: 3.9 (4‐6), 11 males, 7 females, 18.1 (0.9‐22)</p> <p>Group 2: 2.83 (1‐8), 11 males, 7 females, 15 (10.4‐22.5)</p> <p>Group 3: 2.94 (1‐10), 10 males, 8 females,</p> <p>16.33 (10.4‐20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (2 mg/kg 2 hours before, 1 mg/kg 20 minutes before)</p> <p>Group 2: midazolam (0.5 mg/kg) + hydroxyzine (1.5 mg/kg)</p> <p>Group 3: chloral hydrate (50 mg/kg) + hydroxyzine (1.5 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State Behavioral Rating Scale</p> <p>Analysed using Wilcoxon matched pairs test and Kruskal Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Significantly quieter" (mean cardiac rate 152, 146 and 137 in Group 1, Group 2 and Group 3 respectively (no P value given). Data presented graphically suggesting less movement in Group 3 </p> <p>Adverse effects: in Group 3 1/18 experienced oxygen saturation &lt; 90%</p> <p>Monitoring: oxygen saturation and cardiac rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate/promethazine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 24<br/> Mean age (SD) in months:<br/> Group 1 (n = 13), 31.0 (8.6)<br/> Group 2 (n = 11), 35.8 (10.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) + promethazine (1 mg/kg)<br/> Group 2: meperidine (1 mg/kg) + promethazine (1 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Hotelings T test and 2‐sample t‐test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloral hydrate/promethazine group significantly "better" (P &lt; 0.05) for overall evaluation at 4 of the 10 measured time intervals (e.g. mean overall behaviour 15 minutes post‐injection Group 1 = 5.2 (SD 1.1), Group 2 = 4.4 (SD 1.3), P &lt; 0.05) </p> <p>Adverse effects: not reported</p> <p>Significantly more sleep in Group 1 than Group 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment and mean treatment duration was 50.8 (SD 13.3) and 50.9 (SD 17.6) in Groups 1 and 2 respectively </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dexmedetomidine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD): 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2 </p> <p>Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and, end of treatment‐baseline) e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 84</p> <p>Age range in years, mean age (SD) in years:</p> <p>Group 1 (n = 21) 7.34 (2.34)</p> <p>Group 2 (n = 21) 6.71 (2.31)</p> <p>Group 3 (n = 21) 7.76 (2.26)</p> <p>Group 4 (n = 21) 7.24 (2.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: dexmedetomidine (1 µg/kg)</p> <p>Group 2: dexmedetomidine (1.5 µg/kg)</p> <p>Group 3: midazolam (0.2 mg/kg)</p> <p>Group 4: ketamine (5 mg/kg)</p> <p>All intranasal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified AAPD Sedation Record</p> <p>Face, Legs, Activity, Cry and Consolability (FLACC) scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P = 0.378) in overall behaviour was observed</p> <p>No significant difference (P = 0.242 and P = 0.120) in overall success rate of treatment and distribution of sedation levels between the groups </p> <p>Significant difference (P &gt; 0.05) in intra and postoperative analgesic effects reported with Group 1, Group 2 and Group 4 significantly better than Group 3 e.g. intraoperative analgesia score Group 3 = 5.62 (SD 1.12) compared to Group 1 = 3.81 (0.81), Group 2 = 3.67 (0.91) and Group 4 = 3.52 (0.68) </p> <p>Significant difference (P &gt; 0.05) in onset time, recovery time, pulse rate and systolic blood pressure of Group 1 and Group 2 compared to Group 3 and Group 4 was observed </p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ketamine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (10 per group with sufentanil divided into 2 subgroups of 5 each)<br/> Age range = 17 to 62 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (3 mg/kg)<br/> Group 2: midazolam (0.4 mg/kg)<br/> Group 3: sufentanil (1 µg) </p> <p>Group 4: sufentanil (1.5 µg)<br/> All intranasal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation scoring criteria</p> <p>No statistical tests used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groups 1 to 3 had mean sedation score of 4 (acceptable sedation), Group 4 had mean sedation score of 7 (heavy sedation) </p> <p>Mean recovery times (± SD) were 7 (± 7), 3 (± 2), 7 (± 13), and 58 (± 40) minutes for Groups 1‐4 respectively </p> <p>Sleeping mentioned</p> <p>Adverse effects: drowsiness (Group 1), mild obtundation and deep sedation (Group 3), desaturations in 4/5 children on high dose sufentanil </p> <p>Monitoring: pulse oximeter, automatic blood pressure and if necessary capnograph</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (10 per group)</p> <p>Age range 3‐6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.1 mg/kg) (bolus) + 0.004 mg/kg/min (infusion)</p> <p>Group 2: propofol (1 mg/kg) (bolus) + 0.06 mg/kg/min (infusion)</p> <p>Group 3: ketamine (0.5 mg/kg) (bolus) + 0.01 mg/kg/min (infusion)</p> <p>All intravenous</p> <p>All children had premedication 1 hour before of 0.5 mg/kg midazolam and atropine (0.6 mg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed Kruskal Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The maximum level of co‐operation was seen with ketamine then propofol and then midazolam (P &lt; 0.001) </p> <p>At treatment end mean scores were 5.8 ± 0.42, 3.5 ± 1.08 and 3.2 ± 0.42 in ketamine, propofol and midazolam groups respectively </p> <p>Propofol showed the fastest postoperative recovery score followed by ketamine and the midazolam. Sleeping was reported </p> <p>Adverse effects: pain on injection with propofol and intermittent cough</p> <p>Monitoring: vital signs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 100<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 50), 4.3 (1), 24 males and 26 females<br/> Group 2 (n = 50), 4.3 (1.1), 22 males and 28 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (5 mg/kg) + midazolam (0.35 mg/kg)<br/> Group 2: midazolam (1 mg/kg)<br/> All rectal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score<br/> Movement<br/> Crying </p> <p>Overall sedation and behaviour</p> <p>Analysed using McNewman's test (sic), Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant differences in level of sedation with 71% subjects in Group 2 "orientated and calm" compared to 14% in Group 1 30 minutes after administration </p> <p>Significantly less movement and crying (P &lt; 0.05) in Group 1 (58% no movement at all compared to 14% in Group 2) </p> <p>Sleep mentioned</p> <p>Adverse effects: hallucination (Groups 1 (14%) and 2 (42%)), nausea (Group 1)</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant (ketamine/midazolam group)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 30), 4.8 (1.3), 14 males and 16 females<br/> Group 2 (n = 30), 4.9 (1.3), 16 males and 14 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: 0.5 ml/kg of trimeprazine 6 mg/ml + physeptone (methadone) (0.4 mg/ml) + droperidol (0.1 mg/kg)<br/> Group 2: ketamine (12.5 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety<br/> Level of sedation<br/> Movement<br/> Crying<br/> Overall behaviour Analysed using McNemar test, Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation was significantly "better" (very good/excellent 80% and 93% of Group 1 and Group 2 respectively) </p> <p>Overall evaluation good/very good in 67% and 90% of Group 1 and Group 2 respectively</p> <p>Sleeping mentioned</p> <p>Adverse effects: hallucination (9 and 5), restless/irritation 4 and 1, in Group 1 and Group 2 </p> <p>Ketamine also 2 vomiting/nausea, 4 visual disturbances and 4 excess salivation</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 100<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 50), 4.1 (1.3), 27 males and 23 females<br/> Group 2 (n = 50), 4 (1.2), 29 males and 21 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (5 mg/kg) + midazolam (0.35 mg/kg)<br/> Group 2: trimeprazine (3 mg/kg) + methadone (0.2 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt, Ramsay Sedation Score</p> <p>Analysed using McNemar's test, Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant differences (P &lt; 0.05) in level of sedation immediately before treatment with 46% participants in Group 1 "oriented and calm" compared to 84% in Group 2 </p> <p>Overall surgeons rated 94% versus 78% of sedations as good/very good in Group 1 versus Group 2 </p> <p>Sedation rated as poor in significantly more children in Group 2 (24%) than Group 1 (6%) </p> <p>Sleeping mentioned</p> <p>Adverse effects: vomiting (n = 2) and hallucination (n = 10) in Group 1</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 112</p> <p>Age range = 1‐10 years</p> <p>Mean age (SD) in years, gender and weight (SD) in kg:</p> <p>Group 1 (n = 28), 6.54 (1.79), 14 males and 14 females, 18.89 (4.33)</p> <p>Group 2 (n = 28), 6.93 (2.05), 13 males and 15 females, 17.04 (5.33)</p> <p>Group 3 (n = 28), 7.21 (1.98), 11 males and 17 females, 16.93 (4.22)</p> <p>Group 4 (n = 28), 6.82 (2.22), 14 males and 14 females, 16.61 (4.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (8 mg/kg<sup>‐1</sup>) </p> <p>Group 2: dexmedetomidine (3 µg/kg<sup>‐1</sup>) </p> <p>Group 3: dexmedetomidine (4 µg/kg<sup>‐1</sup>) </p> <p>Group 4: dexmedetomidine (5 µg/kg<sup>‐1</sup>) </p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset time, recovery time</p> <p>Sedation rating scale modified from AAPD guidelines</p> <p>Face, Legs, Activity, Cry and Consolability Pain Scale (FLACC)</p> <p>Anterograde amnesia</p> <p>Behaviour score</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 4 had highest "adequate" depth of sedation and "satisfactory" completion of treatment (82.1%, 85.7% respectively), but was not significantly different to Group 1, Group 2 and Group 3 </p> <p>Significant difference (P &lt; 0.001) in lowering of pulse rate and systolic blood pressure in Group 2, Group 3 and Group 4 compared to Group 1 </p> <p>Significant difference (P &lt; 0.001) in onset time, recovery time (except Group 1 and Group 4), intra and postoperative pain scores when comparing the groups e.g. postoperative pain score in Group 1 = 1.54 (0.63) and Group 4 = 1.79 (0.74) were lower compared to Group 2 = 2.43 (0.88) and Group 3 = 2.11 (1.19) </p> <p>Adverse effects: in office vomiting (Group 1 n = 5, Group 4 n = 1), emergency reaction (Group 1 n = 2) </p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (SD) in months:<br/> Group 1 (n = 20) 40.4 (10.2)<br/> Group 2 (n = 20) 37.5 (10.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (6 mg/kg)<br/> Group 2: meperidine (2.0 mg/kg) + promethazine (0.5 mg/kg)<br/> All oral </p> <p>All received nitrous oxide 30%‐50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Good sedation" in 65% of ketamine group and 45% of meperidine/promethazine</p> <p>Overall no statistically significant difference in distribution of sedation outcomes between groups (P = 0.07) </p> <p>Sedation onset time and recovery time both shorter for ketamine (P &lt; 0.001 and P = 0.08 respectively) </p> <p>Adverse effects: vomiting (Groups 1 (n = 8) and 2 (n = 1))</p> <p>Monitoring: precordial stethoscope and pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 4 children receiving meperidine and none in ketamine group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 22<br/> Mean age (SD) in months:<br/> Group 1 (n = 11) 34 (6.28)<br/> Group 2 (n = 11) 33 (6.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (10 mg/kg) + promethazine (1.1 mg/kg)<br/> Group 2: ketamine (10 mg/kg)<br/> All oral </p> <p>All received nitrous oxide 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in mean Houpt score favouring ketamine group (mean score 4.27, SD 0.5) (Group 1 (mean score 3.12, SD 0.29)) (P &lt; 0.05) </p> <p>Adverse effects: 3 patients from Group 2 vomited. Most of the patients reported as being drowsy or asleep after 25 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant from Group 1 due to violent physical movement and crying </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Ketamine/midazolam versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (25% median to 75%) in kg:</p> <p>Group 1 (n = 13), 4.7 (0.6), 10 males, 3 females, 16.5 (15.7‐19.6)</p> <p>Group 2 (n = 14), 5.2 (0.8), 8 males, 6 females, 19.6 (16.7‐23.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg) (oral)</p> <p>Group 2: midazolam (0.5 mg/kg) (oral) + ketamine (3 mg/kg) (oral) + sevoflurane (0.1%‐0.4% inhalation) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> <p>Adverse events</p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference in overall Houpt score between the 2 groups (P &gt; 0.05 data presented graphically) </p> <p>Adverse events: more children in Group 1 reported adverse events at 24 hours than Group 2 (Group 1 n = 10, Group 2 n = 4; P = 0.01) </p> <p>Adverse events seen in all children included: excessive drowsiness 22% (n = 6), vomiting 22% (n = 6) </p> <p>No apnoea /drop in oxygen saturation seen</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment not completed in 1 child from Group 1 due to poor co‐operation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Mean age (unclear, possibly SD) in years, mean weight (unclear, possibly SD) in kg, gender: </p> <p>Group 1 (n = 15), 5.33 (0.62), 18.93 (2.31), 10 males and 5 females</p> <p>Group 2 (n = 15), 5.27 (0.80), 19.07 (3.62), 11 males and 4 females</p> <p>Group 3 (n = 15), 5.20 (0.41), 18.20 (2.34), 9 males and 6 females</p> <p>Group 4 (n = 15), 5.53 (0.99), 20.01 (3.99), 6 males and 9 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (1 mg/kg) (oral)</p> <p>Group 2: midazolam (0.7 mg/kg)</p> <p>Group 3: ketamine (3 mg/kg) + midazolam (0.25 mg/kg)</p> <p>Group 4: no oral premedication</p> <p>40% nitrous oxide oxygen was administered to all participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score, Bispectral Index System</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Scores (RSS) were significantly greater in Group 2 compared to Groups 1, 3 and 4 (P &lt; 0.05) </p> <p>RSS satisfactory/mid‐level satisfactory/unsatisfactory<br/> was as follows: </p> <p>Group 1: 13.3%/53.3%/33.3%</p> <p>Group 2: 54%/20%/26%<br/> Group 3: 33.3%/33.3%/33.3% </p> <p>Group 4: 6.7%/60%/33.3%</p> <p>P value or significance not reported</p> <p>Adverse effects: nausea/vomiting (n = 1/2/3/4), cough (4/4//), hiccough (/1//5), enuresis (/2//), bronchospasm (/1//), hypersalivation (//8/), otalgia (///2), hallucination (//2/), and epistaxis (///1) in patients in groups 1, 2, 3, and 4, respectively </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Figure 5 used to extrapolate data with score 3 given to satisfactory, 2 middle level, 1 unsatisfactory </p> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Age range = 3‐9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)</p> <p>Group 2: tramadol (2 mg/kg)</p> <p>Group 3: triclofos (70 mg/kg)<br/> Group 4: zolpidem (0.4 mg/kg) </p> <p>All oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation rating scale</p> <p>Ease of treatment completion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) in the level of sedation (median scores) with Group 4 &gt; Group 3 &gt; Group 2 = Group 1 </p> <p>Mean score in the ease of treatment shown in the table of results reports Group 4 &gt; Group 3 &gt; Group 2 &gt; Group 1 </p> <p>No statistical difference between (P &gt; 0.05) between Group 1, Group 2, Group 3 in ease of treatment. Group 4 was found to have a statistical difference compared to the other groups (P &lt; 0.001) </p> <p>Adverse effects: not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1 (n = 11), 27.1 (8.3), 6 males and 5 females</p> <p>Group 2 (n = 18, parents refused treatment for 2), 27.7 (5.5), 9 males and 7 females</p> <p>Group 3 (n = 15, parents refused treatment for 1), 27.3 (6.4), 9 males and 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All Groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hour postoperatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 120 (20 per group)</p> <p>Age range: 2‐9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (9.5 mg/kg)</p> <p>Group 2: ketamine (5 mg/kg)</p> <p>Group 3: zolpidem (0.4 mg/kg)</p> <p>Group 4: midazolam (0.4 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 5: midazolam (0.5 mg/kg) + tramadol (2 mg/kg)</p> <p>Group 6: zolpidem (0.4 mg/kg) + tramadol (2 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of action</p> <p>Level of sedation</p> <p>Ease of treatment completion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 4 and 5 the "best" and Groups 3 and 6 the "worst" when compared on level of sedation (P &lt; 0.001) </p> <p>Group 4 had the shortest time of onset of sedation</p> <p>(Data presented graphically)</p> <p>No adverse effects were reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90 (30 per group)<br/> Age range: 3‐9 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)<br/> Group 2: triclofos (70 mg/kg)<br/> Group 3: promethazine (1.2 mg/kg)<br/> All oral </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of sedation</p> <p>Time of onset, time of recovery</p> <p>Statistical techniques not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transformed sedative scores</p> <p>Group 1: 3.3 ± 0.7 (best)</p> <p>Group 2: 3.07 ± 0.6</p> <p>Group 3: 2.73 ± 0.5</p> <p>Both Groups 1 and 2 were statistically significantly better than Group 3 (P &lt; 0.05)</p> <p>Time of onset and time of recovery were both shortest in Group 1</p> <p>Adverse effects: not mentioned</p> <p>Monitoring: blood pressure, heart and respiratory rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 240 (n = 60 per group)</p> <p>Mean age (SD) in months 57.02 (9.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.20 mg/kg (40 mg/ml)) (intranasally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 2: midazolam (0.75 mg/kg (15 mg/3 ml)) (orally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 3: midazolam (0.50 mg/kg (15 mg/3 ml)) (orally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 4: inhalation sedation 50%–50% nitrous oxide/oxygen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bispectral Index System (BIS)</p> <p>Modified scale to classify behaviour</p> <p>Vancouver Recovery Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified scale used to classify behaviour/ respond to treatment/sedation was highest in Group 1 (87%) followed by Group 2 (79%), Group 3 (72%) and Group 4 (55%) respectively </p> <p>No significant difference (P = 0.230 and P = 0.399) in overall success rate between Group 1 and Group 2, Group 2 and Group 3 respectively. Significant difference (P &lt; 0.05) between Group 1 and Group 3. Significant difference Group 4 compared to all other groups </p> <p>BIS values recorded every 5 minutes, Group 2 was most sedated except for at 30 minutes. From 15 minutes to end of treatment all groups had BIS value above 90 </p> <p>Recovery time in minutes was shorter for intranasal midazolam (22.3) compared to 0.50 mg/kg oral midazolam (27.5) and 0.75 mg/kg oral midazolam (29.2) </p> <p>Sleep mentioned</p> <p>Adverse effects:</p> <p>‐ drug administration: vomiting in oral midazolam group (4), nose bleeding intranasal midazolam group (1), transient burning and discomfort nasal midazolam group (not reported) </p> <p>‐ recovery period: vomiting in oral midazolam group (7), coughing in intranasal midazolam group (1), transient burning and discomfort nasal midazolam group (not reported) </p> <p>‐ after discharge: irritability (42%), crying (34%), sleepiness (31%), nausea (5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral)</p> <p>Group 2: diazepam (0.5 mg/kg) (oral)</p> <p>Group 3: midazolam (0.06 mg/kg) (intravenous)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes postdrug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour postsedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam (intravenous) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38</p> <p>Age range = 4‐9 years</p> <p>Gender, mean age in years:</p> <p>Group 1 (n = 18), 8 males and 10 females, 6.27</p> <p>Group 2 (n = 20), 12 males and 8 females, 6.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.05 mg/kg) + ketamine (0.5 mg/kg)<br/> Group 2: midazolam (0.05 mg/kg) + fentanyl (0.5 µg/kg) </p> <p>All intravenous, administered by an anaesthesiologist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental Sedation Teacher Groups System</p> <p>Frankl behaviour rating scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P &gt; 0.05) in intraoperative sedation score and score of operative conditions at 10<sup>th</sup>, 20<sup>th,</sup> 30<sup>th</sup> and 40<sup>th</sup> minute </p> <p>Significant difference (P &lt; 0.05) in the sedation score and score of operating condition in Group 1 and Group 2 at 10‐20 minutes, 10‐30 minutes </p> <p>Adverse effects: not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32</p> <p>Age range = 3‐7 years</p> <p>Mean age (SD) in years: 4.36 (1.6)</p> <p>Group 1 (n = 16), 7 males and 9 females</p> <p>Group 2 (n = 16), 8 males and 8 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: remifentanil (0.1 µg/kg/min) + midazolam (0.01 mg/kg) + propofol (0.5 mg/kg)</p> <p>Group 2: ketamine (0.5 mg/kg) + midazolam (0.1 mg/kg) + propofol (0.5 mg/kg)</p> <p>All intravenous</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bispectral Index System (BIS)</p> <p>DSTG scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.003) with higher BIS values in Group 1 compared to Group 2 </p> <p>DSTG score noted at 9 different time intervals was 5 (eyes closed, no response to mild physical stimulus) in Group 1 and Group 2 </p> <p>Heart rate and respiratory rate showed no significant difference between Group 1 and Group 2 (P = 0.884, P = 0.775 respectively) </p> <p>Significant difference (P &lt; 0.001) with Group 1 having quicker recovery compared to Group 2 ( 9.23 + 2.77, 30.83 + 5.96 minutes) </p> <p>Adverse effects: severe nausea and vomiting was reported in Group 1, number not reported</p> <p>Monitoring: heart rate, respiratory rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (rectal) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90<br/> Median age (age range) in months and gender:<br/> Group 1 (n = 45), 32 (18 to 44), 23 males and 22 females<br/> Group 2 (n = 45),<br/> 29 (15 to 44), 23 males and 22 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: diazepam (0.7 mg/kg)<br/> Group 2: midazolam (0.3 mg/kg)<br/> All rectal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wilton's sedation scale<br/> Acceptance of treatment (Holst) </p> <p>Analysed using Wilcoxon matched pair test and Fisher's exact test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in acceptance of dental procedures (P = 0.07)</p> <p>At 1 hour significantly more children agitated in the diazepam group 13/45 (29%) versus 1/45 (2%) (P = 0.006) </p> <p>Data presented graphically</p> <p>Adverse effects: lasting effect: aggressiveness, tiredness and unco‐ordinated movements in diazepam group, children unusually quiet or lively on next day in Group 2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children did not complete treatment however, it is not possible to extract exact numbers as these data were only presented as bar chart </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sevoflurane versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 411<br/> Mean age (SD) in years:<br/> Group 1 (n = 170), 6.2 (1.9)<br/> Group 2 (n = 241), 6 (1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: 40:60 nitrous oxide/oxygen</p> <p>Group 2: 40:60 nitrous oxide/oxygen + 0.1%‐0.3% sevoflurane</p> <p>All inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham scale level of sedation and failure rate</p> <p>Analysed using Mann‐Whitney U test and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effective sedation: Group 1 215/241 (89%); Group 2 89/170 (52%); (P &lt; 0.0001)</p> <p>Venham scale ‐ relaxed: Group 1 = 32%; Group 2 = 67%</p> <p>Significantly less failure in sevoflurane/nitrous oxide</p> <p>Group 1 48% failed (P &lt; 0.0001); Group 2 11% failed</p> <p>Adverse effects: none mentioned</p> <p>Monitoring: pulse oximeter, capnograph, pretracheal stethoscope, visual assessment, auscultation and visualization of chest movements </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% sevoflurane group completed treatment compared to 52% of nitrous oxide group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 65<br/> Gender, mean weight (SD) in kg, mean age (SD) in years:<br/> Group 1: 13 males and 7 females, 33.6 (11.2), 9.3 (2.2)<br/> Group 2: 15 males and 5 females, 37.6 (14.6), 9.6 (2.3)<br/> Group 3: 4 males and 16 females, 36.1 (11.8), 9.9 (2.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/min) (intravenous) + air (nasal inhalation)<br/> Group 2: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation)<br/> Group 3: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation) + sevoflurane (0.3%) (nasal inhalation) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary: completion of treatment<br/> Secondary: level of co‐operation during treatment, recovery time, perception of anxiety and pain and parent's satisfaction </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completion:</p> <p>Group 1: 10/20 (50%)</p> <p>Group 2: 16/22 (73%)</p> <p>Group 3: 19/23 (83%)</p> <p>(Chi<sup>2</sup> = 5.53, df = 2, P = 0.07) </p> <p>Of the 16 treatment failures in Groups 1 and 2, 9 were subsequently successfully treated with the addition of sevoflurane + nitrous oxide </p> <p>No adverse effects reported</p> <p>Monitoring: pulse oximeter, blood pressure, ECG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 664<br/> Gender, mean weight (SD) in kg, mean age (SD) in years:<br/> Group 1 (n = 222), 81 males, 36.3 (13.4), 9.1 (2.7)<br/> Group 2 (n = 306), 127 males, 37.8 (14.1), 9.5 (2.7)<br/> Group 3 (n = 320), 103 males, 37.7 (14), 9.6 (2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/min) (intravenous) + air (nasal inhalation)<br/> Group 2: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation)<br/> Group 3: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation) + sevoflurane (0.3%) (nasal inhalation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary: completion of treatment<br/> Secondary: level of co‐operation during treatment, recovery time, perception of anxiety and pain and parent's satisfaction </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completion:</p> <p>Group 1: 94/174 (54%)</p> <p>Group 2: 204/256 (80%)</p> <p>Group 3: 249/267 (93%)</p> <p>Chi<sup>2</sup> = 9.64, df = 2, P &lt; 0.001 </p> <p>Adverse effects: 1 faint in Group 1, 6 vomited in Group 3</p> <p>Monitoring: pulse oximeter, blood pressure, ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AAPD = American Academy of Pediatric Dentistry; DSTG scale = Dental Sedation Teachers Group scale; df = degrees of freedom; ECG = electrocardiogram; n = number; SD = standard deviation; SE = standard error. </p> </div> </div> <p> <ul id="CD003877-list-0011"> <li> <p>Where data were only presented in their raw format this was used to calculate the appropriate mean and standard deviations. </p> </li> <li> <p>Data were treated as continuous even though Houpt (and other scales) were commonly used as outcome measure (ranked scores). </p> </li> <li> <p>Houpt was taken as the standard when ranking behaviour i.e. higher values equal better behaviour. Where scales ran in the reverse order, values were transformed so that higher values equalled better behaviour e.g. anxiety scores as measured on the Venham scale have been transformed by subtracting the mean score per group from the maximum possible score (see <a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a> Section 9.2.3.2). </p> </li> <li> <p>Where dosage studies were analysed, the lowest dosage was compared to the highest dosage. Results from the lowest dosage were listed first. </p> </li> </ul> </p> <p>'Summary of findings' tables were produced for data from placebo studies only as in the other groups the large number of different combinations tested made this type of summary difficult to understand. </p> </section> <section id="CD003877-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We proposed conducting subgroup analyses for the following groups provided sufficient data existed. </p> <p> <ul id="CD003877-list-0012"> <li> <p>Age.</p> </li> </ul> </p> <p>This would be subdivided into three groups, 0 to 5, 6 to 11, 12 to 17 (as recommended by the <a href="https://www.bnf.org/" target="_blank">British National Formulary</a> (BNF) when prescribing drugs to children). </p> <p> <ul id="CD003877-list-0013"> <li> <p>Dental procedure.</p> </li> </ul> </p> </section> <section id="CD003877-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was planned a priori to compare the study results for risk of bias. Both fixed and random‐effects model meta‐analyses were undertaken to assess the robustness of the results. </p> <section id="CD003877-sec-0074"> <h5 class="title">Summary of findings</h5> <p>The certainty of the evidence was assessed using GRADE methodology. We produced 'Summary of findings' tables for the main comparisons of the review and the following outcomes: mean Houpt/other behavioral score and good or better behaviour, and adverse events. We used GRADE methods (<a href="./references#CD003877-bbs2-0169" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE 2004</a>), and the GRADEpro online tool for developing the 'Summary of findings' tables (<a href="http://www.guidelinedevelopment.org" target="_blank">www.guidelinedevelopment.org</a>). We assessed the certainty of the body of evidence for each comparison and outcome by considering the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, and the risk of publication bias. We categorised the certainty of each body of evidence as high, moderate, low, or very low. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003877-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003877-sec-0075"></div> <section id="CD003877-sec-0076"> <h3 class="title">Description of studies</h3> <section id="CD003877-sec-0077"> <h4 class="title">Results of the search</h4> <p>As this is the first version of this review to incorporate a PRISMA flow diagram (<a href="#CD003877-fig-0001">Figure 1</a>), only information about searches for the current update are presented, the previous version of the review serves as one particular source of studies. One thousand one hundred and fifty‐six records were identified in this update as possibly meeting the inclusion criteria. We screened the title and abstracts of 180 records and assessed 16 full‐text articles for eligibility. Of these, two studies were excluded, with reasons, bringing the total number of excluded studies (including the 114 from the previous version of this review) to 116. Fourteen studies were found to fulfil the inclusion criteria of the review bringing the total number of included studies (including the 36 from the previous version of this review) to 50. Summary details are given in the <a href="./references#CD003877-sec-0171" title="">Characteristics of included studies</a> and <a href="./references#CD003877-sec-0172" title="">Characteristics of excluded studies</a> tables. </p> <div class="figure" id="CD003877-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003877-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003877-sec-0078"> <h4 class="title">Included studies</h4> <section id="CD003877-sec-0079"> <h5 class="title">Characteristics of the studies</h5> <p>Dates of publication ranged from 1966 to 2017.</p> <p>Studies were undertaken in 16 different countries with the greatest proportion of studies (n = 12, 24%) from the USA (see <a href="./references#CD003877-sec-0171" title="">Characteristics of included studies</a> table for details). </p> <p>Six studies reported a sample size calculation (<a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>). Averley et al conducted a pilot study (<a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>) which refers to the collection of information to enable a sample size calculation to be done, and this pilot was then followed by a full trial (<a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>). However, a sample size calculation was not reported in the published papers for either of these studies. </p> </section> <section id="CD003877-sec-0080"> <h5 class="title">Characteristics of the participants</h5> <p>Age of participants included in the trials ranged from 1 year to 16 years. Mean age (approximation) for all studies was 4.8 years. The mean number of participants was 74.08 (standard deviation (SD) = 109) with a total of 3704 subjects randomised in the 50 included trials. </p> <p>In the majority of studies (n = 39, 78%) subjects were reported as being unco‐operative or anxious at the beginning of the study with the Frankl behavioural rating scale often used to measure baseline behaviour. Sixteen of the included studies reported the use of restrain such as papoose boards or pediwrap to support or restrain children during the dental procedure. Papoose boards were used in seven of the studies conducted in the USA (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>), and also in Brazil (<a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>), China (<a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>), Mexico (<a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>) and Saudi Arabia (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>), and the trials by <a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a> and <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> used a pediwrap. </p> </section> <section id="CD003877-sec-0081"> <h5 class="title">Characteristics of interventions</h5> <p>A wide variety of drugs (n = 34) either singly or in combination were used (Additional <a href="#CD003877-tbl-0007">Table 4</a>) and delivered orally, intranasally, intravenously, rectally, intramuscularly, submucosally, transmucosally or by inhalation depending on the type of drug and experimental aims. Inhalation sedation required a bulky machine and scavenging system. Intranasal sedation was administered by a metered‐dose atomizer. Rectal sedation was usually given with a rectal applicator applied to a syringe inserted 3 to 4 centimetres into the rectum and the buttocks opposed tightly for 1 minute. In some studies, enemas were given to parents to apply 1 hour before each appointment to avoid variations in rectal absorption. </p> <div class="table" id="CD003877-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Frequency of studies in which drug regimens were tested</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug regimen tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + hydroxyzine + midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dexmedetomidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + midazolam + sevoflurane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Melatonin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meperidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meperidine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + sevoflurane + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Propofol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sevoflurane + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sufentanil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triclofos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trimeprazine + methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trimeprazine + physeptone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolpidem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolpidem + tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <p>In 14 of the studies (28%) all participants were administered supplemental nitrous oxide/oxygen (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a>; <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>). The proportion of studies looking at either comparison with a placebo, comparison of the same drug with different dosages, or comparison of different drugs are summarised in Additional <a href="#CD003877-tbl-0004">Table 1</a>, <a href="#CD003877-tbl-0005">Table 2</a>, and <a href="#CD003877-tbl-0006">Table 3</a>. Some of the studies appear in more than one group as they included a combination of these types. </p> <p>Dental treatment was poorly described on the whole, all subjects appeared to have some sort of restoration under rubber dam or extraction with local anaesthetic, but little information was given on type of restoration, number of teeth involved, type of local anaesthetic or if any attempt was made to ensure similar treatment was provided in control and experimental groups. </p> <p>In the following section summary data are presented first, followed by a more detailed breakdown into three classifications. This is intended to help the reader in meaningful interpretation of the data. The three classifications are as follows. </p> <p> <ol id="CD003877-list-0014"> <li> <p>Studies where test drug(s) were compared to a placebo.</p> </li> <li> <p>Studies where differing dosages of the same drug(s) were compared.</p> </li> <li> <p>Studies comparing different drugs, or combinations of drugs.</p> </li> </ol> </p> <p>Within each of the three classifications, studies have been grouped where possible by the chief agent used (e.g. chloral hydrate, nitrous oxide, etc.). This was difficult when collating data for studies comparing different drugs or combinations of drugs, therefore some of the grouping decisions made for this table may appear arbitrary. Nevertheless we feel that this grouping helps the reader to understand these data. Drug groupings are in alphabetical order. Where a study compares different drugs with each other and also with a placebo, it has been filed in the placebo section under a different heading for each drug. It has also been filed in the drug comparison section. Where different routes of administration of the same drug have been compared, this has been filed in the dosage section. </p> </section> <section id="CD003877-sec-0082"> <h5 class="title">Characteristics of outcome measures</h5> <p>Of the outcome measures proposed for this review (completion of treatment, difference in behaviour, difference in postoperative anxiety, and adverse events), meaningful data could only be extracted on behaviour. Postoperative anxiety was rarely mentioned and in most of the studies almost all the participants completed treatment. Adverse events were recorded but this was not done in a uniform manner between studies. </p> <p>Outcome variables reported in the studies were predominantly ordinal (e.g. five‐point scale for increasing movement) or dichotomous in nature (e.g. success/failure). Methods used for statistical analysis in the trials included both non‐parametric (Chi<sup>2</sup> test, Wilcoxon matched pairs, Kruskal‐Wallis, Mann‐Whitney U test, Fishers Exact test, non‐parametric two‐factor ANOVA, McNemar test, sign test) and parametric tests (t‐test, ANOVA, Tukey's range test, Friedman two‐way analysis, method of least squares). </p> <p>Measures of behaviour or level of sedation scales were commonly used (Houpt or modified versions of Houpt used most frequently (n = 19, 40%). Nineteen different types of measurement scales for behaviour or sedation were used and these are summarised in Additional <a href="#CD003877-tbl-0008">Table 5</a> and <a href="#CD003877-tbl-0009">Table 6</a>. </p> <div class="table" id="CD003877-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of behaviour/sedation rating scales</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ramsay Sedation Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Briekopf and Buttner Emotional Status Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frankl Behaviour Rating Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt Behaviour Rating Scale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake, anxious and agitated, restless or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritated: awake, restless, crying</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refusal/distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aborted: no treatment rendered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake, co‐operative, orientated, tranquil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal: awake, calm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unco‐operative/reluctant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor: treatment interrupted, only partial treatment was completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake responds to commands only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive: tired, hardly moving</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐operative/reserved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair: treatment interrupted but eventually completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, brisk response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleepy: drowsy, with reaction but rousable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interested/enjoyed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good: difficult but all treatment was performed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, sluggish response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very good: some limited crying and movement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, no response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excellent: no crying or movement</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>From <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>. </p> </div> </div> <div class="table" id="CD003877-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome measures used (excluding physiological parameters)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Characteristics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐point scale for sleep (awake to asleep); 4‐point scale for movement (1 = violent movement to 4 = no movement); 4‐point scale for crying (1 = hysterical crying to 4 = no crying); 6‐point scale for overall behaviour (1 = no treatment rendered to 4 = difficult but all treatment completed to 6 = excellent/no crying or movement) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified from Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from 1 = treatment aborted, 2 = poor (treatment frequently interrupted), 3 = fair (planned treatment completed), 4 = good (all treatment completed without crying or movement) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified from Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modification not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dichotomous behaviour scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>; <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dichotomous behavioural scale rates specific events of treatment as satisfactory or unsatisfactory </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ohio State University Behavior Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from quiet to crying and struggling</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venham scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point scale ranging from 0 = relaxed to 5 = out of control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mental attitude, hypnotic effect, motor activity and overall sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐point scale for mental attitude (relaxed or agitated); 3‐point scale for hypnotic effect (asleep to or awake); 3‐point scale for motor activity (absent to remarkable); 3‐point scale for sedation (excellent to unsatisfactory) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsay Sedation Scale, movement, crying, overall sedation and behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a>; <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point scale for Ramsay (patient anxious and agitated to no response); 3‐point scale for movement (continuous movement to no movement); 4‐point scale for crying (hysterical crying to no weeping); 4‐point scale for overall sedation (impossible to very good) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐point scale ranging from 1 = unmanageable, unable to examine/treat, to 10 = obtunded: apneic where 5 is ideal (well sedated, co‐operative with normal oximetry) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale ranging from asleep to awake</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for level of sedation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilton's sedation scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Wilton (drowsy to agitated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptance of treatment (Holst, 1987)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a>; <a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Holst (positive to no)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptance of treatment (Al Rakaf, 2001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frankl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Frankl (definitely negative to definitely positive)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modification Barker sedation scoring system, overall quality sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barker sedation score calculated by summing scores given at intervals throughout the treatment; 4‐point rating scale for sedation quality (poor to excellent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global rating scale of overall behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 ratings from excellent to poor‐aborted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐point scale ranging from sleep to excited</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brietkopf and Buttner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from irritated to sleepy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fukuta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐point scale ranging from asleep to violent rejection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐point scale ranging from sleep to excited</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified scale to classify behaviour/response to treatment/sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from success to not accepting treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour/response to treatment rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale ranging from excellent to prohibitive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Dental Sedation Teachers Groups Scale (Ransford, 2010)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale measuring operating conditions ranging from 1 = good to 4 = impossible</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003877-sec-0083"> <h5 class="title">1. Placebo‐controlled studies</h5> <p>There were 12 placebo studies included which investigated oral chloral hydrate (<a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a>), intranasal dexmedetomidine (<a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>), oral diazepam (<a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>), melatonin (<a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>), intramuscular meperidine (<a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>), oral midazolam (<a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>), intravenous midazolam (<a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>), midazolam/ketamine (<a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>), and nitrous oxide (<a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>) (Additional <a href="#CD003877-tbl-0004">Table 1</a>). </p> <p>Where the general medical status of the children was reported they were usually healthy or had mild systemic disease (American Society of Anesthesiologists (ASA) physical status classification system: ASA I and ASA II). Six papers did not report on the gender balance, seven did not report the weight of the children. </p> <p>Times for withholding food prior to the sedation (NPO ‐ nil per os: nothing by mouth) were given in four papers (<a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>). Monitoring of the children during the sedation included blood pressure, heart rate, oxygen saturation, body temperature, and respiratory rate. There was no specified involvement with an anaesthetist during sedation though in some studies patients were assessed by an anaesthetist before treatment. </p> <p>Papoose board or pediwrap was used in one study (<a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>). Nitrous oxide was used in conjunction with the main sedative agents under test in two studies (<a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a>). A range of outcome variables were used and these are summarised in Additional <a href="#CD003877-tbl-0004">Table 1</a>. One study reported recovery times (<a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>) and three gave the total treatment time (<a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>). Three studies used video cameras to record sedation during dental treatment (<a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>). </p> <p>Data from the different drug types are listed below.</p> <section id="CD003877-sec-0084"> <h6 class="title">Oral midazolam</h6> <p>Seven trials compared oral midazolam with placebo (<a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a><a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>). </p> <p><a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> randomised children aged 4 to 10 years to either 7.5 mg of midazolam or placebo (the range of weight of the children included in the trial is not reported but the stated average weight of 21.65 kg would result in a dose equivalent to 0.35 mg/kg). The actual dose in mg/kg would be expected to vary considerably. The authors used means and standard errors to summarise ranked data in each group with only three categories which was thought to be inappropriate. However, subsequent analysis using Wilcoxon's rank test was appropriate. Midazolam was reported to be significantly better than placebo. </p> <p><a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> used a dose of 0.75 mg/kg and noted vomiting and hiccupping in the midazolam group. </p> <p><a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a> described midazolam delivery in their study as being a mixture of oral and transmucosal with a dose of 0.5 mg/kg. </p> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> used the highest dose in this group of trials, of 1 mg/kg. Co‐operation as recorded by the sum of the Ohio State University Behavior Rating Scale (OSUBRS) score at each measurement point was not significantly different than the placebo (P = 0.55). </p> <p><a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a> used the lowest dose of the five trials in this group (0.25 mg/kg). </p> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> used a dose of 0.5 mg/kg. </p> <p><a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> used a dose of 0.5 mg/kg and noted amnesia associated with midazolam use. </p> </section> <section id="CD003877-sec-0085"> <h6 class="title">Nitrous oxide/oxygen</h6> <p>Two studies (<a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>) evaluated nitrous oxide/oxygen sedation compared to placebo and both were assessed as being at high risk of bias. In <a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a> children received 20% to 50% nitrous oxide in oxygen and in <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> participants received up to 40% nitrous oxide in oxygen. No adverse effects were mentioned. </p> </section> <section id="CD003877-sec-0086"> <h6 class="title">Chloral hydrate</h6> <p>In <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a> children were randomly allocated to either 20 mg/kg, 40 mg/kg or 60 mg/kg of chloral hydrate or a placebo and then all children received up to 40% nitrous oxide in oxygen as well. This trial was assessed as being at high risk of bias. </p> </section> <section id="CD003877-sec-0087"> <h6 class="title">Meperidine</h6> <p>Intramuscular meperidine (0.55 mg/kg to 2.2 mg/kg ‐ calculated from mg/lb given in text) was evaluated in a single study (<a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>) which was assessed at unclear risk of bias. </p> </section> <section id="CD003877-sec-0088"> <h6 class="title">Intravenous midazolam</h6> <p>0.06 mg/kg body weight was used in one study, <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>, assessed as at high risk of bias. </p> </section> <section id="CD003877-sec-0089"> <h6 class="title">Oral diazepam</h6> <p>0.5 mg/kg body weight was used in one study, <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>, assessed as at high risk of bias. </p> </section> <section id="CD003877-sec-0090"> <h6 class="title">Midazolam/ketamine</h6> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> used a dose of 0.5 mg/kg midazolam with 3 mg/kg ketamine. </p> </section> </section> <section id="CD003877-sec-0091"> <h5 class="title">2. Dose comparison studies</h5> <p>There were 10 studies which compared different dosages or routes of admission of sedative agents: one used hydroxyzine (<a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>), the remaining nine varied dosage or method of midazolam with six primarily using intranasal midazolam (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>) and three oral midazolam (<a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>) (Additional <a href="#CD003877-tbl-0005">Table 2</a>). </p> <p>All children were assessed as healthy or having mild systemic disease (ASA I and ASA II). Eight studies described the gender balance. Seven recorded the mean weight. Two studies measured baseline anxiety and compared this to anxiety at the end (<a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>). </p> <p>All studies described NPO times which ranged from either a light breakfast (but no milk) up to nothing from midnight. Monitoring was reported in all studies, using a precordial stethoscope, blood pressure unit and electrocardiograph as well as clinical observations. Five studies mentioned the involvement of anaesthetists (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>). </p> <p>Use of papoose board (or equivalent) was mentioned in four studies (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>), one study mentioned manual restraint (<a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>). In four studies nitrous oxide was used in conjunction with the main sedative agent (<a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>). A range of outcome variables were used and these are summarised in Additional <a href="#CD003877-tbl-0005">Table 2</a>. Three studies recorded recovery times (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>) and two gave the total dental treatment time (<a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>). Four studies used video cameras to record dental treatment during sedation (<a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>). </p> <p>In addition to looking at behaviour ratings and sedation, <a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> also assessed the effects of fasting on behaviour. </p> <p>Data from the different drug types are listed below.</p> <section id="CD003877-sec-0092"> <h6 class="title">Hydroxyzine</h6> <p>One study (<a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>) looked at the effect of a dose of hydroxyzine given 24 hours preoperatively (20 mg) at home followed by a second dose at the appointment (3.7 mg/kg) versus hydroxyzine given at the appointment only (3.7 mg/kg). The study was at high risk of bias. All children also received 50% nitrous oxide. <a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a> reported the dose as 20 mg/kg hydroxyzine in the main text but 20 mg in the abstract. </p> </section> <section id="CD003877-sec-0093"> <h6 class="title">Midazolam (intranasal)</h6> <p>Six studies looked primarily at intranasal midazolam (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>). The participants in the <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> and <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> trials all received nitrous oxide inhalation as well at 50% or 45% respectively. All studies were at high risk of bias. </p> <p><a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> compared 0.5 mg intranasal midazolam to either 0.3 mg/kg or 0.4 mg/kg. </p> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> compared intranasal midazolam (0.3 mg/kg) to oral midazolam (0.7 mg/kg). </p> <p><a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> and <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> compared 0.2 mg/kg intranasal midazolam versus 0.2 mg/kg intramuscular midazolam. <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> used the midazolam as a premedication for an unspecified intravenous sedative. </p> <p><a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a> and <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a> compared 0.2 mg/kg intranasal midazolam to 0.2 mg/kg sublingual midazolam. </p> </section> <section id="CD003877-sec-0094"> <h6 class="title">Midazolam (oral)</h6> <p>Three studies (<a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>) evaluated oral midazolam, with participants in <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a> also receiving nitrous oxide inhalation. <a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a> was assessed as being at high risk of bias and in <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a> risk of bias was unclear. </p> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a> compared 0.5 mg/kg oral midazolam versus 0.35 mg/kg rectal midazolam. </p> <p><a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a> randomised children to oral doses of either 0.2 mg/kg, 0.5 mg/kg, 0.75 mg/kg or 1 mg/kg after fasting for 3 to 5 hours. All children also received 40% nitrous oxide in oxygen (Additional <a href="#CD003877-tbl-0005">Table 2</a>). </p> <p><a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a> compared oral doses of 0.5 mg/kg, 0.75 mg/kg and 1 mg/kg. </p> </section> </section> <section id="CD003877-sec-0095"> <h5 class="title">3. Head‐to‐head drug comparison studies</h5> <p>There were 31 studies comparing different drugs and delivery methods which are summarised in Additional <a href="#CD003877-tbl-0006">Table 3</a>. </p> <p>All studies reported children's medical status at baseline. In 14 studies gender was not specified and in 22 papers the mean weight of participants was not described. The age of children in these studies ranged from 1 year to 14 years of age. </p> <p>NPO was not mentioned in 12 of the studies (<a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a>; <a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>; <a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a>; <a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a>). Of those studies reporting NPO, times ranged from midnight to 2 hours before sedation or appointment. Monitoring was well reported in most of the studies and included verbal contact, pulse oximeter, precordial stethoscope, automatic blood pressure, capnograph, nasal respiration monitor, end‐tidal carbon dioxide tension. Fourteen studies mentioned the involvement of anaesthetists (<a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a>; <a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>; <a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a>; <a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>).<br/> <br/> The use of a papoose board was mentioned in nine of the studies (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>), and in seven nitrous oxide/oxygen inhalation was used in conjunction with sedation (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>). A range of outcome variables were used and these are summarised in Additional <a href="#CD003877-tbl-0006">Table 3</a>. Two papers reported dentist and parents preferences after sedation (<a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>). Recovery times were given in 13 papers (<a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a>; <a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>; <a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a>; <a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a>; <a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a>; <a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>), and nine gave the total dental treatment time (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a>). Four studies used video cameras to record sedation during dental treatment (<a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>). </p> <p>Data from drug types is summarised below.</p> <section id="CD003877-sec-0096"> <h6 class="title">Chloral hydrate/hydroxyzine</h6> <p>Six studies investigated chloral hydrate/hydroxyzine and compared it to other agents (<a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a>). In <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> and <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a> all participants also received nitrous oxide inhalation. All studies in this group were assessed at high risk of bias. </p> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a> compared chloral hydrate (70 mg/kg)/hydroxyzine (2 mg/kg) with chloral hydrate (70 mg/kg) alone. </p> <p><a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a> compared oral chloral hydrate (40 mg/kg) plus hydroxyzine (25 mg) with oral triazolam (0.02 mg/kg) in children who also received inhalation of 40% nitrous oxide. </p> <p>In the trial by <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> rectal chloral hydrate (50 mg/kg) was compared with either oral chloral hydrate (50 mg/kg) or oral chloral hydrate (30 mg/kg) plus hydroxyzine (25 mg) in children who all received 30% to 50% inhalational nitrous oxide as well. </p> <p><a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a> compared chloral hydrate (60 mg/kg) plus hydroxyzine (1 mg/kg) to chloral hydrate (60 mg/kg oral) plus hydroxyzine (1 mg/kg oral) plus midazolam (0.1 mg/kg submucosal) in children who all received 50% inhalational nitrous oxide as well. Outcome measures were Houpt and whether or not restraint was required. </p> <p>Chloral hydrate (50 mg/kg) plus hydroxyzine (25 mg) was compared to oral midazolam (0.5 mg/kg) plus acetaminophen (10 mg/kg) (M/A) in <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>. </p> <p>In a trial by <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> children were randomised to sedation with chloral hydrate (50 mg/kg)/hydroxyzine (1.5 mg/kg) or midazolam (0.5 mg/kg)/hydroxyzine (1.5 mg/kg) or hydroxyzine (2 mg/kg plus further 1 mg/kg). </p> </section> <section id="CD003877-sec-0097"> <h6 class="title">Chloral hydrate/promethazine</h6> <p><a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a> compared chloral hydrate (50 mg/kg)/promethazine (1 mg/kg) with meperidine (1 mg/kg)/promethazine (1 mg/kg), in children planned to receive inhalational nitrous oxide as well. </p> </section> <section id="CD003877-sec-0098"> <h6 class="title">Dexmedetomidine</h6> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> randomised patients into four groups for intranasal intervention: dexmedetomidine (1 µg/ kg), dexmedetomidine (1.5 µg/kg), midazolam (0.2 mg/kg), and ketamine (5 mg/kg). </p> </section> <section id="CD003877-sec-0099"> <h6 class="title">Ketamine</h6> <p>Eight studies evaluated ketamine (<a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a>; <a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a>; <a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>; <a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>). In two of these trials (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>) nitrous oxide inhalation was also used at a concentration of 30% to 50% or 35% to 50% respectively. One of the eight trials in this group (<a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>) was assessed at low risk of bias, one (<a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>) at unclear risk of bias, and the remainder at high risk of bias. </p> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> compared 3 mg/kg ketamine with either 0.4 mg/kg midazolam or 1.0 µg/kg or 1.5 µg/kg sufentanil all administered intranasally. </p> <p>Anaesthetists in the trial by <a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a> administered a premedication of 0.5 mg/kg midazolam to all the children followed by a bolus dose plus infusion of either midazolam (0.1 mg/kg followed by 0.004 mg/kg/min), propofol (1 mg/kg followed by 0.06 mg/kg/min) or ketamine (0.5 mg/kg followed by 0.01 mg/kg/min). </p> <p><a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a> compared rectal ketamine (5 mg/kg)/midazolam (0.35 mg/kg) to rectal midazolam (1 mg/kg) alone. </p> <p>In a second study (<a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a>) children were randomised to either an oral dose of 12.5 mg/kg ketamine or 0.5 ml/kg of standard oral premedication (comprising trimeprazine (6 mg/ml)/physeptone (methadone) (0.4 mg/ml)) to which was added droperidol (0.1 mg/ml). </p> <p>The third trial by this group (<a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>) compared oral ketamine (5 mg/kg) plus midazolam (0.35 mg/kg) with a combination of oral trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) administered 30 minutes prior to dental treatment. </p> <p>Two trials evaluated ketamine in combination with inhalation of nitrous oxide (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>). </p> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a> compared oral ketamine (6 mg/kg) with oral meperidine (2 mg/kg) plus promethazine (0.5 mg/kg) in children who had NPO for 6 hours. Nitrous oxide (30% to 50%) was administered to all the children prior to the local anaesthetic. </p> <p>In the trial by <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>, oral ketamine (10 mg/kg) was compared with oral ketamine (10 mg/kg) plus promethazine (1.1 mg/kg) in a trial where all the participants also received 50% nitrous oxide inhalation. </p> <p><a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a> in their trial compared oral ketamine 8 mg/kg<sup>‐1</sup> to oral dexmedetomidine in doses of 3 µg/kg<sup>‐1</sup>, 4 µg/kg<sup>‐1</sup> and 5 µg/kg<sup>‐1</sup>. </p> </section> <section id="CD003877-sec-0100"> <h6 class="title">Midazolam (oral)</h6> <p>Eight studies evaluated oral midazolam compared to other sedatives (<a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>). In two of these trials (<a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>) participants also received nitrous oxide by inhalation. The studies were assessed as being at high risk of bias. </p> <p><a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a> randomised participants to either oral administration of hydroxyzine (1 mg/kg), oral midazolam (0.7 mg/kg), oral administration of ketamine (3 mg/kg) plus midazolam (0.25 mg/kg) or no oral premedication (nitrous oxide alone). All patients in the trial received 40% nitrous oxide. </p> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> compared oral administration of midazolam 0.5 mg/kg, tramadol 2 mg/kg, triclofos 70 mg/kg and zolpidem 0.4 mg/kg. </p> <p><a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> randomised participants to six different oral interventions: midazolam (0.5 mg/kg), ketamine (5 mg/kg), zolpidem (0.4 mg/kg), midazolam (0.4mg/kg) plus ketamine (3 mg/kg), midazolam (0.5 mg/kg) plus tramadol (2 mg/kg) and zolpidem (0.4 mg/kg) plus tramadol (2 mg/kg). </p> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> compared oral midazolam (0.5 mg/kg) plus oral ketamine (5 mg/kg) plus intranasal placebo, with intranasal dexmedetomidine (1 µ/kg) plus oral placebo and a third group of oral and intranasal placebo. </p> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> randomised participants into two oral intervention groups: midazolam (0.5 mg/kg) plus ketamine (3 mg/kg), midazolam 1 mg/kg and compared it to a no sedation group. The study used protective stabilisation. </p> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> compared four interventions: 0.20 mg/kg midazolam (40 mg/ml) intranasally plus inhalation sedation 50%–50% nitrous oxide/oxygen, 0.75 mg/kg midazolam (15 mg/ 3 ml) orally plus inhalation sedation 50%–50% nitrous oxide/oxygen, 0.50 mg/kg midazolam (15 mg/3 ml) orally plus inhalation sedation 50%–50% nitrous oxide/oxygen, and inhalation sedation 50%–50% nitrous oxide/oxygen. Restraint was used. A modified scale was used to classify behaviour/response to treatment/sedation. </p> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> compared midazolam (0.5 mg/kg) to either triclofos (70 mg/kg) or promethazine (1.3 mg/kg), all administered in fruit juice prior to treatment. Sedation scores were reported on an eight‐point scale in which a high score indicated poor sedation. </p> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> randomised participants into four groups: oral midazolam 0.5 mg/kg, oral diazepam 0.5 mg/kg, intravenous midazolam 0.06 mg/kg, and placebo. </p> </section> <section id="CD003877-sec-0101"> <h6 class="title">Midazolam (intravenous)</h6> <p>Two studies, both at high risk of bias, compared intravenous midazolam to other sedatives (<a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a>; <a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>). </p> <p><a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a> randomised participants into two groups for intravenous sedation administration: remifentanil (0.1 µg/kg/min) plus midazolam (0.01 mg/kg) plus propofol (0.5 mg/kg), and ketamine (0.5 mg/kg) plus midazolam (0.1 mg/kg) plus propofol (0.5 mg/kg). </p> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> compared intravenous midazolam (0.05 mg/kg) plus ketamine (0.5 mg/kg) with midazolam (0.05 mg/kg) plus fentanyl (0.5 µg/kg). Additional midazolam (0.25 mg) was administered to both groups if needed. </p> </section> <section id="CD003877-sec-0102"> <h6 class="title">Midazolam (rectal)</h6> <p>Rectal sedation was evaluated by <a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> who compared diazepam (0.7 mg/kg) with midazolam (0.3 mg/kg). </p> </section> <section id="CD003877-sec-0103"> <h6 class="title">Sevoflurane</h6> <p>Three trials evaluated sevoflurane (<a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>), but used different outcome measures. Two were assessed at high and one at unclear (<a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>) risk of bias. </p> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a> compared sevoflurane (0.1% to 0.3%)/nitrous oxide (40%) with nitrous oxide (40%) alone. </p> <p><a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a> was a pilot study which randomised children to either intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation, or 40% nitrous oxide inhalation plus intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation, or inhalation of 0.3% sevoflurane plus 40% nitrous oxide plus intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation. </p> <p>In the subsequent trial (<a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>) the same interventions were used. </p> </section> </section> </section> <section id="CD003877-sec-0104"> <h4 class="title">Excluded studies</h4> <p>Reasons for trial exclusion are summarised in <a href="./references#CD003877-sec-0172" title="">Characteristics of excluded studies</a> table. Reasons included description of the study as using deep sedation, the sedative agent being used as a pre‐medication prior to an anaesthetic, no comparative groups or evaluating outcomes not relevant to this review. We continued to exclude cross‐over trials. </p> </section> </section> <section id="CD003877-sec-0105"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD003877-sec-0106"> <h4 class="title">Allocation</h4> <p>Eleven studies were assessed as low risk of bias with regard to method of sequence generation (<a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>; <a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>). Barring four of these (<a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>) all of the others reported adequate allocation concealment. Two other studies were reported as having adequate allocation concealment, but the method of sequence generation in these studies was not described (<a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>). <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a> used an independent person to select patients, make the random allocation and administer the intervention, this was assessed as unclear risk. <a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a> used an anaesthetist to divide the sample into two groups based on odd and even codes, this was considered to be at unclear risk of bias for allocation concealment. <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>, the principal investigator conducted the subject selection and random allocation, this was assessed to be at high risk of selection bias. In the remaining trials neither the method of sequence generation, nor any concealment of allocation was described, and these studies were assessed as being at unclear risk of selection bias. </p> </section> <section id="CD003877-sec-0107"> <h4 class="title">Blinding</h4> <p>For avoiding performance and detection bias the ideal situation is when the operator, outcome assessor and patient are all blinded to the intervention. However, we acknowledge that in trials of sedative agents in children, blinding of dental operators is difficult in part due to the nature of the equipment and drugs involved, and the need to ensure patient safety during the procedure. Blinding of children participating in these studies is usually possible, especially with young children. Some of the trials incorporated video recordings and one of more outcome assessors, blinded to the allocated treatment, evaluated the outcomes from these recordings. </p> <p>In many trials the outcome was assessed by the operative dentist carrying out the procedure. In some trials the sedatives were administered by a nurse or researcher and the operator, who was blinded to the intervention, undertook the assessment. In other trials the procedures were videotaped and outcomes were assessed from the recordings, but bias is possible if an unblinded operator interacts with the patients in different ways depending on expectations about the effect of a specific sedative. </p> <p>Where studies were described as double‐blinded, this was interpreted to mean participant and outcome assessor were blinded to the allocated treatment. Where the participant and outcome assessor at least were blinded to the treatment, the risk of performance and detection biases were deemed to be low. The outcome assessor and operator could be separate individuals or the same person. </p> <p>Twenty‐three studies were assessed as being at low risk of performance and detection biases (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Al_x002d_Rakaf-2001" target="_blank">Al‐Rakaf 2001</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Avalos_x002d_Arenas-1998" target="_blank">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Averley-2004b" target="_blank">Averley 2004b</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Bui-2002" target="_blank">Bui 2002</a>; <a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Isik-2008a" target="_blank">Isik 2008a</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Jensen-1999" target="_blank">Jensen 1999</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Kapur-2004" target="_blank">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-McKee-1990" target="_blank">McKee 1990</a>; <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Mortazavi-2009" target="_blank">Mortazavi 2009</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Reeves-1996" target="_blank">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Roelofse-1996b" target="_blank">Roelofse 1996b</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Sams-1993" target="_blank">Sams 1993</a>; <a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a>; <a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>; <a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Wan-2006" target="_blank">Wan 2006</a>). </p> <p>In eight trials only the assessor was blinded to the intervention (<a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Lam-2005" target="_blank">Lam 2005</a>; <a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=74944259900446422542110608190228%26format=REVMAN#STD-Veerkamp-1993" target="_blank">Veerkamp 1993</a>). </p> <p>In five trials the operator and the outcome assessor was blinded (<a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>). </p> <p>In three studies only the operator was blinded (<a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>). </p> <p>In four trials there was no blinding (<a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a>; <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a>; <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>). The mother of the patient was aware of the treatment in <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>. In <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> the intravenous midazolam group was not blinded. </p> <p>There was no placebo used in <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>, therefore participants would have been aware that this was the control group. </p> </section> <section id="CD003877-sec-0108"> <h4 class="title">Incomplete outcome data</h4> <p>The number of trial participants included in the outcome evaluations was poorly reported in many trials, and it was sometimes difficult to determine whether or not dropouts had occurred. Twenty‐one studies were at low risk of attrition bias. In three studies the risk of attrition bias was assessed as unclear (<a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>) and in the remainder, where incomplete treatment/sedation failure was not recorded or reported on at all, trials were assessed as being at high risk of attrition bias. </p> </section> <section id="CD003877-sec-0109"> <h4 class="title">Selective reporting</h4> <p>All but four of the included trials reported the outcomes described in the methods sections of the reports, and were deemed to be at low risk of reporting bias. <a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a> and <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a> reported the primary outcome, treatment completion, on all the trial participants who received the allocated intervention, but reported secondary outcomes only on those who were deemed to have undergone successful sedation (69% and 78% respectively) of those who received sedation, and 69% and 65% of those randomised. <a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> did not report on the recovery times in the results. </p> </section> <section id="CD003877-sec-0110"> <h4 class="title">Other potential sources of bias</h4> <p>There were no baseline demographic data reported on the participants in nine trials (<a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>; <a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a>; <a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>), and little or unclear baseline demographic data in a further seven trials (<a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a>; <a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a>; <a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>). There were inconsistencies in two trials (<a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>). In the trial by <a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a> baseline demographic data were only provided for 65% of those randomised. The randomisation code in <a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> was broken early due to significant desaturations in the study and there was a subsequent change to the protocol reducing the high dose sufentanil 1.5 µg/kg to 1.0 µg/kg. In <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> it was not clear if the no sedation group had a placebo intervention or no intervention at all. The remainder of studies was assessed as at low risk of other bias. </p> <section id="CD003877-sec-0111"> <h5 class="title">Overall risk of bias</h5> <p>See <a href="#CD003877-fig-0002">Figure 2</a>. Of the 50 trials included in this review, only one was assessed as being at low risk of bias overall (<a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a>). Nine trials (18%) were assessed as being at unclear risk of bias (<a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>) and in the remaining 40 trials (81%) at least one domain was assessed as being at high risk of bias. </p> <div class="figure" id="CD003877-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003877-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>In common with many other Cochrane Reviews the overall quality of studies was found to be disappointing. Poor reporting was an obvious problem with these studies and this may have masked other defects in design or conduct of these trials. </p> </section> </section> </section> <section id="CD003877-sec-0112"> <h3 class="title" id="CD003877-sec-0112">Effects of interventions</h3> <p>See: <a href="./full#CD003877-tbl-0001"><b>Summary of findings for the main comparison</b> Sedative compared to placebo for children needing dental care</a>; <a href="./full#CD003877-tbl-0002"><b>Summary of findings 2</b> Sedative compared with different dosage of the same sedative for children needing dental care</a>; <a href="./full#CD003877-tbl-0003"><b>Summary of findings 3</b> Sedative compared with a different sedative for children needing dental care</a> </p> <section id="CD003877-sec-0113"> <h4 class="title">1. Placebo‐controlled studies</h4> <p>See Additional <a href="#CD003877-tbl-0004">Table 1</a> We included 12 placebo studies in the review. </p> <section id="CD003877-sec-0114"> <h5 class="title">Oral midazolam</h5> <p>Where possible studies were included in the meta‐analysis using overall behaviour as measured by Houpt (or a scale in the same direction) as an outcome measure. <a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> and <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> did not record Houpt but did use a similar scale (three‐point as opposed to six‐point). Raw data were supplied by <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> and <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> so these were used to calculate mean and standard deviation (satisfactory scored as 3, unsatisfactory as 1 in <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>). <a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> reported standard error so this was converted to standard deviation. <a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a> used a reversed scale so these data were transformed. <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> appeared to have a reporting error whereby test and control results were transposed. Close examination of the paper shows that values for all measures of behaviour reported in Table 2 are the opposite as described in the text i.e. they suggest the intervention worsens behaviour whereas in the text it states that patient behaviour improved. The same is not true for the physiological measures (Table 2 again), subjects in the intervention group had a significantly lower heart rate. We were unable to contact the authors therefore we have decided this most likely represents an error in reporting and have therefore transposed values for the control and intervention groups. <a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> did not report overall behaviour, instead behaviour was recorded at discrete intervals throughout the visit. In addition, behaviour was recorded using OSUBRS as opposed to a scale like Houpt (or similar). OSUBRS runs in the reverse direction to Houpt. We therefore decided not to include this study in the meta‐analysis. </p> <p>The results can be seen in <a href="./references#CD003877-fig-0003" title="">Analysis 1.1</a>. A fixed‐effect model and standardized mean difference (SMD) was used as the scales were not completely alike. Use of oral midazolam produced a significant improvement in behaviour in all of these trials (SMD 1.96, 95% confidence interval (CI) 1.59 to 2.33; P &lt; 0.0001; 6 studies; 202 participants). The considerable heterogeneity (I<sup>2</sup> = 90%, P &lt; 0.00001) in this estimate is likely due to the different tools used to measure the outcome in each trial and the range of doses of oral midazolam used from 0.25 mg/kg to 0.75 mg/kg (see Additional <a href="#CD003877-tbl-0004">Table 1</a>). We assessed the certainty of the evidence as moderate (according to GRADE recommendations). The risk of bias was high or unclear in most studies. The remaining measures were scored as low. We could not assess the risk of publication bias. Oral midazolam probably improves behaviour (moderate‐certainty evidence). </p> </section> <section id="CD003877-sec-0115"> <h5 class="title">Nitrous oxide/oxygen</h5> <p>Two trials (<a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a>) reported changes in favour of nitrous oxide in either behaviour or anxiety, but no data were available from the Nathan trial. Data from <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> was added to the meta‐analysis. In this study they reported anxiety on the Venham scale which is in the opposite direction to Houpt, so scores were transformed for forest plots (<a href="./references#CD003877-fig-0003" title="">Analysis 1.1</a>). No adverse effects were mentioned. We assessed the certainty of evidence as very low (according to GRADE recommendations) due to the risk of bias and imprecision. We are uncertain whether nitrous oxide/oxygen improves behaviour (very low‐certainty evidence). </p> </section> <section id="CD003877-sec-0116"> <h5 class="title">Chloral hydrate (CH)</h5> <p>There was no statistically significant increase in positive behaviour between placebo and any of the oral chloral hydrate groups, and all participants completed treatment regardless of group (<a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a>). There was no statistically significant difference between placebo and the three active chloral hydrate groups combined for the outcome of positive behaviour during the operatory (<a href="./references#CD003877-fig-0004" title="">Analysis 1.2</a>), possibly due to a strong response to the placebo. However, after nitrous oxide/oxygen was administered, there were airway issues with four children (27%) in the 60 mg/kg chloral hydrate group not responding to obstruction. We are uncertain whether chloral hydrate improves behaviour as the certainty of the evidence has been assessed as very low due to the risk of bias, incomplete outcome assessment and imprecision. We could not assess the risk of publication bias. </p> </section> <section id="CD003877-sec-0117"> <h5 class="title">Meperidine</h5> <p>Meperidine was statistically significantly more effective (P &lt; 0.05) than placebo for the outcome of good or better behaviour (good, very good or excellent behaviour) (71% in meperidine groups compared to 13% in placebo) (<a href="./references#CD003877-fig-0004" title="">Analysis 1.2</a>.). However, two patients in the meperidine groups (13%) had unmanageable behaviour and treatment had to be aborted and rescheduled. Nausea and vomiting were more frequent in the meperidine groups (38% versus 7%) and rates showed a dose response (<a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>). Meperidine may improve behaviour (low‐certainty evidence due to unclear risk of bias and imprecission). </p> </section> <section id="CD003877-sec-0118"> <h5 class="title">Intravenous midazolam</h5> <p>Overall behaviour was significantly better in this group when compared to placebo (P = 0.01) (<a href="./references#CD003877-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>). However, we are uncertain whether intravenous midazolam improves behaviour as the certainty of the evidence has been assessed as very low due to high risk of bias and imprecision. We could not assess the risk of publication bias. </p> </section> <section id="CD003877-sec-0119"> <h5 class="title">Oral diazepam</h5> <p>Overall behaviour was not significantly better in this group when compared to placebo (P = 0.18) (<a href="./references#CD003877-fig-0003" title="">Analysis 1.1</a>, <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>). No adverse effects were reported. We are uncertain whether oral diazepam improves behaviour (very low‐quality/certainty evidence). </p> </section> <section id="CD003877-sec-0120"> <h5 class="title">Midazolam/ketamine</h5> <p>0.5 mg/kg midazolam with 3 mg/kg ketamine produced significantly better behaviour (as measured by the sum of the OSUBRS score at each measurement point) than the placebo and oral midazolam (P = 0.03) (<a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>). Because of the way these data were presented, we were unable to include them in the meta‐analysis. </p> </section> </section> <section id="CD003877-sec-0121"> <h4 class="title">2. Dose comparison studies</h4> <p>See Additional <a href="#CD003877-tbl-0005">Table 2</a>. Ten studies compared different dosages or routes of admission of sedative agents. </p> <section id="CD003877-sec-0122"> <h5 class="title">Hydroxyzine</h5> <p><a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a> reported no differences between groups at any of the time points measured. No adverse effects were reported. </p> </section> <section id="CD003877-sec-0123"> <h5 class="title">Midazolam (intranasal)</h5> <p><a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> found that behaviour improved in the group receiving 0.5 mg intranasal midazolam compared to either 0.3 mg/kg or 0.4 mg/kg (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>), but there was no statistically significant improvement in behaviour between 0.4 mg group and 0.3 mg group. The number of patients completing treatment increased also (79%, 96% and 100% in groups 1, 2 and 3 respectively ‐ data from fasting children were used). Authors also reported that fasting made no difference to overall behaviour (P = 0.8286). </p> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> found no differences between groups in mean Houpt behaviour score at any of the times measured ‐ data not available (P = 0.749). As expected, mean time to onset of sedation was much shorter in the intranasal group, but mean duration of sedation (working time) was statistically significantly longer in the group who received oral midazolam (Additional <a href="#CD003877-tbl-0005">Table 2</a>). </p> <p><a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> reported that there was improved behaviour at time of delivery of local anaesthetic and venepuncture in the intramuscular group, and good or excellent sedation was achieved in all of the intramuscular group compared to only 6/11 (54%) of the intranasal group (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). </p> <p><a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> reported no difference with regard to behaviour between the intramuscular and intranasal groups, which both showed improvement from baseline. Induction of sedation, treatment and recovery however was faster in the intranasal group (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). Despite receiving a light snack prior to treatment, none of the children vomited. </p> <p><a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a> reported a decrease in the anxiety after 20 minutes of the sedatives administration in both groups. Although the intranasal group showed more statistically significant decrease in anxiety at various set points during treatment compared to the sublingual group. They could not show a link between measuring salivary cortisol levels and detection of anxiety. </p> <p>Adverse effects were reported by <a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> and <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> and included sneezing, coughing, diplopia and hiccups. </p> </section> <section id="CD003877-sec-0124"> <h5 class="title">Midazolam (oral)</h5> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a> found oral and rectal midazolam to be equally effective with no differences in behaviour between the groups (Additional <a href="#CD003877-tbl-0005">Table 2</a>). However, acceptance of rectal administration by the children was much poorer when compared to oral administration. </p> <p><a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a> reported that children receiving 0.75 mg/kg or 1 mg had a statistically significantly greater sedation score compared to those receiving 0.2 mg/kg or 0.5 mg/kg (P &lt; 0.05) (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). Sedation was considered inadequate in 86%, 38%, 23% and 38% of children in groups 1 to 4 respectively. Three children in group 4 (1 mg/kg) had delayed recovery time and in one patient a desaturation. Hypoxaemia, vomiting and nausea were reported as adverse effects. Authors recommended the 0.75 mg/kg dose as providing adequate sedation with good recovery time and few adverse effects. </p> <p><a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a> reported significant difference in sedation scores with 0.75 mg/kg and 1 mg/kg having higher scores compared to 0.5 mg/kg. No statistically significant difference was found in the sedation score of 0.75 mg/kg and 1 mg/kg groups. Behavioural co‐operation was better in the 1 mg/kg group followed by 0.75 mg/kg and 0.5 mg/kg groups. There was no difference in the duration of treatment between the groups although completion of treatment scores were better in the 1 mg/kg group. Discharge times were the shortest in the 0.5 mg/kg group followed by the 0.75 mg/kg group and the longest in the 1 mg/kg group. Adverse effects of respiratory events and nausea and drowsiness were noted more as the dose of midazolam increased. Authors recommended the 0.75 mg/kg as the optimal dose for effectiveness, acceptability and safety. </p> </section> </section> <section id="CD003877-sec-0125"> <h4 class="title">3. Head‐to‐head drug comparison studies</h4> <p>See Additional <a href="#CD003877-tbl-0006">Table 3</a>. Thirty‐one included studies compared different drugs and delivery methods. </p> <section id="CD003877-sec-0126"> <h5 class="title">Chloral hydrate/hydroxyzine</h5> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a> found significantly decreased crying and movement, but higher rates of oxygen desaturations and deep sedation in the chloral hydrate/hydroxyzine group. Overall there was no statistically significant difference between the groups at the time of giving the local anaesthetic injection (<a href="./references#CD003877-fig-0005" title="">Analysis 2.1</a> and Additional <a href="#CD003877-tbl-0006">Table 3</a>). All participants completed treatment in both groups. </p> <p><a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a> reported that both regimens resulted in similar sedation (Additional <a href="#CD003877-tbl-0006">Table 3</a>) and one child in the chloral hydrate/hydroxyzine group experienced vomiting. </p> <p>In the trial by <a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> good or excellent sedation was achieved by 70% of children in both the rectal chloral hydrate and oral chloral hydrate/hydroxyzine groups suggesting that these two regimens have equivalent sedative effects compared to oral chloral hydrate alone which resulted in good/excellent sedation in 40% of children, but the difference was not statistically significant (<a href="./references#CD003877-fig-0006" title="">Analysis 2.2</a> and Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> <p>In <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a> subjects in the chloral hydrate/midazolam group showed better overall behaviour as measured by Houpt (P = 0.004) and less restraint was required in the chloral hydrate/midazolam group (P &lt; 0.05). </p> <p><a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a> reported no difference in the mean overall behaviour score in each group (<a href="./references#CD003877-fig-0005" title="">Analysis 2.1</a>), though the authors noted that children in the chloral hydrate/hydroxyzine group were in a significantly deeper sleep (P = 0.0015). Treatment was aborted for one participant in the chloral hydrate/hydroxyzine group, and 60% of children in the chloral hydrate/hydroxyzine group compared with 55% of children in the midazolam/acetaminophen group had an overall evaluation of good or better sedation, a difference which was not statistically significant. This suggests that the regimens were similar in terms of effective sedation, but approximately 40% of procedures were still difficult. </p> <p>In the trial by <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> chloral hydrate/hydroxyzine resulted in "quieter" sedation as measured by OHSBRS and mean cardiac rate in each group. Authors did not provide any estimates of statistical significance but comment that although hydroxyzine alone was "not controllable", the addition of either choral hydrate or midazolam resulted in similarly enhanced sedative effects (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> </section> <section id="CD003877-sec-0127"> <h5 class="title">Chloral hydrate/promethazine</h5> <p>In <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a> three patients did not actually receive nitrous oxide because of their behaviour (one in the chloral hydrate/promethazine group displayed excellent behaviour and nitrous oxide was not required, and two children in the meperidine/promethazine group exhibited extreme head body movements such that the hood could not be used). The authors describe that over all 10 time points there was a statistically significantly greater likelihood that children were drowsy or asleep rather than awake and alert in the choral hydrate/promethazine group, but at the time the local anaesthetic injection was administered there was no difference between the two groups (<a href="./references#CD003877-fig-0005" title="">Analysis 2.1</a>). Differences between the groups in movement, crying and overall scores statistically significantly favoured the choral hydrate/promethazine group at 40% of the time points measured and in the remainder there was no difference (<a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>). Both groups completed all planned treatment and there was no difference in mean duration of treatment (Additional <a href="#CD003877-tbl-0006">Table 3</a>). No adverse effects were reported. </p> </section> <section id="CD003877-sec-0128"> <h5 class="title">Dexmedetomidine</h5> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> reported no significant difference in overall behaviour, overall success rate of treatment and distribution of sedation levels between the groups. Midazolam had statistically significant higher intra and post‐operative analgesia scores compared to the other groups. Significant difference in onset time, recovery time, pulse rate and systolic blood pressure of the two dexmedetomidine groups compared to the midazolam and ketamine groups was observed. The authors concluded that all the interventions can be used safely and effectively. </p> </section> <section id="CD003877-sec-0129"> <h5 class="title">Ketamine</h5> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> reported that both ketamine and midazolam induced the same mean sedation score of 4 (where 5 is ideal) and both had short recovery times (7 ± 7 and 3 ± 2 minutes respectively). Use of sufentanil resulted in heavily sedated children and oxygen desaturations; desaturations were of such concern that the operators broke the code during the study to determine which drug was the cause (1.5 µg/kg sufentanil in all four cases). Authors concluded that both intranasal ketamine (3 mg/kg) and midazolam (0.4 mg/kg) resulted in acceptable sedation in children. </p> <p><a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a> found that ketamine showed higher mean overall behaviour scores when compared to either midazolam or propofol (Additional <a href="#CD003877-tbl-0006">Table 3</a>, <a href="./references#CD003877-fig-0007" title="">Analysis 3.1</a>). </p> <p>When rectal ketamine (5 mg/kg)/midazolam (0.35 mg/kg) was compared to rectal midazolam (1 mg/kg) alone (<a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>), both regimens were well accepted by 78% and 70% of children, and only one child in the combination group experienced nausea. The combined regimen resulted in a statistically significant improvement in behaviour. Excessive salivation was reported in 26% and 14% and hallucinations in 14% and 42% of children in the midazolam only and ketamine/midazolam groups respectively (<a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>). In this study treatment was aborted in one patient (2%) in the ketamine/midazolam group (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> <p>In a second study (<a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a>) very good or excellent sedation was achieved in 80% of the SOP (trimeprazine/physeptone/droperidol) group and 93% of the ketamine group (<a href="./references#CD003877-fig-0008" title="">Analysis 3.2</a>) but this difference was not statistically significant. Overall evaluation, which was more subjective, was good/very good in 67% of the SOP group and 90% of the ketamine group, a difference that was statistically significant (Additional <a href="#CD003877-tbl-0006">Table 3</a>). There were more adverse effects in the ketamine group (Additional <a href="#CD003877-tbl-0006">Table 3</a>) but all participants in both groups completed treatment. </p> <p>The third trial by this group (<a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>) compared oral ketamine (5 mg/kg) plus midazolam (0.35 mg/kg) with a combination of oral trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) administered 30 minutes prior to dental treatment. In the group receiving the ketamine/midazolam combination, 46% of children were "oriented and calm" at the start of dental treatment compared to 84% in the other group (<a href="./references#CD003877-fig-0008" title="">Analysis 3.2</a>). However, the more subjective outcome of overall sedation was rated as good or very good in 94% of children in the ketamine/midazolam group compared to 78% in the trimeprazine/methadone group, a statistically significant difference favouring ketamine. However, adverse outcomes of vomiting (4%) and hallucinations (20%) were only observed in the ketamine/midazolam group in this trial. </p> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a> found no statistically significant difference in the distribution of sedation outcomes between the groups (Additional <a href="#CD003877-tbl-0006">Table 3</a>; <a href="./references#CD003877-fig-0007" title="">Analysis 3.1</a>), however four children (20%) had treatment aborted in the meperidine/promethazine group compared to none in the ketamine group. Eight children (40%) in the ketamine vomited, half of them during treatment and the remainder during recovery. </p> <p>In the trial by <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a> there was a statistically significant difference in mean Houpt behaviour score favouring ketamine (<a href="./references#CD003877-fig-0007" title="">Analysis 3.1</a>) compared to ketamine/promethazine. In one child, planned treatment was aborted (ketamine/promethazine group) but vomiting was only observed in the ketamine group (n = 3, 27%). </p> <p><a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a> showed that oral dexmedetomidine at 5 µg/kg<sup>‐1</sup> had the most "adequate" depth of sedation and "satisfactory" completion of treatment, but had no statistically significant difference compared to the other groups. Ketamine 8 mg/kg<sup>‐1</sup>and dexmedetomidine at 5 µg/kg<sup>‐1</sup> had a quicker onset time, prolonged recovery time, and better intra and post‐operative pain score compared to the other groups. Ketamine resulted in more profound retrograde amnesia. 25% (n = 7) sessions with ketamine resulted in adverse effects of vomiting and hallucinations, whereas one patient on dexmedetomidine at 5 µg/kg<sup>‐1</sup> reported vomiting. </p> </section> <section id="CD003877-sec-0130"> <h5 class="title">Midazolam (oral)</h5> <p><a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a> reported that all premedication agents produced better behaviour than just nitrous oxide at all time points (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). Ramsay sedation scores were statistically significantly greater in midazolam plus nitrous oxide group compared to nitrous oxide alone (P &lt; 0.05) (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). There was no statistically significant difference found between midazolam plus nitrous oxide and either hydroxyzine (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>) or midazolam/ketamine (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>). A wide variety of adverse effects were recorded including nausea/vomiting, cough, hiccup, enuresis, bronchospasm, hypersalivation, otalgia, hallucination and epistaxis (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> noted better depth of sedation and ease of treatment in the midazolam and tramadol groups compared to the other interventions. Ease of treatment scores between midazolam, tramadol and triclofos were not significantly different. The authors concluded that midazolam followed by tramadol is best to produce sufficient levels of sedation. </p> <p><a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> reported the most favourable sedation scores in the group receiving midazolam plus ketamine followed by the group receiving midazolam plus tramadol (data only presented graphically in paper) (Additional <a href="#CD003877-tbl-0006">Table 3</a>). No adverse effects were reported. </p> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> found significant difference in improvement of behaviour during treatment compared to baseline in the two groups. Significant difference in the level of sedation in group 1 and group 2 when a comparison is made at specific time stages (treatment‐baseline and end of treatment‐baseline) (e.g. for group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation). No significant difference in sedative efficacy or anxiolysis potential. The authors concluded that success of sedation and ease of treatment was higher in the midazolam/ketamine group compared to the dexmedetomidine group. </p> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> noticed significant differences in behaviour with the midazolam/ketamine group having better behaviour compared to the midazolam group and the no sedation group. All groups showed the same behavioural pattern at the end of the treatment session. Adverse reactions of agitation and vomiting were reported in the midazolam/ketamine group. </p> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> found the highest scores for behaviour for the intranasal midazolam/nitrous oxide followed by oral midazolam 0.75 mg/kg and nitrous oxide, oral midazolam 0.50 mg/kg and nitrous oxide and lastly the inhalation sedation nitrous oxide group. Overall success of operative treatment was significantly better in the intranasal midazolam/nitrous oxide group compared to oral midazolam 0.50 mg/kg and nitrous oxide. Between the intranasal midazolam/nitrous oxide and oral midazolam 0.75 mg/kg and nitrous oxide group no significant difference was reported. This was similar to the two oral midazolam groups where no significant difference was reported. Inhalation sedation with nitrous oxide group showed the least success rate compared to all other groups. Depth of sedation was measured using bispectral index (BIS) values. Oral midazolam 0.75 mg/kg and nitrous oxide group was most sedated except for at 30 minutes after initiation of sedation. From 15 minutes after initiation of sedation to the end of treatment in all groups had BIS values were above 90 and therefore the patients were awake. Recovery time in minutes was shorter for intranasal midazolam compared to oral midazolam groups. Adverse effect reported in the oral midazolam group was of vomiting. In the intranasal group nose bleeding, along with transient burning and discomfort was reported. After discharge irritability, crying, sleepiness and nausea were recorded. The authors concluded that both oral and intranasal midazolam in conjugation with nitrous oxide can be used to achieve moderate sedation. </p> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> sedation scores were reported on an eight‐point scale in which a high score indicated poor sedation. In order to use these data in meta‐analysis (<a href="./references#CD003877-fig-0009" title="">Analysis 4.1</a>) scores were transformed and standard deviations were calculated (Additional <a href="#CD003877-tbl-0006">Table 3</a>). No adverse effects were reported. </p> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> reported that the overall behaviour rating was significantly better in the intravenous midazolam group compared to other groups. Positive behaviour postsedation was significantly approved in the intravenous midazolam group compared to the other groups, no significant difference was reported between the oral midazolam and the oral diazepam. This study did not report standard deviations for the overall behaviour. However, as raw data were reported, these could be calculated. </p> </section> <section id="CD003877-sec-0131"> <h5 class="title">Midazolam (intravenous)</h5> <p>In <a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a> bispectral index system values noted for the ketamine/midazolam/propofol group were all in the range of general anaesthesia, whereas for the remifentanil/midazolam/propofol group at 15 minutes postadministration of the sedation the values were in the range of general anaesthesia. The ketamine/midazolam/propofol group were more deeply sedated compared to the remifentanil/midazolam/propofol group, the difference was statistically significant. Dental Sedation Teachers Group scale (DSTG) in both groups was noted as 5 (eyes closed, no response to mild physical stimulus) during the treatment. Heart rate and respiratory rate showed no significant difference between the two groups. Remifentanil/midazolam/propofol group showed quicker recovery. Adverse effects of severe nausea and vomiting was reported in the remifentanil group. The authors concluded that the remifentanil/midazolam/propofol group produced effective and safe sedation with a shorter recovery time. </p> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> noted no significant difference in the sedation score or score of operative conditions at specific time intervals. The authors concluded that there was no difference between the two interventions </p> </section> <section id="CD003877-sec-0132"> <h5 class="title">Midazolam (rectal)</h5> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> at 10 minutes found no significant difference in sedation level between the groups. After 1 hour there was a statistically significant difference favouring diazepam. More children were agitated with diazepam at 1 hour when comparing rectal midazolam to rectal diazepam (data only presented graphically in paper) (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> </section> <section id="CD003877-sec-0133"> <h5 class="title">Sevoflurane</h5> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a> compared sevoflurane (0.1% to 0.3%)/nitrous oxide (40%) with nitrous oxide (40%) alone. There was a statistically significant difference in rate of effective sedation favouring the sevoflurane/nitrous oxide group (P &lt; 0.001) (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> <p><a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a> was a pilot study which randomised children to either intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation, or 40% nitrous oxide inhalation plus intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation, or inhalation of 0.3% sevoflurane plus 40% nitrous oxide plus intravenous midazolam (0.5 mg/min) titrated to induce adequate sedation. Treatment was successfully completed in 50%, 73% and 83% of children in each group respectively and researchers noted that nine of the 16 children in groups 1 or 2 who failed were subsequently successfully treated with the addition of sevoflurane and nitrous oxide (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> <p>In the subsequent trial (<a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a>) the same interventions were used as in the pilot study and treatment completion rates were 54%, 80% and 94% for groups 1 to 3 respectively. Vomiting only occurred in group 3, but incidence was low (n = 6, 2%) (Additional <a href="#CD003877-tbl-0006">Table 3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003877-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003877-sec-0134"></div> <section id="CD003877-sec-0135"> <h3 class="title" id="CD003877-sec-0135">Summary of main results</h3> <p>See <a href="./full#CD003877-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003877-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD003877-tbl-0003">summary of findings Table 3</a>. </p> <p>In common with the findings from many other systematic reviews, the design and reporting of studies included in this review was mostly poor. In general, the risk of bias for most studies was at best a mix of low and unclear (18% of included trials) and likely to have at least one domain that was high (82% of included trials). Combining data from included studies to facilitate a meta‐analysis was difficult. The enormous range of sedative agents used both in combination and singly, along with the wide range of outcome measures, precluded meta‐analysis of homogenous groups of interventions. </p> <section id="CD003877-sec-0136"> <h4 class="title">Placebo‐controlled studies</h4> <p>It was possible to carry out a meta‐analysis for studies comparing oral midazolam with placebo (<a href="./references#CD003877-fig-0003" title="">Analysis 1.1</a>). There is consistent evidence from six heterogeneous trials, that following administration of oral midazolam the behaviour of children was improved relative to placebo, with variations in the size of the benefit according to the dosage used. Where reported, adverse effects were few and minor. This effect was considered to be moderately sized and of moderate certainty according to the GRADE recommendations. </p> </section> <section id="CD003877-sec-0137"> <h4 class="title">Dose comparison studies</h4> <p>Intranasal midazolam was evaluated in four studies, but the comparators and dosages were different and results conflicting. There is insufficient evidence to determine whether any specific dose of intranasal midazolam is effective. </p> <p>There is weak evidence from two trials that oral midazolam at a dose of 0.5 mg/kg to 0.75 mg/kg is an effective sedative for children. However, one trial administered both nitrous oxide and midazolam so it is difficult to attribute benefit to midazolam alone. </p> </section> <section id="CD003877-sec-0138"> <h4 class="title">Head‐to‐head drug comparison studies</h4> <p>In this group no two studies evaluating the same intervention and comparison found the same effect. There is insufficient evidence to draw any conclusions from these trials. </p> </section> <section id="CD003877-sec-0139"> <h4 class="title">Adverse effects</h4> <p>There is insufficient evidence from trials in this review to support the effectiveness of either chloral hydrate or ketamine. However, it should be noted that chloral hydrate was associated with significant adverse effects, specifically airway issues especially when high doses (&gt; 50 mg/kg) were combined with the use of inhalational nitrous oxide. Ketamine was also associated with significant adverse effects. </p> </section> </section> <section id="CD003877-sec-0140"> <h3 class="title" id="CD003877-sec-0140">Overall completeness and applicability of evidence</h3> <p>It was apparent whilst carrying out this review that there were significant differences in techniques and drugs used between countries and regions. Studies can be loosely grouped into two types, those based on a 'North American' model of sedation and those based on a more 'European' model. The North American model was typified by use of multiple agents (including adjunctive nitrous oxide) at any age, the use of restraint and intent to induce a deeper level of sedation. The European model was typified by use of single agents (typically nitrous oxide or midazolam) with intent to induce lighter levels of sedation. This is most likely due to cultural and legal differences and needs to be considered when making recommendations for the most effective methods of conscious sedation. </p> <p>Interpretation of outcome data related to behaviour was difficult. Over half of the studies used the Houpt or a modified Houpt scoring system to record behaviour, however the remaining studies used a wide variety of methodologies. Even within studies using modified versions of the Houpt scale, there was a large variation in how Houpt was modified. Behaviour was recorded in some studies for the whole episode and in others at a series of discrete points such as application of local anaesthetic or venepuncture. Furthermore, many of the outcome measures used relied on observations of movement, yet in a large proportion of studies patients were restrained in a papoose board. It is difficult to determine how this might have influenced recorded values of behaviour. Interestingly participants often completed treatment regardless of which group they were assigned to. This might reflect a lack of baseline anxiety in all participants which then begs the question as to why they were included in the study. Alternatively given the use of papoose boards and supplemental nitrous oxide oxygen perhaps it is not surprising. </p> <p>The efficacy of a particular agent will be influenced by the baseline anxiety of the child involved. Ideally this should always be recorded and then compared to levels of anxiety after sedation. Baseline values of anxiety were not uniformly reported and very few studies recorded anxiety at the end. </p> <p>The majority of studies involved sedation in children less than 6 years of age, probably because this age range belongs to a 'pre‐co‐operative' group. Treatment needs and management of children will vary as they grow and develop. Techniques that are appropriate in a 3‐year old may not be appropriate in a 12‐year old and vice versa. </p> <p>In most papers the medical status of the children was healthy or having mild systemic disease (American Society of Anesthesiologists (ASA) physical status classification system: ASA I and ASA II). Some of the techniques described may be useful in the management of medically compromised patients, but at present there are no studies carried out in these groups. </p> <p>Little information was provided on restorative treatment carried out in many of the studies, although several articles mentioned the use of local anaesthesia, mouth prop and rubber dam. Obviously the treatment provided may well influence the behaviour and anxiety of the participant. </p> </section> <section id="CD003877-sec-0141"> <h3 class="title" id="CD003877-sec-0141">Quality of the evidence</h3> <p>In general reporting of the trials was poor with data such as method of sequence generation and allocation concealment frequently not reported. Participants were poorly described with important information such as gender or weight often missing. Sample size calculations were either not carried out or not reported, and it is likely that many of the trials lacked statistical power to detect a difference between intervention and control. This would then result in significant imprecision. Statistical methods used varied widely between studies even though outcome measures were sometimes similar. In some instances these tests were arguably inappropriate for the types of data usually produced by these studies. </p> </section> <section id="CD003877-sec-0142"> <h3 class="title" id="CD003877-sec-0142">Potential biases in the review process</h3> <p>In a previous update (<a href="./references#CD003877-bbs2-0183" title="Lourenço‐MatharuL , AshleyPF , FurnessS . Sedation of children undergoing dental treatment. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD003877.pub4] ">Matharu 2012</a>) the decision was made to exclude cross‐over trials. Cross‐over trials were excluded as they are not an appropriate study design when the intervention can have a lasting effect (<i>Cochrane Handbook for Systematic Reviews of Interventions</i> Section 16.4.2, <a href="./references#CD003877-bbs2-0170" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). It is well recognised that previous treatment episodes influence the anxiety associated with dental treatment, especially in children. Evidence to support this can be found in <a href="./references#CD003877-bbs2-0178" title="VeerkampJS , GruythuysenRJM , HoogstratenJ , vanAmerongenWE . Anxiety reduction with nitrous oxide: a permanent solution. Journal of Dentistry for Children1995;62(1):44‐8. ">Veerkamp 1995</a>. In this study, anxiety in children who received a treatment phase under nitrous oxide was compared with children who received treatment without nitrous oxide approximately 72 weeks after the first phase. They found that overall and peak scores for anxiety were significantly reduced (P &lt; 0.05) in the nitrous oxide group at the start of the second treatment phase when compared to the control group. This decision resulted in a significant proportion of included studies from earlier versions becoming excluded. We felt this approach was justified. </p> </section> <section id="CD003877-sec-0143"> <h3 class="title" id="CD003877-sec-0143">Agreements and disagreements with other studies or reviews</h3> <p>A related review was published by the National Institute for Health and Care Excellence (NICE) on sedation in children and young people (<a href="./references#CD003877-bbs2-0176" title="National Institute for Health and Care Excellence (NICE). Sedation for diagnostic and therapeutic procedures in children and young people. Clinical Guideline CG112. Available from www.nice.org.uk/guidance/cg1122010. ">NICE 2010</a>). It was different from this Cochrane Review in that it considered sedation for any medical or dental therapeutic procedure, and it also was restricted to procedures that could be used within the regulatory framework of England and Wales. Randomised controlled trials with less than 20 subjects were excluded, cross‐over studies were included. <a href="./references#CD003877-bbs2-0176" title="National Institute for Health and Care Excellence (NICE). Sedation for diagnostic and therapeutic procedures in children and young people. Clinical Guideline CG112. Available from www.nice.org.uk/guidance/cg1122010. ">NICE 2010</a> recommended for dentistry that only midazolam or nitrous oxide be used. In common with this review they found "surprisingly few high‐quality published reports and clinical trials." </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003877-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003877-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003877-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sedatives versus placebo, Outcome 1 Mean Houpt/other behavioural score." data-id="CD003877-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Sedatives versus placebo, Outcome 1 Mean Houpt/other behavioural score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sedatives versus placebo, Outcome 2 Good or better behaviour." data-id="CD003877-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Sedatives versus placebo, Outcome 2 Good or better behaviour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chloral hydrate (CH), Outcome 1 Overall behaviour (ordinal scale, Houpt or similar)." data-id="CD003877-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Chloral hydrate (CH), Outcome 1 Overall behaviour (ordinal scale, Houpt or similar). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chloral hydrate (CH), Outcome 2 Good or better behaviour." data-id="CD003877-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Chloral hydrate (CH), Outcome 2 Good or better behaviour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ketamine, Outcome 1 Overall behaviour (ordinal scale, Houpt or similar)." data-id="CD003877-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Ketamine, Outcome 1 Overall behaviour (ordinal scale, Houpt or similar).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ketamine, Outcome 2 Good or better behaviour." data-id="CD003877-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Ketamine, Outcome 2 Good or better behaviour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Midazolam (versus other), Outcome 1 Overall behaviour (ordinal scale, Houpt or similar)." data-id="CD003877-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Midazolam (versus other), Outcome 1 Overall behaviour (ordinal scale, Houpt or similar). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Midazolam (versus other), Outcome 2 Good or better sedation." data-id="CD003877-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Midazolam (versus other), Outcome 2 Good or better sedation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003877-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/urn:x-wiley:14651858:media:CD003877:CD003877-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_t/tCD003877-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Nitrous oxide, Outcome 1 Overall behaviour (ordinal scale, Houpt or similar)." data-id="CD003877-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Nitrous oxide, Outcome 1 Overall behaviour (ordinal scale, Houpt or similar).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/media/CDSR/CD003877/image_n/nCD003877-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003877-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sedative compared to placebo for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Sedative compared to placebo for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sedative</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Midazolam (oral) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>midazolam (oral)</b> group was on average <b>1.96 SDs higher</b> (1.59 higher to 2.33 higher) than the placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>Adverse events: vomiting/hiccupping reported in 1 study. Amnesia reported in 1 study</p> <p>Oral midazolam probably improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Midazolam (intravenous) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>midazolam (intravenous)</b> group was on average <b>1.21 SDs higher</b> (0.24 higher to 2.18 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether intravenous midazolam improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Nitrous oxide </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>nitrous oxide</b> group was on average <b>0.69 SDs higher</b> (0.13 higher to 1.26 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether nitrous oxide improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt/other behavioural score</b> ‐ Diazepam (oral) </p> <p><b>SD units:</b> investigators measure behaviour using different scales ‐ Higher values mean better behaviour </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The Houpt/other behavioural score in the <b>diazepam (oral)</b> group was on average <b>0.62 SDs higher</b> (0.28 lower to 1.53 higher) than the placebo group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb 0.2 SD represents a small difference, 0.5 a moderate difference, and 0.8 a large difference </p> <p>No adverse events reported</p> <p>Uncertain whether oral diazepam improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Good or better behaviour ‐ Chloral hydrate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.80 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: associated with airway problems</p> <p>Uncertain whether chloral hydrate improves behaviour</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>533 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>709 per 1000<br/> (427 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Good or better behaviour ‐ Meperidine</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.33<br/> (1.45 to 19.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: nausea, vomiting and unmanageable behaviour were associated with meperidine use </p> <p>Meperidine may improve behaviour</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>711 per 1000<br/> (193 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>*</sup><b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (lack of blinding and randomisation processes unclear).<br/> <sup>2</sup>Downgraded for imprecision (large confidence interval and small numbers).<br/> <sup>3</sup>Downgraded for imprecision (large confidence interval).<br/> <sup>4</sup>Downgraded for risk of bias (randomisation unclear and incomplete outcome assessment).<br/> <sup>5</sup>Downgraded for risk of bias (randomisation unclear) and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sedative compared to placebo for children needing dental care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003877-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sedative compared with different dosage of the same sedative for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Sedative compared with different dosage of the same sedative for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> different dosage of the same sedative </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (any mode of delivery)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 (10)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is insufficient evidence to determine whether any specific dose of intranasal midazolam is effective </p> <p>There is weak evidence from two trials that oral midazolam at a dose of 0.5 mg/kg to 0.75 mg/kg is an effective sedative for children. However, one trial administered both nitrous oxide and midazolam so it is difficult to attribute benefit to midazolam alone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Hydroxyzine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is insufficient evidence to determine whether any specific dose of hydroxyzine is effective </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias, inconsistency and/or imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sedative compared with different dosage of the same sedative for children needing dental care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003877-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sedative compared with a different sedative for children needing dental care</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Sedative compared with a different sedative for children needing dental care</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children needing dental care<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> sedative<br/> <b>Comparison:</b> different sedative </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Chloral hydrate/hydroxyzine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 (6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>No two studies evaluating the same intervention and comparison found the same effect. There is insufficient evidence to draw any conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Chloral hydrate/promethazine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Dexmedetomidine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 (2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Ketamine versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>494 (8)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Ketamine/midazolam versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (oral) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>654 (7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Midazolam (intravenous) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 (2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐ Midazolam (rectal) versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 (1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any behavioural score ‐</p> <p>Sevoflurane versus</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1140 (3)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias, inconsistency and/or imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sedative compared with a different sedative for children needing dental care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Placebo study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Group 1 (n = 15), mean age 3.6 years, 11 males, 4 females</p> <p>Group 2 (n = 15), mean age 3.3 years, 7 males, 8 females<br/> Group 3 (n = 15), mean age 3.8 years, 9 males, 6 females<br/> Group 4 (n = 15), mean age 3.9 years, 7 males, 8 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo<br/> Group 2: chloral hydrate (20 mg/kg)<br/> Group 3: chloral hydrate (40 mg/kg)<br/> Group 4: chloral hydrate (60 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour evaluations Completion of treatment</p> <p>Analysed using Chi<sup>2</sup> and Fisher's exact test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference (P &lt; 0.05) seen between placebo and 60 mg/kg chloral hydrate group for outcome of positive behaviour in operatory. No statistically significant differences between placebo and other groups </p> <p>Data reported as numbers and percentage per group, at different stages of the treatment and displayed in graphical form </p> <p>Adverse effects: not clear, 4 children failed to respond to obstruction (Group 4) after nitrous oxide/oxygen started </p> <p>Monitoring: cardiovascular and respiratory monitoring mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dexmedetomidine (intranasal)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD) kg: 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2<br/> Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and end of treatment‐baseline) (e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation) </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Diazepam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter (e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively)) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Melatonin</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1: n = 15, 4.87 (0.99), 7 males, 8 females, 18.87 (2.5)</p> <p>Group 2: n = 15, 4.93 (1.11), 7 males, 8 females, 17.87 (3.88)</p> <p>Group 3: n = 15, 4.93 (1.10), 8 males, 7 females, 18.6 (3.31)</p> <p>Group 4: n = 15, 5.01 (1.03), 9 males, 6 females, 19.73 (4.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: melatonin (3 mg)</p> <p>Group 2: melatonin (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: placebo</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed with Kruskal‐Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score significantly higher (i.e. more sedated) for Group 3 versus all other groups (P &lt; 0.05). Sedation significantly likely to be scored as satisfactory in Group 3 versus other groups (P &lt; 0.05). Data presented graphically. No sedations scored as unsatisfactory in Group 3 </p> <p>Adverse effects: vomiting, hiccupping and coughing seen in all groups, amnesia reported in Group 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Meperidine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60<br/> Mean age (SE) in months:<br/> Group 1: n = 15, 36.5 (2.7)<br/> Group 2: n = 15, 41.7 (3)<br/> Group 3: n = 15, 35.9 (2.7)<br/> Group 4: n = 15, 43 (2.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo<br/> Group 2: meperidine (0.25 mg/lb)<br/> Group 3: meperidine (0.50 mg/lb)<br/> Group 4: meperidine (1 mg/lb) </p> <p>All intramuscular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt<br/> Dichotomous Behavior Scale </p> <p>10‐point behaviour scale</p> <p>Global Rating Scale</p> <p>Analysed using Kruskal‐Wallis, multivariant analysis of covariance (MANCOVA) and Mann‐Whitney U test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global rating scale (good to excellent) significantly favoured meperidine compared to placebo. All doses of meperidine were significantly better than placebo (P &lt; 0.05) for values of global sedation scale. All 3 scales significantly contributed to overall MANCOVA. Global rating reported as individual frequencies </p> <p>Sleep mentioned</p> <p>Adverse effects: sleep/drowsiness (Groups 1 and 3), nausea/vomiting (Groups 3 and 4), hyperexcited (Group 3) </p> <p>Monitoring: precordial stethoscope, automatic sphygmomanometer, pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant from 0.25 mg/lb group and 1 from 0.5 mg/lb group became unmanageable and treatment was not completed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam (intravenous)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32<br/> Age range = 4 to 10 years<br/> 17 males and 15 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (7.5 mg) (regardless of weight)<br/> Group 2: placebo<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall sedation mental attitude<br/> Hypnotic effects<br/> Motor activity Ease of treatment<br/> Analysed using Wilcoxon rank </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam significantly better than placebo (P &lt; 0.001) in all categories. Data presented graphically </p> <p>Sleeping mentioned</p> <p>Adverse effects and monitoring: not mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1: n = 15, 4.87 (0.99), 7 males, 8 females, 18.87 (2.5)</p> <p>Group 2: n = 15, 4.93 (1.11), 7 males, 8 females,</p> <p>17.87 (3.88)</p> <p>Group 3: n = 15, 4.93 (1.10), 8 males, 7 females, 18.6 (3.31)</p> <p>Group 4: n = 15, 5.01 (1.03), 9 males, 6 females, 19.73 (4.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: melatonin (3 mg)</p> <p>Group 2: melatonin (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: placebo</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed with Kruskal‐Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score significantly higher (i.e. more sedated) for Group 3 versus all other groups (P &lt; 0.05). Sedation significantly likely to be scored as satisfactory in Group 3 versus other groups (P &lt; 0.05). Data presented graphically. No sedations scored as unsatisfactory in Group 3 </p> <p>Adverse effects: vomiting, hiccupping and coughing seen in all groups, amnesia reported in Group 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Age: younger than 4 years old ‐ no differences at baseline with regards to age, sex and body weight </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral/transmucosal)<br/> Group 2: placebo (same volume) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation score, treatment completion, time</p> <p>No statistical tests described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly better sedation in Group 1 (mean 3.75, SD 0.85) compared to Group 2 (mean 4.6, SD 0.5) (P &lt; 0.01). 18 completed Group 1 versus 7 Group 2 (P &lt; 0.01) </p> <p>Monitored with pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (SD) years: 3.99 (0.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo</p> <p>Group 2: midazolam (0.25 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant improvement in overall behaviour in midazolam group compared to placebo group (5.1 versus 1.6, P &lt; 0.05) </p> <p>Adverse effects: none</p> <p>Monitoring: pulse oximeter, precordial stethoscope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 20 patients aborted treatment in placebo group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1: n = 11, 27.1 (8.3), 6 males, 5 females</p> <p>Group 2: n = 18 (parents refused treatment for 2), 27.7 (5.5), 9 males, 7 females</p> <p>Group 3: n = 15 (parents refused treatment for 1), 27.3 (6.4), 9 males, 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hours post‐operatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: oral midazolam (0.5 mg/kg)</p> <p>Group 2: oral diazepam (0.5 mg/kg)</p> <p>Group 3: intravenous midazolam (0.06 mg/kg)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes post drug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour post sedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Group 1: n = 19</p> <p>Group 2: n = 21</p> <p>Mean age (range) in years all subjects: 7.3 (5‐10)</p> <p>Mean weight (range) in kg all subjects:</p> <p>22.9 (16‐32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: placebo</p> <p>Group 2: midazolam (0.5 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsey</p> <p>Brietkopf and Buttner scale</p> <p>Frankl scale</p> <p>Houpt scale</p> <p>Analysed using 1‐way ANOVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scores significantly lower in placebo group for all outcomes (P &lt; 0.001)</p> <p>Adverse effects: 15 subjects reported amnesia ‐ all in the midazolam group</p> <p>Monitoring: blood pressure, pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam and ketamine (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD) kg: 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2 </p> <p>Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and end of treatment‐baseline) e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1: n = 11, 27.1 (8.3), 6 males, 5 females</p> <p>Group 2: n = 18 (parents refused treatment for 2), 27.7 (5.5), 9 males, 7 females</p> <p>Group 3: n = 15 (parents refused treatment for 1), 27.3 (6.4), 9 males, 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All Groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hours post‐operatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Nitrous oxide</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0031" title="NathanJE , VenhamLL , WestMS , WerboffJ . The effects of nitrous oxide on anxious young pediatric patients across sequential visits: a double‐blind study. ASDC Journal of Dentistry for Children1988;55(3):220‐30. ">Nathan 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 35<br/> Age range = 48 to 72 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: no intervention</p> <p>Group 2: placebo</p> <p>inhalation</p> <p>Group 3: 20‐50:50 nitrous oxide/oxygen</p> <p>inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham<br/> Parental questionnaire<br/> Behavioral screening instrument </p> <p>Ratings of anxiety and behaviour analysed using 2‐way ANOVA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly lower anxiety and behaviour ratings in nitrous oxide group (P &lt; 0.05). Data presented graphically </p> <p>Adverse effects: not mentioned Monitoring: precordial electrodes: heart rate using Epstein's measure of mean heart rate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 56<br/> Group 1: n = 27<br/> Group 2: n = 29<br/> Age range all subjects = 6 to 11 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: behaviour management</p> <p>Group 2: up to 40:60 nitrous oxide/oxygen</p> <p>All inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham scale</p> <p>Analysed using t‐test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Venham scores from T1 p177 transformed for forest plots</p> <p>Significantly better outcome (P &lt; 0.05) in nitrous oxide group (mean overall score Group 1 = 2.84, SD 0.80, Group 2 = 3.45, SD 0.92) </p> <p>Adverse effects and monitoring not mentioned</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ANOVA = analysis of variance; MANCOVA = multivariant analysis of covariance; n = number; SD = standard deviation; SE = standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Placebo study outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosage study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Hydroxyzine</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30</p> <p>14 females, 16 males</p> <p>Mean age (SD) months:</p> <p>Group 1</p> <p>61.9 (11.9)</p> <p>Group 2</p> <p>53.7 (12.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (20 mg 24 hours before) + hydroxyzine (3.7 mg/kg at the appointment)</p> <p>Group 2: hydroxyzine (3.7 mg/kg at the appointment)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using ANOVA and Mann‐Whitney</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences at any time point. At 20 minutes Houpt Group 1, 5.2 (SD 1.5) and Group 2, 4.6 (SD 1.6) </p> <p>No adverse effects reported in either group</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (intranasal)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38 children<br/> Mean age (SD) in years and gender:<br/> Group 1 (n = 12)<br/> 3.75 (0.75), 6 males, 6 females<br/> Group 2 (n = 13)<br/> 4.3 (0.65), 6 males, 7 females<br/> Group 3 (n = 13)<br/> 4 (0.71), 6 males, 7 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.3 mg/kg)<br/> Group 2: midazolam (0.4 mg/kg)<br/> Group 3: midazolam (0.5 mg/kg)<br/> All intranasal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Tukey's range test and non‐parametric 2‐factor ANOVA</p> <p>Duration of sedation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in Houpt behavioural scores between Group 3 and Group 1 (P &lt; 0.0001) and between Group 3 and Group 2 (P &lt; 0.01) </p> <p>No difference in outcomes between fasting and no‐fasting in each group (P = 0.8286)</p> <p>None of the children were asleep</p> <p>Adverse effects: sneezing and coughing during administration and drowsiness (Groups 1 and 2), diplopia (only in Group 3) </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79% 0.3 mg/kg, 96% 0.4 mg/kg and 100% 0.5 mg/kg completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 23 (12 Group 1, 11 Group 2)</p> <p>Mean age (range) in years: 5.13 (2‐9)</p> <p>Mean weight (range) in kg: 21.74 (12‐30)</p> <p>15 males, 7 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intramuscular)</p> <p>Group 2: midazolam (0.2 mg/kg) (intranasal)</p> <p>All used as premed for unspecified intravenous sedation drug</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Mann‐Whitney. Inter‐examiner variability assessed using Spearmans rank correlation </p> <p>Good/excellent sedation levels in each group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients more deeply sedated in Group 1 at time of local anaesthesia administration and venepuncture (P &lt; 0.048, P &lt; 0.015 respectively). 1 observer found Group 1 (intramuscular) significantly more effective than Group 2 (P &lt; 0.04). Not significant for the second observer (P = 0.056). Individual outcomes for each observer not reported </p> <p>Good/excellent sedation 12/12 (100%) in intramuscular group and 6/11 (54%) in the intranasal group </p> <p>Children more likely to be drowsy in Group 1</p> <p>Adverse effects: none reported</p> <p>Monitoring: heart rate, respiratory rate, blood pressure, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completed by all participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (unclear, possibly SD) in months; mean weight (unclear, possibly SD) in kg; gender: </p> <p>Group 1 (n = 20) 40.8 (11), 17 (3.6), 11 males, 9 females</p> <p>Group 2 (n = 20) 38.5 (9.8), 16.2 (4), 10 males, 10 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.7 mg/kg) (oral)</p> <p>Group 2: midazolam (0.3 mg/kg) (nasal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt ‐ domains of sleep movement and crying but no overall measure. Analysed with ANOVA, Chi<sup>2</sup> statistic and t‐test </p> <p>Mean time of onset and mean working time in each group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented on graphs only and text states no significant differences in Houpt using multivariate ANOVA (P = 0.749) </p> <p>Onset of sedation mean 5.55 minutes (SD 2.2) for nasal and mean 15.5 minutes (SD 5) for oral (P &lt; 0.001) </p> <p>Mean working time was 29.3 minutes (SD 11.6) for nasal and &amp; 38.1 min (SD 7.58) for PO (P = 0.007) </p> <p>Adverse effects: none reported, no differences between groups.</p> <p>Monitoring: oxygen saturation, heart rate, respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Group 1: 11 males, 9 females, mean age (SD) in years 3.4 (0.6), mean weight (SD) in kg 12.2 (1.2) </p> <p>Group 2: 8 males, 12 females, mean age (SD) in years 3.5 (0.7), mean weight (SD) in kg 12.6 (1.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intramuscular)</p> <p>Group 2: midazolam (0.2 mg/kg) (intranasal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt and Fukuta. Analysed using Chi<sup>2</sup> statistic and Mann‐Whitney U test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in behaviour between groups (Chi<sup>2</sup> = 0.37, P = 0.83), but both groups showed improvement from baseline. Intranasal midazolam was significantly faster acting at all time points and allowed a shorter treatment time overall (P &lt; 0.001) </p> <p>Mean onset times 15.7 ± 2.0 minutes intramuscular versus 10.8 ± 2.0 minutes intranasal</p> <p>Adverse effects: 2 patients in the intramuscular group and 6 patients in the intranasal group showed instances of sneezing/coughing/hiccups after the administration of the sedative (difference not statistically significant) </p> <p>No fasting pretreatment and no vomiting in either group</p> <p>Monitoring: heart rate, respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Score 3 given to excellent, 2 to satisfactory, 1 to unsatisfactory</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 20</p> <p>Age range = 4‐7 years</p> <p>Group 1 (n = 10)</p> <p>Group 2 (n = 10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg) (intranasal)</p> <p>Group 2: midazolam (0.2 mg/kg) (sublingual)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham's Clinical Anxiety Scale</p> <p>Salivary cortisol level</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant decrease in anxiety in Group 1 (P = 0.004) and Group 2 (P = 0.0.003) 20 minutes after drug administration </p> <p>Group 1 showed statistically significant decrease in anxiety at each of the 4 points of measurement during operative procedure (T1, T2, T3, T4), whereas Group 2 did not show statistically significant change at T1, T2 and T3 </p> <p>No significant difference in salivary cortisol levels before and after drug administration in Group 1 and Group 2 (P = 0.07, P = 0.38 respectively) </p> <p>No significant correlation between decrease in clinical anxiety and salivary cortisol level in Group 1 and Group 2 (P = 0.554, P = 0.457 respectively) </p> <p>Adverse effects: not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Mean age (SD) in years, gender, weight (SD) in kg:</p> <p>Group A: 5.1 (1.07), 12 males and 8 females, 17.5 (4.39)</p> <p>Group B: 5.2 (1.15), 12 males and 8 females, 17.4 (4.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group A: midazolam (0.2 mg/kg) (intranasal)</p> <p>Group B: midazolam (0.2 mg/kg) (sublingual)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham's Clinical Anxiety Scale</p> <p>Acceptance (<a href="./references#CD003877-bbs2-0003" title="Al‐RakafH , BelloLL , TurkustaniA , AdenubiJO . Intra‐nasal midazolam in conscious sedation of young paediatric dental patients. International Journal of Paediatric Dentistry2001;11(1):33‐40. ">Al‐Rakaf 2001</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference in Venham's anxiety score between groups at baseline or at the end time point (T4) </p> <p>Mean (SD) Venham's score at T4 in Group A 0.35 (0.59) and Group B 0.45 (1.10) P = 0.001 </p> <p>Statistically significant difference in acceptance with better acceptance in Group B compared to Group A (95% versus 40%, P = 0.001) </p> <p>Adverse effects not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 50</p> <p>Mean age (unclear, possibly SD) in years; mean weight (unclear, possibly SD) in kg; gender: </p> <p>Group 1 (n = 25), 5.36 (1.7), 19.068 (3.43), 18 males and 7 females</p> <p>Group 2 (n = 25), 4.96 (1.513), 17.804 (3.08), 12 males and 13 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral)</p> <p>Group 2: midazolam (0.35 mg/kg) (rectal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score, acceptance of application, acceptance of local anaesthesia, operating conditions, state of amnesia </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acceptance of application significantly better in oral group (72% excellent in oral group compared to 20% excellent in rectal group, P &lt; 0.05) </p> <p>No significant difference seen (P &gt; 0.05) between acceptance of local anaesthesia, state of amnesia or operating conditions. Ramsay's Sedation Scores not reported </p> <p>Adverse effects: no significant difference (P &gt; 0.05) in adverse effects between groups (56% oral, 44% rectal, included hypoxaemia, vomiting and nausea, disinhibition) </p> <p>Monitoring: oxygen saturation, heart rate, blood pressure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completed by all participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (SD) in kg:</p> <p>Group 1 (n = 14), 4.6 (1.2), 7 males and 7 females, 15.6 (2.8)</p> <p>Group 2 (n = 13), 4.4 (1.0), 8 males and 5 females, 16.2 (2.4)</p> <p>Group 3 (n = 13), 4.4 (0.9), 6 males and 7 females, 16.1 (2.4)</p> <p>Group 4 (n = 13), 4.3 (0.9), 5 males and 8 females, 15.8 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.2 mg/kg)</p> <p>Group 2: midazolam (0.5 mg/kg)</p> <p>Group 3: midazolam (0.75 mg/kg)</p> <p>Group 4: midazolam (1 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score</p> <p>Analysed using Kruskal‐Wallis, Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At the 20 minute time point, mean Ramsay Sedation Score was 1.2 (0.4), 1.6 (0.5), 2.2 (0.6), 2.7 (1.0) in Groups 1‐4 respectively. Children in Groups 3 and 4 were more sedated than children in Groups 1 and 2 (P &lt; 0.05) </p> <p>Sedation considered inadequate in 12/14, 5/13, 3/13 and 5/13 in Groups 1‐4 respectively</p> <p>Mean recovery time was 45 (0), 45 (0), 47.3 (8.3), and 57.7 (42.8) minutes in Groups 1‐4 respectively </p> <p>Adverse effects: most of the adverse effects were seen in Group 4 with 1 patient desaturating and 3 presenting with delayed recovery, no adverse effects in Group 1 and "very few" in Groups 2 and 3 </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90 (30 per group)</p> <p>Age range = 3‐10 years</p> <p>Mean age (SD) in years, weight (SD) in kg:</p> <p>Group 1: 5.6 + 1.85 years, 19.2 + 3.68 kg</p> <p>Group 2: 5.6 + 1.67 years, 19.7 + 3.38 kg</p> <p>Group 3: 6.2 + 2.00 years, 20.3 + 3.65 kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)</p> <p>Group 2: midazolam (0.75 mg/kg)</p> <p>Group 3: midazolam (1 mg/kg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wisconsin Sedation Scale</p> <p>Houpt behavioural rating scale</p> <p>Parent satisfaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation and behaviour co‐operation scores were noted at baseline, 15 minutes, 30 minutes and 45 minutes. Significant difference with sedation scores in Group 1 lower than Group 2 and Group 3 (P &lt; 0.001) </p> <p>No significant difference (P &lt; 0.001) in sedation score of Group 2 and Group 3 except at baseline </p> <p>Behavioural co‐operation score was significantly lower (P &lt; 0.001) in Group 1 compared to Group 2 and Group 3. Significant difference (P &lt; 0.001) in behaviour scores of Group 2 and Group 3 with Group 2 having lower scores at baseline and 45 minutes </p> <p>Significant difference (P = 0.025) in completion scores between Group 1 and Group 3 </p> <p>No significant difference (P = 0.43) in duration between the groups</p> <p>Significant difference in discharge time between the groups. Group 1 had shorter mean inpatient stay (85 minutes + 18.5, P &lt; 0.001) compared to Group 2 (103.7 + 13.3 minutes) and Group 3 (137 + 14.7 minutes) </p> <p>Significant difference in parent satisfaction (P &lt; 0.001) where Group 1 is lower than Group 2 and Group 3. No significant difference (P = 0.147) between Group 2 and Group 3 </p> <p>Adverse effects: respiratory events Group 2 (3/30), Group 3 (10/30)</p> <p>Nausea and drowsiness Group 1 (3/30), Group 2 (7/30), Group 3 (12/30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 20% (n = 6), Group 2 6.7% (n = 2) did not complete treatment</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ANOVA = analysis of variance; n = number; SD = standard deviation.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dosage study outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drug comparison study outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate/hydroxyzine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (SD) in months and gender:<br/> Group 1 (n = 20), 27.7 (2.9), 13 males and 7 females<br/> Group 2 (n = 20), 29.2 (3.6), 14 males and 6 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (70 mg/kg)<br/> Group 2: chloral hydrate (70 mg/kg) + hydroxyzine (2 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using Kruskal‐Wallis and Mann‐Whitney U tests</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P &gt; 0.05) for overall behaviour evaluation (mean values reported at 7 different time intervals e.g. at injection mean behaviour Group 1 = 4.9 (SD 1.1), Group 2 = 5.0 (SD 0.68) </p> <p>Crying and movement evaluations significantly better (P &lt; 0.05) at 45‐60 minutes after application of rubber dam for Group 1 </p> <p>Sleep mentioned</p> <p>Adverse effects: Group 1 15%‐30% children has oxygen saturation &lt; 90% but in Group 2 range was 10%‐45% </p> <p>Monitoring: precordial stethoscope, pulse oximeter and sphygmomanometer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (age range) in months:<br/> Group 1 (n = 20), 44 (21 to 74)<br/> Group 2 (n = 20), 42 (23 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate<br/> (40 mg/kg) + hydroxyzine (25 mg)<br/> Group 2: triazolam (0.02 mg/kg) </p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt. Analysed using ANOVA and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences between groups (mean overall behaviour Group 1 and Group 2 the same with a value of 4.3 (SE 0.4354) </p> <p>Sleeping mentioned</p> <p>Adverse effects: vomiting (1 child in Group 1)</p> <p>Monitoring: pulse oximeter and precordial stethoscope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30<br/> Mean age in months:<br/> Group 1 (n = 10), 39.6<br/> Group 2 (n = 10), 42<br/> Group 3 (n = 10), 38.4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) (oral)<br/> Group 2: chloral hydrate (50 mg/kg) (rectal)<br/> Group 3: chloral hydrate (30 mg/kg) + hydroxyzine (25 mg) (oral) </p> <p>All received nitrous oxide inhalation 30%‐50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Barker<br/> Overall quality sedation </p> <p>Behavioural data not statistically analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good or excellent sedation achieved in 4/10, 7/10 and 7/10 of children in oral chloral hydrate, rectal chloral hydrate and oral chloral hydrate/hydroxyzine groups respectively </p> <p>Adverse effects: not mentioned</p> <p>Monitoring: precordial stethoscope and pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 31</p> <p>Mean age in months (SD), gender, mean weight in kg (SD):</p> <p>CH Group 44.5 (14.1), 6 males and 9 females, 15.6 (2.7)</p> <p>CH‐M Group 34.3 (9.3), 11 males and 5 females, 15.1 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CH Group: chloral hydrate (60 mg/kg) + hydroxyzine (1 mg/kg) (both oral)</p> <p>CH‐M Group: chloral hydrate (60 mg/kg oral) + hydroxyzine (1 mg/kg oral) + midazolam (0.1 mg/kg submucosal) </p> <p>All received nitrous oxide inhalation 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Requirement for restraint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects in the CH‐M Group showed better overall behaviour as measured by Houpt. Mean score 0.47 (SD 0.5) in CH Group versus 0.81 (0.39) in CH‐M Group, P = 0.004 </p> <p>Less restraint was required in the CH‐M Group (P &lt; 0.05)</p> <p>Adverse effects: not reported</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (age range) in months, gender:<br/> Group 1 (n = 20), 48 (32 to 73), 11 males and 9 females<br/> Group 2 (n = 20), 42 (27 to 70), 10 males and 10 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) +<br/> hydroxyzine (25 mg)<br/> Group 2: midazolam (0.5 mg/kg) + acetaminophen (10 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Wilcoxon matched pairs test and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects in chloral hydrate/hydroxyzine group were in a significantly deeper sleep (P &lt; 0.05). Data presented graphically. Sleeping mentioned </p> <p>Adverse effects: not reported</p> <p>Monitoring: pulse oximeter, precordial stethoscope and capnograph</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant from chloral hydrate/hydroxyzine group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 54</p> <p>Mean age (age range) in years; mean weight (range) in kg; gender:</p> <p>Group 1: 3.9 (4‐6), 11 males, 7 females, 18.1 (0.9‐22)</p> <p>Group 2: 2.83 (1‐8), 11 males, 7 females, 15 (10.4‐22.5)</p> <p>Group 3: 2.94 (1‐10), 10 males, 8 females,</p> <p>16.33 (10.4‐20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (2 mg/kg 2 hours before, 1 mg/kg 20 minutes before)</p> <p>Group 2: midazolam (0.5 mg/kg) + hydroxyzine (1.5 mg/kg)</p> <p>Group 3: chloral hydrate (50 mg/kg) + hydroxyzine (1.5 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State Behavioral Rating Scale</p> <p>Analysed using Wilcoxon matched pairs test and Kruskal Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Significantly quieter" (mean cardiac rate 152, 146 and 137 in Group 1, Group 2 and Group 3 respectively (no P value given). Data presented graphically suggesting less movement in Group 3 </p> <p>Adverse effects: in Group 3 1/18 experienced oxygen saturation &lt; 90%</p> <p>Monitoring: oxygen saturation and cardiac rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Chloral hydrate/promethazine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 24<br/> Mean age (SD) in months:<br/> Group 1 (n = 13), 31.0 (8.6)<br/> Group 2 (n = 11), 35.8 (10.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: chloral hydrate (50 mg/kg) + promethazine (1 mg/kg)<br/> Group 2: meperidine (1 mg/kg) + promethazine (1 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Hotelings T test and 2‐sample t‐test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloral hydrate/promethazine group significantly "better" (P &lt; 0.05) for overall evaluation at 4 of the 10 measured time intervals (e.g. mean overall behaviour 15 minutes post‐injection Group 1 = 5.2 (SD 1.1), Group 2 = 4.4 (SD 1.3), P &lt; 0.05) </p> <p>Adverse effects: not reported</p> <p>Significantly more sleep in Group 1 than Group 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment and mean treatment duration was 50.8 (SD 13.3) and 50.9 (SD 17.6) in Groups 1 and 2 respectively </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dexmedetomidine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 36</p> <p>Age range = 3‐9 years</p> <p>Mean age (SD) in years: 4.60 + 1.99</p> <p>Mean weight (SD): 15.62 + 4.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: intranasal normal saline, oral midazolam (0.5 mg/kg) + oral ketamine (5 mg/kg) in 30 ml of mango juice </p> <p>Group 2: intranasal dexmedetomidine (1 µ/kg), 30 ml of mango juice</p> <p>Group 3: intranasal normal saline, 30 ml of mango juice</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Observer Assessment of Alertness and Sedation (MOAAS)</p> <p>Houpt scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.007) in behaviour during treatment compared to baseline in Group 1 and Group 2 </p> <p>Significant difference in the level of sedation in Group 1 and Group 2 when a comparison is made at specific time stages (treatment‐baseline and, end of treatment‐baseline) e.g. for Group 1 treatment‐baseline comparison shows significant difference (P = 0.002) in the level of sedation </p> <p>No significant difference between Group 1 and Group 2 in sedative efficacy or anxiolysis potential </p> <p>Adverse effects: not reported</p> <p>Monitoring: blood pressure, heart rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 84</p> <p>Age range in years, mean age (SD) in years:</p> <p>Group 1 (n = 21) 7.34 (2.34)</p> <p>Group 2 (n = 21) 6.71 (2.31)</p> <p>Group 3 (n = 21) 7.76 (2.26)</p> <p>Group 4 (n = 21) 7.24 (2.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: dexmedetomidine (1 µg/kg)</p> <p>Group 2: dexmedetomidine (1.5 µg/kg)</p> <p>Group 3: midazolam (0.2 mg/kg)</p> <p>Group 4: ketamine (5 mg/kg)</p> <p>All intranasal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified AAPD Sedation Record</p> <p>Face, Legs, Activity, Cry and Consolability (FLACC) scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P = 0.378) in overall behaviour was observed</p> <p>No significant difference (P = 0.242 and P = 0.120) in overall success rate of treatment and distribution of sedation levels between the groups </p> <p>Significant difference (P &gt; 0.05) in intra and postoperative analgesic effects reported with Group 1, Group 2 and Group 4 significantly better than Group 3 e.g. intraoperative analgesia score Group 3 = 5.62 (SD 1.12) compared to Group 1 = 3.81 (0.81), Group 2 = 3.67 (0.91) and Group 4 = 3.52 (0.68) </p> <p>Significant difference (P &gt; 0.05) in onset time, recovery time, pulse rate and systolic blood pressure of Group 1 and Group 2 compared to Group 3 and Group 4 was observed </p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Ketamine versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (10 per group with sufentanil divided into 2 subgroups of 5 each)<br/> Age range = 17 to 62 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (3 mg/kg)<br/> Group 2: midazolam (0.4 mg/kg)<br/> Group 3: sufentanil (1 µg) </p> <p>Group 4: sufentanil (1.5 µg)<br/> All intranasal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation scoring criteria</p> <p>No statistical tests used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groups 1 to 3 had mean sedation score of 4 (acceptable sedation), Group 4 had mean sedation score of 7 (heavy sedation) </p> <p>Mean recovery times (± SD) were 7 (± 7), 3 (± 2), 7 (± 13), and 58 (± 40) minutes for Groups 1‐4 respectively </p> <p>Sleeping mentioned</p> <p>Adverse effects: drowsiness (Group 1), mild obtundation and deep sedation (Group 3), desaturations in 4/5 children on high dose sufentanil </p> <p>Monitoring: pulse oximeter, automatic blood pressure and if necessary capnograph</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 30 (10 per group)</p> <p>Age range 3‐6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.1 mg/kg) (bolus) + 0.004 mg/kg/min (infusion)</p> <p>Group 2: propofol (1 mg/kg) (bolus) + 0.06 mg/kg/min (infusion)</p> <p>Group 3: ketamine (0.5 mg/kg) (bolus) + 0.01 mg/kg/min (infusion)</p> <p>All intravenous</p> <p>All children had premedication 1 hour before of 0.5 mg/kg midazolam and atropine (0.6 mg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed Kruskal Wallis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The maximum level of co‐operation was seen with ketamine then propofol and then midazolam (P &lt; 0.001) </p> <p>At treatment end mean scores were 5.8 ± 0.42, 3.5 ± 1.08 and 3.2 ± 0.42 in ketamine, propofol and midazolam groups respectively </p> <p>Propofol showed the fastest postoperative recovery score followed by ketamine and the midazolam. Sleeping was reported </p> <p>Adverse effects: pain on injection with propofol and intermittent cough</p> <p>Monitoring: vital signs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 100<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 50), 4.3 (1), 24 males and 26 females<br/> Group 2 (n = 50), 4.3 (1.1), 22 males and 28 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (5 mg/kg) + midazolam (0.35 mg/kg)<br/> Group 2: midazolam (1 mg/kg)<br/> All rectal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score<br/> Movement<br/> Crying </p> <p>Overall sedation and behaviour</p> <p>Analysed using McNewman's test (sic), Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant differences in level of sedation with 71% subjects in Group 2 "orientated and calm" compared to 14% in Group 1 30 minutes after administration </p> <p>Significantly less movement and crying (P &lt; 0.05) in Group 1 (58% no movement at all compared to 14% in Group 2) </p> <p>Sleep mentioned</p> <p>Adverse effects: hallucination (Groups 1 (14%) and 2 (42%)), nausea (Group 1)</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant (ketamine/midazolam group)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 30), 4.8 (1.3), 14 males and 16 females<br/> Group 2 (n = 30), 4.9 (1.3), 16 males and 14 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: 0.5 ml/kg of trimeprazine 6 mg/ml + physeptone (methadone) (0.4 mg/ml) + droperidol (0.1 mg/kg)<br/> Group 2: ketamine (12.5 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety<br/> Level of sedation<br/> Movement<br/> Crying<br/> Overall behaviour Analysed using McNemar test, Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation was significantly "better" (very good/excellent 80% and 93% of Group 1 and Group 2 respectively) </p> <p>Overall evaluation good/very good in 67% and 90% of Group 1 and Group 2 respectively</p> <p>Sleeping mentioned</p> <p>Adverse effects: hallucination (9 and 5), restless/irritation 4 and 1, in Group 1 and Group 2 </p> <p>Ketamine also 2 vomiting/nausea, 4 visual disturbances and 4 excess salivation</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 100<br/> Mean age (SD) in years, gender:<br/> Group 1 (n = 50), 4.1 (1.3), 27 males and 23 females<br/> Group 2 (n = 50), 4 (1.2), 29 males and 21 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (5 mg/kg) + midazolam (0.35 mg/kg)<br/> Group 2: trimeprazine (3 mg/kg) + methadone (0.2 mg/kg)<br/> All oral </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt, Ramsay Sedation Score</p> <p>Analysed using McNemar's test, Chi<sup>2</sup> and Fisher's Exact tests </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant differences (P &lt; 0.05) in level of sedation immediately before treatment with 46% participants in Group 1 "oriented and calm" compared to 84% in Group 2 </p> <p>Overall surgeons rated 94% versus 78% of sedations as good/very good in Group 1 versus Group 2 </p> <p>Sedation rated as poor in significantly more children in Group 2 (24%) than Group 1 (6%) </p> <p>Sleeping mentioned</p> <p>Adverse effects: vomiting (n = 2) and hallucination (n = 10) in Group 1</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0044" title="SinghC , PandeyRK , SaksenaAK , ChandraG . A comparative evaluation of analgo‐sedative effects of oral dexmedetomidine and ketamine: a triple‐blind, randomized study. Pediatric Anesthesia2014;24(12):1252‐9. ">Singh 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 112</p> <p>Age range = 1‐10 years</p> <p>Mean age (SD) in years, gender and weight (SD) in kg:</p> <p>Group 1 (n = 28), 6.54 (1.79), 14 males and 14 females, 18.89 (4.33)</p> <p>Group 2 (n = 28), 6.93 (2.05), 13 males and 15 females, 17.04 (5.33)</p> <p>Group 3 (n = 28), 7.21 (1.98), 11 males and 17 females, 16.93 (4.22)</p> <p>Group 4 (n = 28), 6.82 (2.22), 14 males and 14 females, 16.61 (4.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (8 mg/kg<sup>‐1</sup>) </p> <p>Group 2: dexmedetomidine (3 µg/kg<sup>‐1</sup>) </p> <p>Group 3: dexmedetomidine (4 µg/kg<sup>‐1</sup>) </p> <p>Group 4: dexmedetomidine (5 µg/kg<sup>‐1</sup>) </p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset time, recovery time</p> <p>Sedation rating scale modified from AAPD guidelines</p> <p>Face, Legs, Activity, Cry and Consolability Pain Scale (FLACC)</p> <p>Anterograde amnesia</p> <p>Behaviour score</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 4 had highest "adequate" depth of sedation and "satisfactory" completion of treatment (82.1%, 85.7% respectively), but was not significantly different to Group 1, Group 2 and Group 3 </p> <p>Significant difference (P &lt; 0.001) in lowering of pulse rate and systolic blood pressure in Group 2, Group 3 and Group 4 compared to Group 1 </p> <p>Significant difference (P &lt; 0.001) in onset time, recovery time (except Group 1 and Group 4), intra and postoperative pain scores when comparing the groups e.g. postoperative pain score in Group 1 = 1.54 (0.63) and Group 4 = 1.79 (0.74) were lower compared to Group 2 = 2.43 (0.88) and Group 3 = 2.11 (1.19) </p> <p>Adverse effects: in office vomiting (Group 1 n = 5, Group 4 n = 1), emergency reaction (Group 1 n = 2) </p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40<br/> Mean age (SD) in months:<br/> Group 1 (n = 20) 40.4 (10.2)<br/> Group 2 (n = 20) 37.5 (10.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (6 mg/kg)<br/> Group 2: meperidine (2.0 mg/kg) + promethazine (0.5 mg/kg)<br/> All oral </p> <p>All received nitrous oxide 30%‐50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Houpt</p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Good sedation" in 65% of ketamine group and 45% of meperidine/promethazine</p> <p>Overall no statistically significant difference in distribution of sedation outcomes between groups (P = 0.07) </p> <p>Sedation onset time and recovery time both shorter for ketamine (P &lt; 0.001 and P = 0.08 respectively) </p> <p>Adverse effects: vomiting (Groups 1 (n = 8) and 2 (n = 1))</p> <p>Monitoring: precordial stethoscope and pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 4 children receiving meperidine and none in ketamine group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 22<br/> Mean age (SD) in months:<br/> Group 1 (n = 11) 34 (6.28)<br/> Group 2 (n = 11) 33 (6.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: ketamine (10 mg/kg) + promethazine (1.1 mg/kg)<br/> Group 2: ketamine (10 mg/kg)<br/> All oral </p> <p>All received nitrous oxide 50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference in mean Houpt score favouring ketamine group (mean score 4.27, SD 0.5) (Group 1 (mean score 3.12, SD 0.29)) (P &lt; 0.05) </p> <p>Adverse effects: 3 patients from Group 2 vomited. Most of the patients reported as being drowsy or asleep after 25 minutes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental treatment aborted in 1 participant from Group 1 due to violent physical movement and crying </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Ketamine/midazolam versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (SD) in years, gender, mean weight (25% median to 75%) in kg:</p> <p>Group 1 (n = 13), 4.7 (0.6), 10 males, 3 females, 16.5 (15.7‐19.6)</p> <p>Group 2 (n = 14), 5.2 (0.8), 8 males, 6 females, 19.6 (16.7‐23.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg) (oral)</p> <p>Group 2: midazolam (0.5 mg/kg) (oral) + ketamine (3 mg/kg) (oral) + sevoflurane (0.1%‐0.4% inhalation) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt</p> <p>Analysed using Mann‐Whitney U test</p> <p>Adverse events</p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference in overall Houpt score between the 2 groups (P &gt; 0.05 data presented graphically) </p> <p>Adverse events: more children in Group 1 reported adverse events at 24 hours than Group 2 (Group 1 n = 10, Group 2 n = 4; P = 0.01) </p> <p>Adverse events seen in all children included: excessive drowsiness 22% (n = 6), vomiting 22% (n = 6) </p> <p>No apnoea /drop in oxygen saturation seen</p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment not completed in 1 child from Group 1 due to poor co‐operation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (oral) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Mean age (unclear, possibly SD) in years, mean weight (unclear, possibly SD) in kg, gender: </p> <p>Group 1 (n = 15), 5.33 (0.62), 18.93 (2.31), 10 males and 5 females</p> <p>Group 2 (n = 15), 5.27 (0.80), 19.07 (3.62), 11 males and 4 females</p> <p>Group 3 (n = 15), 5.20 (0.41), 18.20 (2.34), 9 males and 6 females</p> <p>Group 4 (n = 15), 5.53 (0.99), 20.01 (3.99), 6 males and 9 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: hydroxyzine (1 mg/kg) (oral)</p> <p>Group 2: midazolam (0.7 mg/kg)</p> <p>Group 3: ketamine (3 mg/kg) + midazolam (0.25 mg/kg)</p> <p>Group 4: no oral premedication</p> <p>40% nitrous oxide oxygen was administered to all participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Score, Bispectral Index System</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramsay Sedation Scores (RSS) were significantly greater in Group 2 compared to Groups 1, 3 and 4 (P &lt; 0.05) </p> <p>RSS satisfactory/mid‐level satisfactory/unsatisfactory<br/> was as follows: </p> <p>Group 1: 13.3%/53.3%/33.3%</p> <p>Group 2: 54%/20%/26%<br/> Group 3: 33.3%/33.3%/33.3% </p> <p>Group 4: 6.7%/60%/33.3%</p> <p>P value or significance not reported</p> <p>Adverse effects: nausea/vomiting (n = 1/2/3/4), cough (4/4//), hiccough (/1//5), enuresis (/2//), bronchospasm (/1//), hypersalivation (//8/), otalgia (///2), hallucination (//2/), and epistaxis (///1) in patients in groups 1, 2, 3, and 4, respectively </p> <p>Monitoring: pulse oximeter</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Figure 5 used to extrapolate data with score 3 given to satisfactory, 2 middle level, 1 unsatisfactory </p> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 60</p> <p>Age range = 3‐9 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)</p> <p>Group 2: tramadol (2 mg/kg)</p> <p>Group 3: triclofos (70 mg/kg)<br/> Group 4: zolpidem (0.4 mg/kg) </p> <p>All oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sedation rating scale</p> <p>Ease of treatment completion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P &lt; 0.001) in the level of sedation (median scores) with Group 4 &gt; Group 3 &gt; Group 2 = Group 1 </p> <p>Mean score in the ease of treatment shown in the table of results reports Group 4 &gt; Group 3 &gt; Group 2 &gt; Group 1 </p> <p>No statistical difference between (P &gt; 0.05) between Group 1, Group 2, Group 3 in ease of treatment. Group 4 was found to have a statistical difference compared to the other groups (P &lt; 0.001) </p> <p>Adverse effects: not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 44</p> <p>Average age below 36 months</p> <p>Mean age (SD) in months, gender:</p> <p>Group 1 (n = 11), 27.1 (8.3), 6 males and 5 females</p> <p>Group 2 (n = 18, parents refused treatment for 2), 27.7 (5.5), 9 males and 7 females</p> <p>Group 3 (n = 15, parents refused treatment for 1), 27.3 (6.4), 9 males and 4 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 2: midazolam (1 mg/kg)</p> <p>Group 3: no sedation</p> <p>Group 1 and 2 oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ohio State University Behavior Rating Scale (OSUBRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference in behaviour (P = 0.003) between Group 1 and Group 2 and Group 1 and Group 3 (P = 0.03) when sedatives used </p> <p>Behaviour during various stages of treatment sessions was observed e.g. for local anaesthetic administration OSUBRS score for Group 1 was lower than Group 2 (P = 0.06) and Group 3 (P = 0.02) </p> <p>During rubber dam placement OSUBRS score for Group 1 was lower than Group 2 (P = 0.01) and Group 3 (P = 0.07). All Groups showed same behavioural pattern at the end of the treatment session (P = 0.25) </p> <p>Sleep mentioned</p> <p>Adverse effects: within 24 hour postoperatively Group 1 presented with agitation and vomiting in 3 children </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants completed treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 120 (20 per group)</p> <p>Age range: 2‐9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (9.5 mg/kg)</p> <p>Group 2: ketamine (5 mg/kg)</p> <p>Group 3: zolpidem (0.4 mg/kg)</p> <p>Group 4: midazolam (0.4 mg/kg) + ketamine (3 mg/kg)</p> <p>Group 5: midazolam (0.5 mg/kg) + tramadol (2 mg/kg)</p> <p>Group 6: zolpidem (0.4 mg/kg) + tramadol (2 mg/kg)</p> <p>All oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of action</p> <p>Level of sedation</p> <p>Ease of treatment completion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 4 and 5 the "best" and Groups 3 and 6 the "worst" when compared on level of sedation (P &lt; 0.001) </p> <p>Group 4 had the shortest time of onset of sedation</p> <p>(Data presented graphically)</p> <p>No adverse effects were reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90 (30 per group)<br/> Age range: 3‐9 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg)<br/> Group 2: triclofos (70 mg/kg)<br/> Group 3: promethazine (1.2 mg/kg)<br/> All oral </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of sedation</p> <p>Time of onset, time of recovery</p> <p>Statistical techniques not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transformed sedative scores</p> <p>Group 1: 3.3 ± 0.7 (best)</p> <p>Group 2: 3.07 ± 0.6</p> <p>Group 3: 2.73 ± 0.5</p> <p>Both Groups 1 and 2 were statistically significantly better than Group 3 (P &lt; 0.05)</p> <p>Time of onset and time of recovery were both shortest in Group 1</p> <p>Adverse effects: not mentioned</p> <p>Monitoring: blood pressure, heart and respiratory rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 240 (n = 60 per group)</p> <p>Mean age (SD) in months 57.02 (9.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.20 mg/kg (40 mg/ml)) (intranasally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 2: midazolam (0.75 mg/kg (15 mg/3 ml)) (orally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 3: midazolam (0.50 mg/kg (15 mg/3 ml)) (orally) + inhalation sedation 50%–50% nitrous oxide/oxygen </p> <p>Group 4: inhalation sedation 50%–50% nitrous oxide/oxygen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bispectral Index System (BIS)</p> <p>Modified scale to classify behaviour</p> <p>Vancouver Recovery Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified scale used to classify behaviour/ respond to treatment/sedation was highest in Group 1 (87%) followed by Group 2 (79%), Group 3 (72%) and Group 4 (55%) respectively </p> <p>No significant difference (P = 0.230 and P = 0.399) in overall success rate between Group 1 and Group 2, Group 2 and Group 3 respectively. Significant difference (P &lt; 0.05) between Group 1 and Group 3. Significant difference Group 4 compared to all other groups </p> <p>BIS values recorded every 5 minutes, Group 2 was most sedated except for at 30 minutes. From 15 minutes to end of treatment all groups had BIS value above 90 </p> <p>Recovery time in minutes was shorter for intranasal midazolam (22.3) compared to 0.50 mg/kg oral midazolam (27.5) and 0.75 mg/kg oral midazolam (29.2) </p> <p>Sleep mentioned</p> <p>Adverse effects:</p> <p>‐ drug administration: vomiting in oral midazolam group (4), nose bleeding intranasal midazolam group (1), transient burning and discomfort nasal midazolam group (not reported) </p> <p>‐ recovery period: vomiting in oral midazolam group (7), coughing in intranasal midazolam group (1), transient burning and discomfort nasal midazolam group (not reported) </p> <p>‐ after discharge: irritability (42%), crying (34%), sleepiness (31%), nausea (5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 40</p> <p>Age range = 2‐10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/kg) (oral)</p> <p>Group 2: diazepam (0.5 mg/kg) (oral)</p> <p>Group 3: midazolam (0.06 mg/kg) (intravenous)</p> <p>Group 4: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Houpt scale</p> <p>Child behaviour questionnaire</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour was assessed in terms of sleep, crying and movement at 30 minutes postdrug administration in Group 1, Group 2 and Group 4 or 5 minutes in Group 3. At placement of blood pressure cuff, during administration of local anaesthesia or use of hand piece and every 15 minutes thereafter e.g. at administration of local anaesthetic agent or use of hand piece significantly lower (P &lt; 0.001) sleep in Group 4 compared to other groups. Significantly less crying in Group 3 compared to Group 1, Group 2 and Group 4 (P &lt; 0.001, P &lt; 0.01 and P &lt; 0.05 respectively) </p> <p>Overall behaviour rating was significantly better (P &lt; 0.001) in Group 3 compared to other groups </p> <p>Positive behaviour postsedation: no significant difference between Group 1 and Group 2. Significant improvement (P &lt; 0.05) in Group 3 compared to Group 2 </p> <p>Sleeping mentioned</p> <p>Adverse effects: not reported</p> <p>Monitoring: oxygen saturation, respiratory rate, blood pressure and respiratory rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Midazolam (intravenous) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 38</p> <p>Age range = 4‐9 years</p> <p>Gender, mean age in years:</p> <p>Group 1 (n = 18), 8 males and 10 females, 6.27</p> <p>Group 2 (n = 20), 12 males and 8 females, 6.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.05 mg/kg) + ketamine (0.5 mg/kg)<br/> Group 2: midazolam (0.05 mg/kg) + fentanyl (0.5 µg/kg) </p> <p>All intravenous, administered by an anaesthesiologist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental Sedation Teacher Groups System</p> <p>Frankl behaviour rating scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference (P &gt; 0.05) in intraoperative sedation score and score of operative conditions at 10<sup>th</sup>, 20<sup>th,</sup> 30<sup>th</sup> and 40<sup>th</sup> minute </p> <p>Significant difference (P &lt; 0.05) in the sedation score and score of operating condition in Group 1 and Group 2 at 10‐20 minutes, 10‐30 minutes </p> <p>Adverse effects: not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0011" title="EshghiA , MohammadpourM , KavianiN , TahririanD , AkhlaghiN . Comparative evaluation of bispectral index system after sedation with midazolam and propofol combined with remifentanil versus ketamine in uncooperative during dental procedures. Dental Research Journal2016;13(1):1‐6. ">Eshghi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32</p> <p>Age range = 3‐7 years</p> <p>Mean age (SD) in years: 4.36 (1.6)</p> <p>Group 1 (n = 16), 7 males and 9 females</p> <p>Group 2 (n = 16), 8 males and 8 females</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: remifentanil (0.1 µg/kg/min) + midazolam (0.01 mg/kg) + propofol (0.5 mg/kg)</p> <p>Group 2: ketamine (0.5 mg/kg) + midazolam (0.1 mg/kg) + propofol (0.5 mg/kg)</p> <p>All intravenous</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bispectral Index System (BIS)</p> <p>DSTG scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant difference (P = 0.003) with higher BIS values in Group 1 compared to Group 2 </p> <p>DSTG score noted at 9 different time intervals was 5 (eyes closed, no response to mild physical stimulus) in Group 1 and Group 2 </p> <p>Heart rate and respiratory rate showed no significant difference between Group 1 and Group 2 (P = 0.884, P = 0.775 respectively) </p> <p>Significant difference (P &lt; 0.001) with Group 1 having quicker recovery compared to Group 2 ( 9.23 + 2.77, 30.83 + 5.96 minutes) </p> <p>Adverse effects: severe nausea and vomiting was reported in Group 1, number not reported</p> <p>Monitoring: heart rate, respiratory rate, oxygen saturation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Midazolam (rectal) versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 90<br/> Median age (age range) in months and gender:<br/> Group 1 (n = 45), 32 (18 to 44), 23 males and 22 females<br/> Group 2 (n = 45),<br/> 29 (15 to 44), 23 males and 22 females </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: diazepam (0.7 mg/kg)<br/> Group 2: midazolam (0.3 mg/kg)<br/> All rectal </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wilton's sedation scale<br/> Acceptance of treatment (Holst) </p> <p>Analysed using Wilcoxon matched pair test and Fisher's exact test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference in acceptance of dental procedures (P = 0.07)</p> <p>At 1 hour significantly more children agitated in the diazepam group 13/45 (29%) versus 1/45 (2%) (P = 0.006) </p> <p>Data presented graphically</p> <p>Adverse effects: lasting effect: aggressiveness, tiredness and unco‐ordinated movements in diazepam group, children unusually quiet or lively on next day in Group 2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some children did not complete treatment however, it is not possible to extract exact numbers as these data were only presented as bar chart </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sevoflurane versus</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 411<br/> Mean age (SD) in years:<br/> Group 1 (n = 170), 6.2 (1.9)<br/> Group 2 (n = 241), 6 (1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: 40:60 nitrous oxide/oxygen</p> <p>Group 2: 40:60 nitrous oxide/oxygen + 0.1%‐0.3% sevoflurane</p> <p>All inhalation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venham scale level of sedation and failure rate</p> <p>Analysed using Mann‐Whitney U test and Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effective sedation: Group 1 215/241 (89%); Group 2 89/170 (52%); (P &lt; 0.0001)</p> <p>Venham scale ‐ relaxed: Group 1 = 32%; Group 2 = 67%</p> <p>Significantly less failure in sevoflurane/nitrous oxide</p> <p>Group 1 48% failed (P &lt; 0.0001); Group 2 11% failed</p> <p>Adverse effects: none mentioned</p> <p>Monitoring: pulse oximeter, capnograph, pretracheal stethoscope, visual assessment, auscultation and visualization of chest movements </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% sevoflurane group completed treatment compared to 52% of nitrous oxide group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0005" title="AverleyPA , LaneI , SykesJ , GirdlerNM , SteenN , BondS . An RCT pilot study to test the effects of intravenous midazolam as a conscious sedation technique for anxious children requiring dental treatment ‐ an alternative to general anaesthesia. British Dental Journal2004;197(9):553‐8. ">Averley 2004a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 65<br/> Gender, mean weight (SD) in kg, mean age (SD) in years:<br/> Group 1: 13 males and 7 females, 33.6 (11.2), 9.3 (2.2)<br/> Group 2: 15 males and 5 females, 37.6 (14.6), 9.6 (2.3)<br/> Group 3: 4 males and 16 females, 36.1 (11.8), 9.9 (2.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/min) (intravenous) + air (nasal inhalation)<br/> Group 2: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation)<br/> Group 3: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation) + sevoflurane (0.3%) (nasal inhalation) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary: completion of treatment<br/> Secondary: level of co‐operation during treatment, recovery time, perception of anxiety and pain and parent's satisfaction </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completion:</p> <p>Group 1: 10/20 (50%)</p> <p>Group 2: 16/22 (73%)</p> <p>Group 3: 19/23 (83%)</p> <p>(Chi<sup>2</sup> = 5.53, df = 2, P = 0.07) </p> <p>Of the 16 treatment failures in Groups 1 and 2, 9 were subsequently successfully treated with the addition of sevoflurane + nitrous oxide </p> <p>No adverse effects reported</p> <p>Monitoring: pulse oximeter, blood pressure, ECG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003877-bbs2-0006" title="AverleyPA , GirdlerNM , BondS , SteenN , SteeleJ . A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane. Anaesthesia2004;59(9):844‐52. ">Averley 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 664<br/> Gender, mean weight (SD) in kg, mean age (SD) in years:<br/> Group 1 (n = 222), 81 males, 36.3 (13.4), 9.1 (2.7)<br/> Group 2 (n = 306), 127 males, 37.8 (14.1), 9.5 (2.7)<br/> Group 3 (n = 320), 103 males, 37.7 (14), 9.6 (2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: midazolam (0.5 mg/min) (intravenous) + air (nasal inhalation)<br/> Group 2: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation)<br/> Group 3: midazolam (0.5 mg/min) (intravenous) + nitrous oxide (40%) (nasal inhalation) + sevoflurane (0.3%) (nasal inhalation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary: completion of treatment<br/> Secondary: level of co‐operation during treatment, recovery time, perception of anxiety and pain and parent's satisfaction </p> <p>Analysed using Chi<sup>2</sup> test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment completion:</p> <p>Group 1: 94/174 (54%)</p> <p>Group 2: 204/256 (80%)</p> <p>Group 3: 249/267 (93%)</p> <p>Chi<sup>2</sup> = 9.64, df = 2, P &lt; 0.001 </p> <p>Adverse effects: 1 faint in Group 1, 6 vomited in Group 3</p> <p>Monitoring: pulse oximeter, blood pressure, ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>AAPD = American Academy of Pediatric Dentistry; DSTG scale = Dental Sedation Teachers Group scale; df = degrees of freedom; ECG = electrocardiogram; n = number; SD = standard deviation; SE = standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drug comparison study outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Frequency of studies in which drug regimens were tested</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug regimen tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + hydroxyzine + midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloral hydrate + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dexmedetomidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketamine + midazolam + sevoflurane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Melatonin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meperidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meperidine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + sevoflurane + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam + tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Propofol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sevoflurane + nitrous oxide/oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sufentanil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triclofos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trimeprazine + methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trimeprazine + physeptone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolpidem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolpidem + tramadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Frequency of studies in which drug regimens were tested</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of behaviour/sedation rating scales</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ramsay Sedation Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Briekopf and Buttner Emotional Status Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frankl Behaviour Rating Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Houpt Behaviour Rating Scale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake, anxious and agitated, restless or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritated: awake, restless, crying</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refusal/distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aborted: no treatment rendered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake, co‐operative, orientated, tranquil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal: awake, calm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unco‐operative/reluctant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poor: treatment interrupted, only partial treatment was completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awake responds to commands only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactive: tired, hardly moving</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Co‐operative/reserved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair: treatment interrupted but eventually completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, brisk response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleepy: drowsy, with reaction but rousable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interested/enjoyed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good: difficult but all treatment was performed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, sluggish response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very good: some limited crying and movement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asleep, no response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excellent: no crying or movement</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>From <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of behaviour/sedation rating scales</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003877-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome measures used (excluding physiological parameters)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Characteristics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0004" title="Avalos‐ArenasV , Moyao‐GarciaD , Nava‐OcampoAA , Zayas‐CarranzaRE , Fragoso‐RiosR . Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation?. Current Medical Research and Opinion1998;14(4):219‐26. ">Avalos‐Arenas 1998</a>; <a href="./references#CD003877-bbs2-0010" title="BuiT , ReddenRJ , MurphyS . A comparison study between ketamine and ketamine‐promethazine combination for oral sedation in pediatric dental patients. Anesthesia Progress2002;49(1):14‐8. ">Bui 2002</a>; <a href="./references#CD003877-bbs2-0012" title="FaytrounyM , OkteZ , KucukyavuzZ . Comparison of two different dosages of hydroxyzine for sedation in the paediatric dental patient. International Journal of Paediatric Dentistry2007;17(5):378‐82. ">Faytrouny 2007</a>; <a href="./references#CD003877-bbs2-0014" title="GomesHS , GomesHS , Sado‐FilhoJ , CostaLR , CostaPS . Does sevoflurane add to outpatient procedural sedation in children? A randomised clinical trial. BMC Pediatrics2017;17(1):86. ">Gomes 2017</a>; <a href="./references#CD003877-bbs2-0022" title="LamC , UdinRD , MalamedSF , GoodDL , ForrestJL . Midazolam premedication in children: a pilot study comparing intramuscular and intranasal administration. Anesthesia Progress2005;52(2):56‐61. ">Lam 2005</a>; <a href="./references#CD003877-bbs2-0024" title="MalhotraPU , ThakurS , SinghalP , ChauhanD , JayamC , SoodR , et al. Comparative evaluation of dexmedetomidine and midazolam‐ketamine combination as sedative agents in pediatric dentistry: a double‐blinded randomized controlled trial. Contemporary Clinical Dentistry2016;7(2):186‐92. ">Malhotra 2016</a>; <a href="./references#CD003877-bbs2-0026" title="MeyerM , MourinoAP , FarringtonFH . Comparison of triazolam to a chloral hydrate/hydroxyzine combination in the sedation of pediatric dental patients. Pediatric Dentistry1990;12(5):283‐7. ">Meyer 1990</a>; <a href="./references#CD003877-bbs2-0030" title="MortazaviM , PourhashemiSJ , KhosraviMB , AshtariS , GhaderiF . Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry. Daru2009;17(2):79‐82. ">Mortazavi 2009</a>; <a href="./references#CD003877-bbs2-0033" title="ParkM , KimY , JungS , BeakK . Safety and efficacy of submucosal midazolam when combined with oral chloral hydrate, hydroxyzine and nitrous oxide sedation by using Houpt's scale. Journal of the Korean Dental Society of Anesthesiology2006;6:103‐12. ">Park 2006</a>; <a href="./references#CD003877-bbs2-0034" title="RaiK , HegdeM , GoelK . Sedation in uncooperative children undergoing dental procedures: a comparative evaluation of midazolam, propofol and ketamine. Journal of Clinical Pediatric Dentistry2007;32(1):1‐4. ">Rai 2007</a>; <a href="./references#CD003877-bbs2-0035" title="ReevesST , WiedenfeldKR , WrobleskiJ , HardinCL , PinoskyML . A randomized double‐blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. ASDC Journal of Dentistry for Children1996;63(2):95‐100. ">Reeves 1996</a>; <a href="./references#CD003877-bbs2-0039" title="SamsDR , CookEW , JacksonJG , RoebuckBL . Behavioral assessments of two drug combinations for oral sedation. Pediatric Dentistry1993;15(3):186‐90. ">Sams 1993a</a>; <a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a>; <a href="./references#CD003877-bbs2-0045" title="SomriM , ParisinosCA , KharoubaJ , CherniN , SmidtA , Abu RasZ , et al. Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study. International Journal of Paediatric Dentistry2012;22(4):271‐9. ">Somri 2012</a>; <a href="./references#CD003877-bbs2-0048" title="TyagiP , DixitU , TyagiS , JainA . Sedative effects of oral midazolam, intravenous midazolam and oral diazepam. Journal of Clinical Pediatric Dentistry2012;36(4):383‐8. ">Tyagi 2012</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐point scale for sleep (awake to asleep); 4‐point scale for movement (1 = violent movement to 4 = no movement); 4‐point scale for crying (1 = hysterical crying to 4 = no crying); 6‐point scale for overall behaviour (1 = no treatment rendered to 4 = difficult but all treatment completed to 6 = excellent/no crying or movement) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified from Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0002" title="Alfonzo‐EcheverriEC , BergJH , WildTW , GlassNL . Oral ketamine for pediatric outpatient dental surgery sedation. Pediatric Dentistry1993;15(3):182‐5. ">Alfonzo‐Echeverri 1993</a>; <a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from 1 = treatment aborted, 2 = poor (treatment frequently interrupted), 3 = fair (planned treatment completed), 4 = good (all treatment completed without crying or movement) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified from Houpt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0023" title="Lee‐KimSJ , FadaviS , PunwaniI , KoerberA . Nasal versus oral midazolam sedation for pediatric dental patients. Journal of Dentistry for Children2004;71(2):126‐30. ">Lee‐Kim 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modification not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dichotomous behaviour scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a>; <a href="./references#CD003877-bbs2-0028" title="MoorePA , MickeyEA , HargreavesJA , NeedlemanHL . Sedation in pediatric dentistry: a practical assessment procedure. Journal of the American Dental Association1984;109(4):564‐9. ">Moore 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dichotomous behavioural scale rates specific events of treatment as satisfactory or unsatisfactory </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ohio State University Behavior Rating Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0029" title="MoreiraTA , CostaPS , CostaLR , Jesus‐FrançaCM , AntunesDE , GomesHS , et al. Combined oral midazolam‐ketamine better than midazolam alone for sedation of young children: a randomized controlled trial. International Journal of Paediatric Dentistry2013;23(3):207‐15. ">Moreira 2013</a>; <a href="./references#CD003877-bbs2-0047" title="Torres‐PerezJ , Tapia‐GarciaI , Rosales‐BerberMA , Hernandez‐SierraJF , Pozos‐GuillenAJ . Comparison of three conscious sedation regimens for pediatric dental patients. Journal of Paediatric Dentistry2007;31(2):183‐6. ">Torres‐Perez 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from quiet to crying and struggling</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venham scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0021" title="LahoudGY , AverleyPA . Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial. Anaesthesia2002;57(5):446‐50. ">Lahoud 2002</a>; <a href="./references#CD003877-bbs2-0040" title="ShanmugaavelAK , AsokanS , BabyJJ , PriyaG , Gnana DeviJ . Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation ‐ A randomized controlled trial. Journal of Clinical Pediatric Dentistry2016;40(1):81‐7. ">Shanmugaavel 2016a</a>; <a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a>; <a href="./references#CD003877-bbs2-0049" title="VeerkampJS , GruythuysenRJ , HoogstratenJ , vanAmerongenWE . Dental treatment of fearful children using nitrous oxide. Part 4: Anxiety after two years. ASDC Journal of Dentistry for Children1993;60(4):372‐6. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 2: The parents' point of view. ASDC Journal of Dentistry for Children1992;59(2):115‐9. VeerkampJS , GruythuysenRJ , vanAmerongenWE , HoogstratenJ . Dental treatment of fearful children using nitrous oxide. Part 3: Anxiety during sequential visits. ASDC Journal of Dentistry for Children1993;60(3):175‐82. VeerkampJS , vanAmerongenWE , HoogstratenJ , GroenHJ . Dental treatment of fearful children, using nitrous oxide. Part I: Treatment times. ASDC Journal of Dentistry for Children1991;58(6):453‐7. ">Veerkamp 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point scale ranging from 0 = relaxed to 5 = out of control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mental attitude, hypnotic effect, motor activity and overall sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0013" title="AuilB , CornejoG , GallardoF . Flunitrazepam and diazepam compared as sedatives in children. ASDC Journal of Dentistry for Children1983;50(6):442‐4. GallardoF , CornejoG , BorieR . Oral midazolam as premedication for the apprehensive child before dental treatment. Journal of Clinical Pediatric Dentistry1994;18(2):123‐7. ">Gallardo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐point scale for mental attitude (relaxed or agitated); 3‐point scale for hypnotic effect (asleep to or awake); 3‐point scale for motor activity (absent to remarkable); 3‐point scale for sedation (excellent to unsatisfactory) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramsay Sedation Scale, movement, crying, overall sedation and behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0007" title="AydintugYS , OkcuKM , GunerY , GunaydinY , SencimenM . Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Military Medicine2004;169(4):270‐3. ">Aydintug 2004</a>; <a href="./references#CD003877-bbs2-0008" title="BayginO , BodurH , IsikB . Effectiveness of premedication agents administered prior to nitrous oxide/oxygen. European Journal of Anaesthesiology2010;27(4):341‐6. ">Baygin 2010</a>; <a href="./references#CD003877-bbs2-0015" title="IsikB , BayginO , BodurH . Premedication with melatonin vs midazolam in anxious children. Pediatric Anesthesia2008;18(7):635‐41. ">Isik 2008a</a>; <a href="./references#CD003877-bbs2-0016" title="IsikB , BayginO , BodurH . Oral midazolam premedication in anxious children: effectiveness of different doses. Anestezi Dergisi2008;16(1):34‐40. ">Isik 2008b</a>; <a href="./references#CD003877-bbs2-0036" title="RoelofseJA , JoubertJJ , RoelofsePG . A double‐blind randomized comparison of midazolam alone and midazolam combined with ketamine for sedation of pediatric dental patients. Journal of Oral and Maxillofacial Surgery1996;54(7):838‐44. ">Roelofse 1996a</a>; <a href="./references#CD003877-bbs2-0038" title="RoelofseJA , LouwLR , RoelofsePG . A double‐blind randomized comparison of oral trimeprazine‐methadone and ketamine‐midazolam for sedation of pediatric dental patients for oral surgical procedures. Anesthesia Progress1998;45(1):3‐11. ">Roelofse 1998</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐point scale for Ramsay (patient anxious and agitated to no response); 3‐point scale for movement (continuous movement to no movement); 4‐point scale for crying (hysterical crying to no weeping); 4‐point scale for overall sedation (impossible to very good) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0001" title="AbramsR , MorrisonJE , VillasenorA , HencmannD , DaFonsecaM , MuellerW . Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress1993;40(3):63‐6. ">Abrams 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐point scale ranging from 1 = unmanageable, unable to examine/treat, to 10 = obtunded: apneic where 5 is ideal (well sedated, co‐operative with normal oximetry) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0018" title="KapurA , ChawlaHS , GoyalA , GaubaK , BhardwajN . Efficacy and acceptability of oral‐transmucosal midazolam as a conscious sedation agent in pre‐school children. Journal of the Indian Society of Pedodontics and Preventive Dentistry2004;22(3):109‐13. ">Kapur 2004</a>; <a href="./references#CD003877-bbs2-0020" title="KoiralaB , PandeyRK , SaksenAK , KumarR , SharmaS . A comparative evaluation of newer sedatives in conscious sedation. Journal of Clinical Pediatric Dentistry2006;30(4):273‐6. ">Koirala 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale ranging from asleep to awake</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation scoring system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0037" title="RoelofseJA , JoubertJJ , SwartLC , StanderI , RoelofsePG . An evaluation of the effect of oral ketamine and standard oral premedication in the sedation of paediatric dental patients. Journal of the Dental Association of South Africa1996;51(4):197‐201. ">Roelofse 1996b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for level of sedation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilton's sedation scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Wilton (drowsy to agitated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptance of treatment (Holst, 1987)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0017" title="JensenB , SchroderU , ManssonU . Rectal sedation with diazepam or midazolam during extractions of traumatized primary incisors: a prospective, randomized, double‐blind trial in Swedish children aged 1.5‐3.5 years. Acta Odontologica Scandinavica1999;57(4):190‐4. ">Jensen 1999</a>; <a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Holst (positive to no)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acceptance of treatment (Al Rakaf, 2001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0041" title="ShanmugaavelAK , AsokanS , JohnJB , PriyaPR , RaajaMT . Comparison of drug acceptance and anxiety between intranasal and sublingual midazolam sedation. Pediatric Dentistry2016;38(2):106‐11. ">Shanmugaavel 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frankl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a>; <a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale for Frankl (definitely negative to definitely positive)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modification Barker sedation scoring system, overall quality sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0027" title="MoodyEHJr , MourinoAP , CampbellRL . The therapeutic effectiveness of nitrous oxide and chloral hydrate administered orally, rectally, and combined with hydroxyzine for pediatric dentistry. ASDC Journal of Dentistry for Children1986;53(6):425‐9. ">Moody 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barker sedation score calculated by summing scores given at intervals throughout the treatment; 4‐point rating scale for sedation quality (poor to excellent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global rating scale of overall behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0025" title="McKeeK , NazifMM , JacksonDL , BarnhartDC , CloseJ , MoorePA . Dose‐responsive characteristics of meperidine sedation in preschool children. Pediatric Dentistry1990;12(4):222‐7. ">McKee 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 ratings from excellent to poor‐aborted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0043" title="SinghN , PandeyRK , SaksenaAK , JaiswalJN . A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. Journal of Clinical Pediatric Dentistry2002;26(2):161‐4. ">Singh 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐point scale ranging from sleep to excited</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brietkopf and Buttner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0050" title="WanK , JingQ , ZhaoJZ . Evaluation of oral midazolam as conscious sedation for pediatric patients in oral restoration. Chinese Medical Sciences Journal2006;21(3):163‐6. ">Wan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from irritated to sleepy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fukuta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0042" title="ShashikiranND , ReddySV , YavagalCM . Conscious sedation ‐ an artist's science! An Indian experience with midazolam. Journal of the Indian Society of Pedodontics and Preventive Dentistry2006;24(1):7‐14. ">Shashikiran 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7‐point scale ranging from asleep to violent rejection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0009" title="BhatnagarS , DasUM , BhatnagarG . Comparison of oral midazolam with oral tramadol, triclofos and zolpidem in the sedation of pediatric dental patients: an in vivo study. Journal of the Indian Society of Pedodontics and Preventive Dentistry2012;30(2):109‐14. ">Bhatnagar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐point scale ranging from sleep to excited</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified scale to classify behaviour/response to treatment/sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0032" title="ÖzenB , MalamedSF , CetinerS , ÖzalpN , ÖzerL , AltunC . Outcomes of moderate sedation in paediatric dental patients. Australian Dental Journal2012;57(2):144‐50. ">Özen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale ranging from success to not accepting treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour/response to treatment rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0046" title="SurendarMN , PandeyRK , SaksenaAK , KumarR , ChandraG . A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. Journal of Clinical Paediatric Dentistry2014;38(3):255‐61. ">Surendar 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐point scale ranging from excellent to prohibitive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Dental Sedation Teachers Groups Scale (Ransford, 2010)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003877-bbs2-0019" title="KavianiN , AshrafiS , JabbarifarSE , GhaffariE . The efficacy of two intravenous sedative drugs in management of uncooperative children for dental treatments. Journal of Dentistry2015;16(1 Suppl):29‐34. ">Kaviani 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐point scale measuring operating conditions ranging from 1 = good to 4 = impossible</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Outcome measures used (excluding physiological parameters)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/full#CD003877-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003877-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sedatives versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean Houpt/other behavioural score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Midazolam (oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.59, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Midazolam (intravenous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.24, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Nitrous oxide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.13, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Diazepam (oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [‐0.28, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Good or better behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Chloral hydrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Meperidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sedatives versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003877-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chloral hydrate (CH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall behaviour (ordinal scale, Houpt or similar) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CH vs CH/hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 CH/hydroxyzine vs triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 CH/hydroxyzine vs midazolam/acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 CH/promethazine vs meperidine/promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 CH/hydroxyzine vs CH/hydroxyzine/midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Good or better behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CH vs CH/hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.24, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chloral hydrate (CH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003877-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ketamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall behaviour (ordinal scale, Houpt or similar) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Ketamine vs midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ketamine vs propofol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Ketamine/midazolam vs trimeprazine/methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Ketamine vs meperidine/promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Ketamine vs ketamine/promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Good or better behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ketamine vs trimeprazine/methadone/droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Ketamine/midazolam vs trimeprazine/methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ketamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003877-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Midazolam (versus other)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall behaviour (ordinal scale, Houpt or similar) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Midazolam (low dose) vs midazolam (high dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Midazolam (intramuscular) vs midazolam (intranasal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Midazolam vs ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Midazolam vs nitrous oxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Midazolam vs hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Midazolam vs midazolam/ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Midazolam vs promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Midazolam vs triclofos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Midazolam vs propofol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Midazolam/acetaminophen vs CH/hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Midazolam/ketamine vs trimeprazine/methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Midazolam (oral) vs midazolam (intravenous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Midazolam vs diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Good or better sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Midazolam (rectal) vs diazepam (rectal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Midazolam (versus other)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003877-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nitrous oxide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall behaviour (ordinal scale, Houpt or similar) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nitrous oxide vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nitrous oxide vs midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nitrous oxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003877.pub5/references#CD003877-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003877.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003877-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003877-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003877-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003877-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003877-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003877-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003877-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003877-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD003877-note-0010">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD003877-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003877-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003877-note-0020">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003877\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003877\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003877\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003877\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003877\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003877.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003877.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003877.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003877.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003877.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726986128"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003877.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726986132"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003877.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea10698daf401',t:'MTc0MDcyNjk4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 